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Abstract  
 
Over the past two decades there has been an explosion in the number of 
cases of Kaposi’s sarcoma (KS) in parts of sub-Saharan Africa, where 
Kaposi’s sarcoma associated-herpesvirus (KSHV) and HIV are relatively 
prevalent.  Currently KS is the most commonly reported cancer in 
Uganda causing significant morbidity and mortality. Limiting KSHV 
transmission or halting disease progression could prevent KS.  Here, I 
describe an investigation of factors that might impact on transmission of 
KSHV and report the first prospective study of antibody titre to KSHV to 
determine risk of KS from Africa.  
 
Stored samples from Medical Research Council, Uganda cohorts were 
tested using an ELISA to KSHV antigens.  Results from a birth cohort 
found that among both mothers and children malaria parasitaemia was 
identified as a novel association with KSHV seropositivity.  Among 
children HIV exposure and HIV infection was associated with antibodies 
to KSHV.  A random effects meta-analysis conducted to clarify wider 
evidence of an association between KSHV and HIV found that HIV was 
associated with an increased prevalence of antibodies to KSHV in 
mothers and children. A case-control study nested within a longitudinal 
HIV cohort found among individuals who develop KS, antibody titres to 
KSHV are higher and increased over time compared to adults who did 
not. 
 
It is plausible that control of malaria may also reduce the spread of 
KSHV.  How malaria may interact with KSHV and if malaria control will 
reduce transmission are key future questions.  Prevention and treatment 
of HIV with anti-retroviral therapy may lower KSHV transmission 
between mothers and children. For individuals with HIV-KSHV co-
infection, increasing antibody titre to KSHV precedes development of KS.  
Research is required to elucidate co-factors driving progression to cancer.  
A clinically valid tool to screen for risk of HIV-associated KS is urgently 
needed. 
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Chapter 1: Introduction to thesis  
 
1.1 Introduction  
 
Kaposi’s sarcoma (KS) is a neoplasm observed in individuals with 
immune compromise including HIV infection (HIV-associated KS) or after 
solid organ transplantation due to the use of immunosuppressive drugs 
(iatrogenic KS)1.  KS also occurs in people without overt immune 
suppression in the Mediterranean (classic KS) and Africa (endemic KS)2.  
All four epidemiological forms of KS are identical histologically and 
characterised by pronounced lymphangio and angiogenesis1. Substantial 
molecular and serological evidence supports Kaposi’s sarcoma-associated 
herpesvirus (KSHV) as the causal agent of all forms of KS1, 3, 4.  
Worldwide patterns of KSHV seroprevalence show a striking geographical 
variation5.  The reasons underlying this remain unclear, but are 
important to understand as the occurrence of KS in a population is 
strongly correlated with KSHV seroprevalence.   
 
Studies from sub-Saharan Africa report high KSHV prevalence6-25, with 
primary infection beginning in childhood and increasing with age7, 9, 10, 12, 
13, 15, 16, 22, 25.  There is considerable evidence, too, that KSHV 
transmission occurs via saliva26, 27 and in Africa transmission from 
mothers7, 13, 23, 25, is likely to be an important route. Risk factors 
governing childhood vulnerability to infection with KSHV remain only 
partly elucidated.  Exposures in childhood including HIV, other infectious 
diseases and socioeconomic conditions may be key.  Understanding 
transmission dynamics is a prerequisite for the development of strategies 
to prevent spread and the subsequent diseases associated with KSHV.   
 
Infection with KSHV alone does not confer a high risk of developing KS, 
implying that other factors are likely involved28.  The most important co-
factor associated with KS development among KSHV infected individuals 
is HIV infection.  KS is the most common tumour arising in HIV-infected 
persons, and is an AIDS-defining illness.  In the United States during the 
nineties, KS was reported to be over 20,000 times more common in 
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persons infected with HIV than in the general population and over 300 
times more common in people with HIV than in other immunosuppressed 
hosts, such as renal transplant recipients29. In the era of HIV, the cancer 
registry in Kampala, Uganda reports KS as the commonest cancer in 
adults and children30-32.  Not all HIV-KSHV co-infected individuals develop 
KS33 and understanding the evolution of biomarkers such as KSHV 
antibodies in asymptomatic KSHV-HIV co-infected individuals may be key 
to identifying individuals at highest risk of KS.  Screening for risk of KS 
may be particular important in resource poor settings were access to ART 
and cancer treatments are limited. While HIV is one of the strongest 
predictors of KS development in KSHV infected individuals, the 
occurrence of KS in HIV-negative individuals suggests host, viral or 
environmental co-factors predisposing to KSHV oncogenesis34. An 
improved understanding of the epidemiology of KS and KSHV may give 
clues to additional as yet unknown factors.   
 
1.1.2 Thesis aim 
 
This thesis specifically addresses the following primary research 
questions: 
1. Are HIV and other common infectious agents present in Uganda 
risk factors for antibodies to KSHV among mothers and their 
children? 
2. Are measures of socioeconomic status associated with maternal 
and childhood KSHV seropositivity? 
3. What is the level of evidence in published literature for HIV as a 
co-factor for KSHV seroprevalence among mother-child pairs? 
4. Among HIV-KSHV co-infected adults resident in Uganda, does the 
pattern of antibody titre to KSHV differ between those who 
develop KS compared to those who do not? 
 
Questions 1,2 and 4 outlined above were conducted within the context of 
existing cohorts at the MRC Uganda Research Unit on AIDS (MRC) and 
the Uganda Virus Research Institute (UVRI). The first cohort, the Entebbe 
Mother and Baby Study (EMaBS) was a large Wellcome Trust funded 
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double blind randomised placebo controlled trial, which was designed to 
determine the impact of helminth infections and their treatment on 
vaccine responses and infectious disease outcomes35. The second was a 
cohort of HIV-infected adults recruited from a long standing MRC/UVRI 
General Population Cohort (GPC)36.  HIV positive individuals were 
followed at regular intervals in a dedicated study clinic, which provided 
clinical care and anti-retroviral therapy (ART).  KSHV serology technology 
was transferred to MRC/UVRI from the National Cancer Institute (NCI), 
USA.  Access to the rich datasets held at MRC/UVRI and the opportunity 
to link KSHV serology results provides the opportunity to address 
important primary and secondary questions on the epidemiology of KSHV 
in Uganda.  Question 3 was addressed by a systematic literature review 
and meta-analysis. The intent of this study is to bring additional clarity to 
the evidence of the role of HIV as a co-factor for KSHV transmission 
between mothers and their children.  
 
1.2 Thesis structure 
 
First, the dramatic change in the clinico-epidemiological profile of KS in 
the era of HIV will be described.   HIV-associated KS is an aggressive 
cancer with high mortality and is a major public health concern in 
Uganda. The association of detection and titre of antibodies to KSHV and 
risk of HIV-associated KS is presented.  Next, the occurrence of KS in 
individuals without overt immune suppression is discussed. Patterns of 
occurrence of classic and endemic KS may suggest co-factors for 
oncogenesis in addition to HIV.  Regional patterns of KSHV 
seroprevalence may suggest potential co-factors for KSHV infection. Of 
key interest in this thesis is KSHV seroprevalence among mothers and 
children in Uganda.  Childhood is a major risk period for primary KSHV 
infection and mothers are likely the child’s predominant source.  HIV is 
potentially an important co-factor in KSHV transmission, but other local 
factors in Uganda may also be important including parasites.  The results 
chapters then present; (1) a study of risk factors for KSHV seropositivity 
in mothers and their children in Uganda; (2) a meta-analysis of the 
association between HIV and KSHV in mothers, pregnant women and 
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children, and (3) an investigation of antibody titre against KSHV and risk 
of developing HIV-associated KS.  The final chapter is a discussion of the 
results their implications.  	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Chapter 2: Kaposi’s sarcoma  
 
2.1 Chapter contents 
 
The epidemiology of KS dramatically altered in the era of HIV.  In 
Uganda KS is now the commonest cancer in HIV-infected individuals.  
The epidemiology of KS among individuals without evident immune 
deficiency may reveal clues as to potential co-factors for disease 
development. To potentially screen for and prevent HIV-associated KS, 
risk factors that precede development of this tumour are important to 
determine.  Antibody titres to KSHV are a potential biomarker for 
screening for risk of KS. 
Objectives: 
I. To describe the epidemiology of KS in the era of HIV.  
II. To describe the epidemiology of the forms of KS not associated 
with overt immune suppression (so called classic and endemic KS).   
III. To review risk factors for HIV-associated KS.  A critical review of 
relevant literature available in PubMed on risk of KS development 
and antibody titres to KSHV in HIV infected adults is presented. 
Summary: The presence of HIV infection is one of the strongest 
predictors of risk for KS in KSHV infected individuals.  Detection of 
antibodies to KSHV precedes and is predictive of development of HIV-
associated KS. 
 
2.2 Introduction 
 
KS was first described by Moritz Kaposi’s in 187237.  He reported a skin 
tumour on the lower limbs of older men of Mediterranean or Ashkenazi 
Jewish descent which he named “idiopathic multiple pigmented 
sarcoma”38. Subsequently, in the 1950’s and 1960’s KS was reported on 
the lower limbs of older black men resident in sub-Saharan Africa39.  
Reports described a tumour with a striking geographical distribution with 
highest rates in North East and Eastern Zaire (Democratic Republic of 
Congo), Rwanda, Burundi, Uganda, Malawi, Tanzania, Rhodesia 
(Zimbabwe) and Kenya39-47. KS presenting in older men in the 
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Mediterranean and Africa was considered a relatively rare indolent 
tumour at this time2.  Cases of KS subsequent to solid organ transplant 
have been reported in the literature since the 1970’s in individuals of 
Mediterranean, Jewish, Arabic, Caribbean, or African descent48.  The 
relative rarity of KS was to change in the 1980’s.  In 1981 the Centers 
for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly 
Review reported the occurrence of KS and pneumocystis pneumonia 
among men who have sex with men (MSM)49. This report heralded the 
advent of the HIV epidemic 49. HIV changed both the clinical occurrence 
and the epidemiology of KS.   HIV-associated KS became recognised as 
an aggressive cancer with high morbidity and mortality50. As the HIV 
epidemic progressed in Africa, KS became the most commonly reported 
cancer in many countries in this region51.  The high prevalence of KS in 
countries such as Uganda is a major health problem due to the lack of 
potential treatment options including ART and chemotherapy.  In 1994 a 
gamma herpesvirus was identified in KS biopsies by Chang and Moore4.  
The virus was named Kaposi’s sarcoma-associated herpes virus (KSHV) 
or human herpesvirus 8 (HHV-8).  In a recent comprehensive review of 
the role of KSHV in the aetiology of KS, conducted by the International 
Agency for Research on Cancer 52, it was concluded that KSHV is a class 
1 carcinogen (defined as being ‘definitely carcinogenic to man’) and the 
principle underlying cause of the malignancy. 
 
2.3 Clinical-epidemiological forms of Kaposi’s sarcoma 
 
KS is a low-grade tumour of endothelial origin53. KS tumours are noted to 
have a large inflammatory and vascular component50.  Historically, the 
first disease associated with KSHV infection was KS. However, it soon 
became acknowledged that two other conditions were also linked to this 
virus: primary effusion lymphoma and Castleman's disease. KSHV is the 
aetiological agent for four clinical-epidemiological types of KS (Table 1): 
 
HIV-associated: This type of KS is the most common tumour arising in 
HIV-infected persons, and is an AIDS-defining illness in the CDC 
guidelines.   HIV-associated KS typically has an aggressive clinical 
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behaviour characterized by disseminated muco-cutaneous and visceral 
lesions.  
 
Classic: An indolent cutaneous proliferative disease, mainly affecting the 
lower extremities of older men of Mediterranean and Jewish origin54, 55.  
Apparent immune deficiency is not associated with this type of KS.  
 
Endemic: The endemic form of KS is found in equatorial Africa and 
typically affects older men, but is also reported to occur in children. It is 
not thought to be associated with overt immune suppression40.  
 
Iatrogenic or transplant-associated: KS may occur after solid organ 
transplantation due to the use of immunosuppressive drugs such as 
calcineurin inhibitors. Transplant-associated KS is similar to HIV-
associated KS in its clinical presentation and usually regresses with 
reduction in immunosuppression56. 
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2.4 Worldwide occurrence of Kaposi’s sarcoma 
 
 
Worldwide patterns of HIV-associated KS incidence broadly mirror that of 
HIV-KSHV co-infection.  Currently, the prevalence of HIV-associated KS 
greatly eclipses the occurrence of the other clinical-epidemiological types 
of this cancer29.  The HIV epidemic has significantly changed the public 
health importance of KS, which is reflected in the current magnitude of 
research effort.   Iatrogenic or post-transplant KS most commonly occurs 
in the setting of solid organ transplant in populations where KSHV is 
relatively prevalent48.  KS in individuals without overt immune 
suppression tend to occur in specific geographical locations in equatorial 
Africa (endemic) and the Mediterranean (classic), with a distinct age and 
sex bias40, 57.  The pathogenesis of classic and endemic KS among KSHV 
infected individuals remains an enigma. Investigation of the underlying 
pathogenesis of KS in individuals without HIV and iatrogenic 
immunosuppression may reveal subtle and indeed key mechanisms of 
oncogenesis.  
 
2.4.1 The epidemiology of HIV-associated Kaposi’s sarcoma 
 
HIV is the strongest risk factor for development of KS in a KSHV infected 
individual. In the United States, before the introduction of ART, KS was 
over 20,000 times more common in persons infected with HIV than in 
the general population and over 300 times more common in HIV infected 
subjects than in other immunosuppressed hosts, such as renal transplant 
recipients29, 58.  The reported relative risk of HIV-associated KS among 
individuals in Africa is lower than in studies from North America58, 59.  
This is likely due to higher background occurrence of endemic KS in 
Africa.  
 
In North America and Europe, KS is a cancer predominantly found in 
HIV-infected MSM, the risk group with highest KSHV seroprevalence.  KS 
is much less common in HIV-infected heterosexuals, injection drug users, 
transfusion recipients, women, children and haemophiliac patients, all of 
whom tend to have a lower KSHV seroprevalence compared to MSM29.  In 
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sub-Saharan Africa, a dramatic increase in the occurrence of KS has been 
reported over the past 30 years51, 60.  In Africa, although KS is more 
common in men than in women, the sex-ratio is much less disparate, a 
consequence of similar HIV and KSHV prevalence in men and women51, 
60.   
 
In Uganda, the Kampala Cancer Registry has shown a significant increase 
in the incidence of KS in the era of the HIV epidemic32 (Figure 2.1) with 
narrowing of the sex-ratio and a dramatic rise in reported cases in 
children.  Registration of KS in the 1960’s was likely “endemic” type39, 41, 
46, 47, an indolent tumour affecting the legs of predominantly men, with 
risk increasing with age.  In the time period between 1971 and 1991 the 
surge in reported occurrence of KS reflects HIV-associated KS31, 32.   By 
the late 1990’s, KS was the commonest reported cancer among men in 
Uganda and second only to cancer of the cervix among women31, 32.  
 
 
Figure 2.1: Age-standardized rates (world standard population) of KS reported by the 
Kampala Cancer Registry, Uganda in four time periods for men, women and children.   
Data taken from Trends in cancer incidence in Kyadondo County, Uganda, 1960- 1997, 
British Journal of Cancer (2000) 82(9), 1585, Wabinga H.R. et al.32 
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In South Africa a similar increase in the incidence of KS, in men and 
women has been reported in the era of HIV59.  In Zambia, KS in infants 
and young children occurred almost exclusively after the advent of the 
HIV epidemic with a near equal sex-ratio61.  Similar changes are reported 
in other African countries51.  
 
In the Mediterranean, where classic type KS is endemic, the arrival of 
HIV also caused an increase in KS incidence and the ratio of male-to-
female cases to drop from 10:1 to 3:162. 
 
KS is infrequently reported among HIV-infected patients in Asia. In a 
study of 248 patients infected with HIV in Bangkok, Thailand, no KS was 
reported63.  There is a paucity of published literature about HIV-
associated KS in Asia and comprehensive cancer registry data is required 
to confirm KS epidemiology. 
 
ART has lead to marked declines in the incidence of HIV-associated KS.  
In data derived from USA population-based cancer registries, KS rates 
among white men rose from 0.5 per 100,000 people per year in 1973, to 
between 31.3 and 33.3 from 1987 through 1991, and then declined to 
2.8 in 1998 with the advent of ART64.  In another North American study, 
the standardized incidence ratio for KS within a HIV-infected population 
compared to the general population fell from 22,100 to 3640 (1990-1995 
to 1996-2002) with the widespread use of ART65.   The 5-year survival 
rates for patients with HIV-related KS in North America has improved 
from about 10% (1980-1995) to 50% (1996-2005)66.  Much of this 
improvement in survival is attributed to ART.  Data on the impact of ART 
on KS incidence in Africa is lacking, in part due to the paucity of cancer 
registration.  It may be expected that the impact of ART roll-out will be 
less in this region due to limits in ART coverage and that HIV-infected 
individuals commonly present with advanced AIDS defining illnesses.  
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2.4.2 The epidemiology of iatrogenic or post-transplant Kaposi’s 
sarcoma 
 
Post-transplant KS tends to occur in countries that carry out a high per 
capita number of organ transplants and have a significant population 
prevalence of KSHV: Iran, Israel, Greece, Italy67-70.  A study in Iran 
reported KS as the commonest tumour type in solid organ transplant 
recipients67, as have studies in Israel68, Italy69 and Greece70.  KS is seen 
most often in patients whose immunosuppressive treatment regime 
includes calcineurin inhibitors such as cyclosporine. 
 
2.4.3 The epidemiology of Kaposi’s sarcoma among individuals 
without overt immune suppression 
 
 
Forms of KS that occur without overt immunosuppression (classic and 
endemic KS) have distinct geographical, age and gender influences2.  
These factors may have profound aetiological significance, but they 
remain unclear at present.  It is important to discriminate classic and 
endemic type KS from KS that occurs in individuals with profound 
immune deficiency (HIV and post transplantation) because the 
epidemiological distributions are very different.  A paucity of robust 
worldwide seroprevalence studies and major limitations in cancer 
registration hampers research.  This is particularly problematic in sub-
Saharan Africa and parts of Asia and South America where health care 
systems and collections of epidemiological data are very limited. 
 
2.4.3.1 Geographic and Ethnic variation of Classic and Endemic 
type Kaposi’s sarcoma 
 
The incidence rates of classic type KS in reports from Europe  vary (Table 
2.2)54, 55, 71-84.  Low rates are reported in England84, Scotland83, 
Denmark75 and Sweden76, with slightly higher rates reported from France 
and Spain54.  Relatively high rates are reported in Greece73, North and 
Central Italy78, the Faroe Islands and Iceland77. The highest incidence 
rates in Europe are reported in Sardinia and Southern Italy (Sassari)78 
	  	   24	  
(Table 2.2). Outside Europe, low rates of KS are reported in older men in 
the USA82, Canada54 and Australia81. Israel reports relatively high rates of 
classic KS, especially among individuals of Jewish descent54, 55, 71, 72.   
 
 
 
Figure 2.2: Measure of classic or endemic KS among men over the age of 65 years.  The 
databases and studies used in this figure are tabulated in Table 2.2.   The literature 
search is described in the general methods section.  
 
 
Reports have suggested that the incidence of Classic KS may be 
increasing in Europe and Israel54, 74.  This was noted prior to the AIDS 
epidemic and as a separate phenomenon to the increased rate of KS 
after immunosuppressive therapy for solid organ transplants.  It remains 
unclear whether this is due to greater registration of cancers due to 
improved access to healthcare and better diagnosis classification, 
changes in the general population including aging and immigration of 
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individuals from higher risk areas to countries in Europe with lower KS 
incidence, or due to an increase in factors driving KS development.  
 
The published data on rates of endemic KS in Africa come from historical 
data collected in the 1960’s and 70’s39-47.  More recent data on the 
occurrence of endemic KS in Africa can only be inferred from reports of 
KS in older men (Table 2.2)32, 85-90.  The first report was published in 
1961 by Oettle who described endemic KS as being predominately found 
in older black men and suggested environmental factor(s) could best 
explain its distribution39.  The highest rates at this time were found in a 
band across central and East Africa. The rate of endemic KS appeared to 
fall off towards West and South Africa39, 46.  In Uganda, geographical 
restriction of the cancer over relatively small distances, with the highest 
occurrence along the North Western border with the Congo (West Nile) 
and in the South West (Ankole and Kigezi) has been reported (Figure 
2.3)40, 41, 46.  In Kenya, the highest incidence rates were reported among 
the Kikuyu, Embu and Meru tribes living in areas of high altitude with 
moderate rainfall.  Much lower incidence was observed in hot dry areas 
along Lake Victoria and the coastal regions40, 42.  In Tanzania low rates of 
endemic KS were found along the Coast in Dodoma and Dar a Salaam 
with highest rates in Mwanza, on the shores of Lake Victoria40, 42.  
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Figure 2.3: Estimated cumulative incidence rates for KS per 1000 men aged 0-64.  Data 
taken from The geographical distribution of Kaposi’s's sarcoma and of lymphomas in 
Africa before the AIDS epidemic, British Journal of Cancer (1998); 78(11), 1521, Cook-
Mozaffari, P. et al.40 
 
KS that resembles classic or endemic KS has been reported in Argentina, 
Colombia and Peru91-93.  Amerindian populations in the Brazilian Amazon 
basin have very high KSHV seroprevalence94 but only a small number of 
reports of classic KS in this population are currently in published 
literature91-93.  Given the limitations of cancer registries in Brazil95, it is 
currently difficult to interpret this information. Classic type KS is rarely 
reported in the Far East although case reports do exist96. 
 
Migrant studies suggest that risk for Classic KS may be associated with 
country of birth.  Iscovich et al54 reported incidence rates of classic KS 
among Jews born and living in Israel were different from immigrants; 
Jewish immigrants born in Africa have the highest incidence rates (ASR 
>27.0, 95% CI 1.4-2.4).  Individuals born in Eastern Europe have 
intermediate rates (ASR between 14-18) and those born in Western 
Europe and Iran have the lowest rates (ASR 5.5, 95% CI 0.3-0.6).  A 
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study conducted in the USA reported the highest incidence rate of classic 
KS is in Jews born in Eastern Europe and Mediterranean countries97.  
Furthermore, second-generation American born Jews are at lower risk for 
classic KS than their parents97.  During the 1950’s the rate of endemic KS 
in South Africa among immigrants from the Netherlands was significantly 
lower than Bantu people living in a similar area39.  The differential rates 
of KS may be due to variation in host or viral genetic or environmental 
risk factors for KSHV infection or KS development.   
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2.4.3.2 Age and sex variations of Classic and Endemic type 
Kaposi’s sarcoma 
 
Classic KS has an overwhelming male predominance, with a male-to-
female ratio of approximately 10:1 to 15:154.  Endemic KS in Africa is 
reported to be about eight to ten times more common in men than in 
women40.  KS most commonly occurs in individuals over the age of 50 
years54.  
 
2.5 The pathogenesis of Kaposi’s sarcoma  
 
Increased risk of KS among individuals with immunosuppression is well 
recognised.   A key element for KSHV pathogenesis and KS development 
is T-cell immunity98. In situations associated with loss of T-cell function 
such as HIV infection and after an organ transplant, the incidence of KS 
in those infected with KSHV dramatically increases.   
 
HIV is associated with the absence of KSHV-specific T-cell responses99, 
100, increases in KSHV viral load99 and progression of KS100. Anti-
retroviral therapy is associated with regression of KS and decreasing 
KSHV detection, and this is accompanied by restoration of numbers and 
functions of KSHV-specific CD4 positive 98, 101, 102 and CD8 positive T-
cells98, 102-104.  
 
KS development in KSHV infected individuals after solid organ transplant 
is linked to the use of calcineurin inhibitors. This class of drugs prevents 
organ rejection by immunosuppression largely through T-cell inhibition.  
Loss of KSHV-specific T-cells has been demonstrated with calcineurin 
inhibitors, with recovery and remission of KS on stopping medication105. 
The majority of post-transplant KS patients are KSHV seropositive prior 
to transplantation, suggesting that reactivation of latent virus is 
responsible for the disease 106, 107. 
 
While obvious immune suppression is not evident in classic and endemic 
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types of KS, more subtle modulation of immune function may be present.  
In an Italian study, patients with classic KS were found to have a 
significantly lower total lymphocyte count than KSHV seropositive 
individuals without KS108.  An increased risk of classic KS was associated 
with topical109 and systemic corticosteroid110 use in a case control study 
of individuals with the cancer compared to KSHV seropositive controls.  
Classic and endemic KS are strongly associated with increasing age.  Old 
age is characterized by progressive alternations to the immune system 
including declining effectiveness of T-cells and immune deficiency111, that 
may be important in KS pathogenesis.  
 
2.6 Risk factors for Kaposi’s sarcoma 
 
A substantial body of work shows that KSHV infection is necessary for KS 
development, but not all those infected develop the cancer.  This points 
to the presence and/or inter-play of risk factors in addition to infection 
with KSHV.   For all four clinical-epidemiological types of KS, replicating 
virus has an important role in the pathogenesis of the cancer108, 112-114.  
KSHV viral replication can be estimated indirectly by detection of KSHV 
viral load in body fluids or antibody titration in plasma and serum. Other 
risk factors include host immunomodulating genes, KSHV sub-types and 
environmental co-factors1. 
 
In this section risk factors for HIV-associated KS will be discussed; first 
laboratory measurable markers of viral replication and then background 
host and other viral factors.  Second, risk factors for KS in individuals 
without overt immune will be outlined, with emphasis placed on 
potentially subtle co-factors that may be revealed in the absence of HIV 
or immune suppression.  
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2.6.1 Laboratory measurable risk factors for HIV-associated 
Kaposi’s sarcoma 
 
The identification of laboratory measurable risk factors that precede and 
are predictive of the development if HIV-associated KS is important 
because the cancer is aggressive, highly morbid and is not curable.  To 
be able to accurately predict individuals at the highest risk of KS may 
allow for screening and prevention. Antibody titre to KSHV antigens and 
the quantification of KSHV viral load in PBMC are obvious choices.  While 
currently not clinically validated tools, KSHV antibody titre and viral load 
are relatively easy to perform measures of KSHV activity.  Studies have 
shown that the detection of KSHV DNA in peripheral blood mononuclear 
cells (PBMCs) and high KSHV antibody titres are associated with the risk 
of development of HIV-associated KS33, 113, 115-117.   
 
2.6.2 Kaposi’s sarcoma-associated herpes virus load and risk of 
Kaposi’s sarcoma 
 
In studies from North American and Northern European cohorts, KSHV 
DNA detection in PBMCs of HIV-infected individuals without KS predicts 
the subsequent appearance of KS lesions113, 114, 118-120.  In cross-sectional 
studies from sub-Saharan Africa HIV-infected individuals with KS have 
significantly higher KSHV viral loads in PBMCs121 and in plasma122 
compared to HIV-seropositive individuals without KS.  In studies from 
Uganda and Zimbabwe, among individuals with HIV-associated KS, 
increasing KSHV viral load is associated with the extent of KS lesions and 
the development of new KS lesions112, 123.  Among HIV-infected 
individuals undetectable KSHV viral load in PBMCs is associated with 
regression of KS lesions124.  
 
While evidence suggests that quantification of KSHV viral load is 
informative for detecting risk of KS, detection of KSHV viral load prior to 
KS development can be problematic. The technique is limited because (1) 
KSHV viral DNA loads in PBMCs are frequently not high enough to be 
detected125, (2) assay costs are high, (3) through-put is low and (4) a 
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relatively sophisticated laboratory is required.  These issues have limited 
the use of KSHV viral load assays in sub-Saharan Africa.  
 
2.6.4 Antibodies to Kaposi’s sarcoma-associated herpesvirus 
 
Compared to assays to detect KSHV DNA, antibody assays offer potential 
through-put automation.  KSHV serological assays are the tool used in 
this thesis. A comprehensive peer reviewed monograph has been 
published by IARC (monographs volume 100B)126 which includes a 
number of tables presenting evidence for a causal association between 
the presence of KSHV viral load or antibodies and KS126.  This review was 
not repeated, but for this thesis it was essential to establish the evidence 
of association of the detection of antibody to KSHV and risk of HIV-
associated KS. KSHV as the aetiological cause of KS was assumed.  
Hence, two critical literature searches were carried out in PubMed.  First, 
the association between the detection of antibodies to KSHV and HIV-
associated KS in sub-Saharan Africa was investigated16, 127-131 (Table 
2.3).  This search was to ascertain that among KSHV endemic 
populations the presence of antibodies to KSHV is associated with HIV-
associated KS. The potential concern in regions with a high background 
prevalence of KSHV infection is that the detection of antibodies to KSHV 
may not differentiate between individuals with HIV-associated KS and 
HIV-infected individuals without KS.  Next, a search was conducted for 
longitudinal studies registered on PubMed investigating the association of 
antibodies to KSHV preceding HIV-associated KS diagnosis and 
subsequent risk of development of HIV-associated KS33, 115-117, 127, 132-137 
(Table 2.4). This search was widened to include all studies of HIV-
associated KS regardless of population location.  The methods and 
limitations of both searches are presented within the general methods 
chapter.  
 
In all studies identified investigating antibodies to KSHV in HIV-infected 
individuals with and without KS, the prevalence of antibodies was higher 
in individuals with HIV associated-KS than in HIV-positive individuals 
without KS (Table 2.3).  Two studies estimated the risk of HIV-associated 
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KS by increasing fluorescent intensity signal to KSHV antigens128, 131.   In 
a study by Newton et al high fluorescent intensity to a KSHV antigen was 
associated with about a ten-fold increase in risk of KS, although the 
trend in the estimated ORs was driven by the difference in KSHV 
seronegative individuals compared to those defined as having medium or 
high fluorescent intensity128. Sitas et al, reported that KS was more 
frequent among those with high intensity fluorescent signals for 
antibodies against KSHV131. 
 
Six studies presented analysis for the risk of prevalent antibodies to 
KSHV prior to development of HIV-associated KS (Table 2.4): one 
reported null findings33, while five reported an increased risk117, 134-137.  
Two studies117, 136 reported an increased risk of KS with increasing 
antibodies to KSHV.  Low antibody titre to KSHV was associated with an 
increased risk of 25 (95% CI 3.2-192.6) of developing KS, while high 
titre was associated with an increased risk of 52 (95% CI 6.1-441.3), 
compared to being KSHV seronegative136.  Newton et al reported an 
increased risk of KS with increasing latent antibodies and lytic optical 
density measured by ELISA, although the trend was not linear117. 
 
Eleven studies were identified that investigated the presence or level of 
compared t, and all but  
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2.7 Other risk factors for the development of HIV-associated 
Kaposi’s sarcoma 
 
While KSHV-HIV co-infection rates explain the majority of KS occurrence, 
host and viral factors may influence KSHV associated disease expression, 
since not all HIV-KSHV infected individuals develop KS.   
 
Measures of HIV-associated immune deficiency predict the development 
of KS113. The CD4 count is an important factor associated with the 
development of HIV-associated KS. KS risk among ART-naïve individuals 
with HIV resident in Europe steeply increased with decreasing CD4 cell 
count (HR for <50 versus 350 cells µl-1, 12.9; 95% CI 9.6–17.2)138. In a 
case series of homosexual men resident in the UK, a new diagnosis of KS 
while on ART, the rate ratios for developing KS for patients with CD4 
counts <200, 200-349, and 350-499 cells/mm3 were 18.9 (95% CI 8.5-
42.1), 3.6 (95% CI 1.4-9.0), and 4.1 (95% CI 1.7-9.7), compared to 
patients with ≥500 cells/mm3139.  Among ART users, a nadir CD4 count 
prior to ART initiation is also important with a greatly increased risk of KS 
with a CD4 count below 50 cellsµl−1 (HR for <50 versus 350 cells µl−1, 
5.4; 95% CI, 2.1–13.8)138. High HIV RNA level (> 5.0 log10 copies/ml) is 
associated with an increased risk of KS development  (HR adjusted for 
CD4, 4.0; 95% CI, 2.2–7.2 per log10).  Another study reported an 
increased risk of HIV-associated KS with increasing HIV RNA levels 
(relative hazard for one log10 increase HIV RNA 3.3 (95% CI 1.9-5.7). 
 
Genetic polymorphisms in host immune genes are obvious research 
targets.  KS plaques are associated with inflammation and angiogenesis 
and KS is more common among individuals with immune deficiency.  The 
majority of work has focused on HLA and cytokine genes.  Results have 
not been overwhelming but this could mean that the wrong genes are 
being studied.  HLA-DRB1 was implicated in one study in the 
development of KS in KSHV infected individuals with HIV co-infection140.  
Other groups identified an IL-6 promoter genotype associated with 
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altered gene expression as a risk factor for development of KS in HIV-
infected men141. 
 
In a HIV-infected cohort a haemoglobin of less than 8.5g/dl was 
associated with antibodies to KSHV and high KSHV viral load142.  
Multicentric Castleman’s disease (MCD) is a frequently fatal disease 
associated with reactivation of KSHV.  In a recent study of MCD, in the 
multiple regression analysis, low haemoglobin was the strongest 
predictor of elevated KSHV viral load143.  
Corticosteroid therapy is associated with development of HIV-associated 
KS144, 145.  This is important due to the frequent use of steroids of a 
number of immune and infectious disorders associated with HIV.    
 
 
2.8 Risk factors for Kaposi’s sarcoma among Kaposi’s sarcoma-
associated herpesvirus infected individuals without overt forms 
of immune suppression 
 
This section briefly discusses factors that may explain development of KS 
without overt immune suppression. Co-factors for development of KS 
may set risk of disease at the time of primary KSHV infection, or later in 
the trajectory of infection and oncogenesis.  
 
2.8.1 Viral factors 
 
KSHV can be classified into major sub-types defined by the variability of 
the K1 open reading frame.  The five major subtypes (A, B, C, D and E) 
of KSHV146 have a distinctive worldwide geographic distribution94, 146-148.  
These sub-types do not correlate with patterns of KS occurrence or 
severity149.  Recent research has focused on KSHV microRNA sequences.  
Distinct polymorphisms in KSHV mircoRNA sequences have been 
reported in individuals with MCD150, HIV-associated KS151 and KSHV-
associated inflammatory cytokine syndrome (KICS)152.  Both MCD and 
KICS are characterised by very high KSHV viral loads and presumably 
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near-complete loss of viral control.  It is plausible that variant microRNA 
sequences may be associated with a more aggressive KSHV phenotype.  
 
2.8.2  Host factors 
 
KS in individuals without overt immune suppression has an overwhelming 
male predominance. In regions where endemic and classic types of KS 
occur, KSHV seroprevalence is similar in men and women. Historical 
studies have hypothesized that female sex hormones may be 
protective153 or male sex hormones promote154 for KS development. 
Alternatively, men and women may be differentially exposed to an 
environmental factor or factors. Epidemiological and biological data are, 
however, lacking.  The strong association between older age and classic 
and endemic KS may imply that exposure to factors over a long period is 
required.  Alternatively, factors associated with old age, such as 
progressive alternations to the immune system may be important, as 
discussed above111.  
 
Classic KS in Mediterranean men has been associated with HLA-DR5 and 
HLA-B18155, but no HLA association was found in a study of Jewish 
patients with classic KS156.  An interleukin-6-promoter polymorphism was 
identified in a familial case of classic KS, in which the disease occurred in 
four siblings who had no recognised underlying immunodeficiency157.  No 
HLA aberrations have been reported with endemic KS133.  Polymorphisms 
in the tumour suppressor gene p53 have not been reported to be a risk 
factor for the development of classic and endemic KS158.  Among KSHV-
seropositive Italians, classic KS risk was associated with diplotypes of 
IL8RB and IL-13159, 160.  
 
Classic KS has been reported to be associated with reduced haematocrit 
and reduced haemoglobin (<12g/dL)108.  In the anaemic state the total 
oxygen content of the blood is reduced and the blood fails to deliver 
oxygen to the tissues (hypoxia). KS has a tendency to occur in relatively 
hypoxic tissues; the edges of wounds or on the lower extremities161 
which has led to the hypothesis that anaemia or hypoxia may be co-
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factors for KS development. Hypoxia induces reactivation and replication 
of KSHV in vitro162. Cells exposed to hypoxic conditions accumulate 
hypoxia-inducible factors (HIF1/2), which control transcriptional 
activation of a number of genes responsive to low cellular oxygen163.  The 
KSHV genome contains at least two lytic genes with hypoxia response 
elements164.  Hypoxia may also induce KSHV reactivation via reactive 
oxygen species (ROS)165, 166.  ROS are highly reactive molecules 
containing oxygen and peroxides.  They are produced as a by-product of 
oxygen metabolism and are involved in normal cell functions.  Markers of 
oxidative stress are key features of KS lesions165, 166.  It has been shown 
that the ROS hydrogen peroxide induces KSHV reactivation directly166, 
and via inhibition of the NF-κβ pathway167.  In mouse models anti-
oxidants inhibit KSHV lytic replication and development of KSHV-related 
diseases168.  
 
2.8.3 Environmental factors 	  
An intriguing part of the clinical presentation of class and endemic KS is 
the location of the cancer on the lower limbs.  Areas of high incidence of 
endemic KS are characterised by a common geological substrate, 
composed of fertile reddish-brown volcanic clay soils.  Volcanic 
mountains fringe the western branch of the Great Rift Valley in eastern 
Congo, in western Uganda and Tanzania, and further south in Malawi169. 
The unusually high prevalence of endemic forms of KS in regions of 
intercontinental rifts and volcanism may point to prolonged exposure to 
indigenous iron oxide rich volcanic soils as a common aetiological risk 
factor2.  An association between classic KS and contact with soils has also 
been postulated; classic KS is found in areas with high iron and alumino-
silicate clays170.  A study of the geographic association with KS40 reported 
that areas where KS was relatively common were equatorial, humid and 
with an altitude of over 600m, where the population is mostly rural and 
likely to come into contact with ferrisol and ferralitic soils.  However, the 
absence of these environmental factors was not found for many areas 
with a low reported incidence of KS; both the Kenyan Rift valley and 
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Ethiopian plateau have these environments but low KS rates.  Whether 
these environmental factors are direct risk factors for KS or they are 
surrogate markers of another exposure is not known. 
 
 
2.9  Chapter Conclusion  
 
The presence of HIV infection is one of the strongest predictors of risk for 
KS in KSHV infected individuals.  The detection of antibodies to KSHV 
precedes and is predictive of development of HIV-associated KS.  The 
epidemiology of forms of KS not associated with overt immune 
suppression (so called classic and endemic KS) has distinct geographical, 
age and gender associations.  The pattern of occurrence of classic and 
endemic KS may reveal subtle co-factors for KS oncogenesis.   
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Chapter 3: The epidemiology of Kaposi’s sarcoma-associated 
herpesvirus. 
 
3.1 Chapter contents 	  
KSHV infection is universally found in KS tumours.  KSHV infection per 
se, is deemed necessary but not sufficient for KS development.  The 
majority of those infected with KSHV do not develop the neoplasm.  The 
incidence of KS largely mirrors KSHV seroprevalence in populations.  It is 
therefore of key importance to first understand which populations are at 
greatest risk of infection with KSHV.  Geographical differences of KSHV 
seroprevalence may suggest the involvement of as yet unknown host 
genetic, viral or environmental factors for risk of KSHV infection.  
Objectives:  
I. To describe general patterns of KSHV seroprevalence in adult 
populations around the world. 
II. To give a brief overview of KSHV sero-epidemiology in North 
America, Europe and Asia. 
III. To present a detailed description of patterns of KSHV seroprevalence 
in Africa and Uganda.  A critical review of relevant literature will be 
presented. 
IV. To discuss reasons underlying any potential geographical differences 
in KSHV sero-epidemiology and if this points to potential co-factors 
for infection. 
V. To overview key risk factors for KSHV seropositivity in sub-Saharan 
Africa. 
Summary: There is marked geographical variation in KSHV 
seroprevalence.  This has a profound influence on worldwide differences 
in KS incidence.  Epidemiological studies are needed to clarify potential 
reasons underlying this.  
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3.2 Serological assays for Kaposi’s sarcoma herpesvirus 
 
Epidemiological studies have used serologic tests to study patterns of 
infection with KSHV. KSHV encodes multiple antigenic proteins that are 
generally divided into in two groups, depending on the phase of the cell 
cycle when they are produced: lytic and latent. Serological assays are 
commonly either immunofluorescence assays (IFA) or enzyme-linked 
immunosorbent assays (ELISAs). IFAs are based on primary effusion 
lymphoma cell lines with expression of latent and lytic phase proteins. 
ELISAs are commonly based on recombinant proteins or peptides. 
 
In order to critically interpret worldwide patterns of KSHV seroprevalence 
it is key to understand both the limitations and strengths of the 
serological assays.  Marked discordance of KSHV seroprevalence between 
different assay types and laboratories has been reported.  In one study a 
test panel of serum samples from HIV-associated KS patients were 
tested for antibodies to KSHV using six assays (three different IFAs and 
three different ELISAs). The seroprevalence ranged from 61 to 100%. 
The same study also reported testing a panel of serum samples from 
children using the same six assays. KSHV seroprevalence ranged from 
0% to 20%171. Other groups have reported similar disagreements 
between assays and laboratories125, 172-174.  Possible reasons for variation 
in results are described below.   
 
Firstly, assay outcomes may differ if different antigenic products of KSHV 
have been used.  The immune response to antigenic KSHV epitopes is 
complex and not completely understood. Individual humoral responses 
on exposure to KSHV antigens are highly variable (For review see 
Robey102). The most consistently antigenic KSHV gene products; K8.1, 
ORF 73 and ORF 65, tend to be selected for epidemiological studies.   
 
Secondly, the choice between IFA and ELISA for detection of antibodies 
may influence the results. IFAs have been considered the reference test 
for detecting antibodies to KSHV175 but have a number of operational and 
performance issues.  The process of immunostaining for IFAs is laborious 
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and cannot be automated for a high throughput of samples.  IFA scoring 
is highly subjective and day-to-day variability in sensitivity is frequently 
high.  Sensitivity of IFAs in detecting antibodies to KSHV may be as low 
as about 60%172.  
 
Thirdly, it is important when selecting a KSHV antigen to consider length 
and conformation to maximize immunogenicity. Assays that use full 
length proteins expressed by a baculovirus system in insect cells have a 
better sensitivity and specificity compared to peptides or bacterially-
expressed proteins175.  
 
Fourthly, the algorithm for testing including definition of cut-off and use 
of more than one assay or antigen may affect the results.  The definition 
of seropositivity to KSHV is generally determined based on the ability to 
discriminate between groups with KSHV-associated disease and groups of 
healthy blood donors from populations were KSHV infection is rare.  The 
majority of epidemiological studies test for only one or two KSHV 
antigens, which may lead to under estimation of KSHV seropositivity.  
 
Assay limitations must be acknowledged when interpreting potential 
patterns of KSHV across populations and within risk groups.   
 
While KSHV serological assays have important limitations they have 
allowed important observations (For review see Tedeschi176) on global 
patterns of KSHV burden.  ELISAs for KSHV antibody detection have 
allowed automated testing of large numbers of samples for 
epidemiological studies. Careful evaluation of testing algorithms in 
different test populations using full-length insect cell-expressed protein 
has increased reproducibility and performance. ELISAs based on KSHV 
proteins K8.1 and ORF 73 used in this thesis have been rigorously 
developed by the Viral Oncology Section (VOS), National Cancer Institute 
(NCI). They have been shown to be reproducible, with a high specificity 
and sensitivity175 and have been used in over 40 epidemiologic studies 
worldwide.  
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3.3 Worldwide seroprevalence of Kaposi’s sarcoma-associated 
herpesvirus 
 
Figure 3.1 shows a world map derived from studies measuring antibodies 
to KSHV in “healthy” subjects without KS such as blood donors, or HIV 
negative subjects8, 11, 13, 14, 16-21, 24, 25, 28, 94, 129, 177-191. The methods for 
constructing this map are presented within the general methods chapter. 
Figure 3.1 shows a band of very high (greater than 60%) KSHV 
seroprevalence across East and Central Africa.  Antibodies to KSHV are 
also detected in a high proportion of populations studied in Southern 
Africa and in an indigenous population resident in the Brazilian Amazon 
region. KSHV seroprevalence is moderately high (16-30%) in studies in 
Brazil (outside of the Amazonian region), West Africa, Egypt and the 
Mediterranean.  The remaining areas of North America, Central America, 
China, Europe and East and South East Asia have low KSHV 
seroprevalence (less than 15%).  
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Figure 3.1: World map of KSHV seroprevalence from studies conducted between 1998 
and 2012.  Studies included needed to state that the population tested was without KS, 
“healthy”, blood donors and/or HIV negative.   
1Non-VOS: Study not conducted by Viral Oncology Section, National Cancer Institute 
2VOS: Study conducted by Viral Oncology Section, National Cancer Institute 
3KSHV-%: KSHV seroprevalence 
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KSHV seroprevalence will be briefly described for each major region in 
turn; North America and Northern Europe, South America, the 
Mediterranean, Asia and sub-Saharan Africa. Risk factors for KSHV 
seropositivity and transmission vary by geographic region and will be 
described under each major region.  A greater emphasis will be placed on 
KSHV epidemiology in Africa.  A discussion on the geographic variation in 
KSHV seroprevalence will then follow.  
 
3.3.1 Kaposi’s sarcoma-associated herpesvirus sero-epidemiology 
in North America and Northern Europe 
 
KSHV seroprevalence in the North American and Northern European 
general population is commonly reported as being about 1-3%127, 179, 192.  
In a USA based comprehensive study of KSHV seroprevalence using the 
National Health and Nutrition Examination Survey (NHNES) which 
sampled 13,894 adults from the US general population between 1988 
and 1994, the overall seroprevalence was low (around 1-2%)179.   
 
Relatively high levels of KSHV seroprevalence are reported in men who 
have sex with men (MSM).  In the NHNES, KSHV seropositivity in MSM 
was six-fold higher than in heterosexual individuals179.  Within MSM 
populations HIV infection is a major risk factor for KSHV seropositivity, 
with reported seroprevalence in HIV infected MSM of up to 77%129, 192-194.  
Self-reported markers of high-risk sexual behaviour in MSM are also 
associated with KSHV seropositivity. In MSM cohorts KSHV seropositivity 
is associated with increasing numbers of male partners179, 193, 195, history 
of a sexually transmitted infection193, antibodies to hepatitis B179 and 
herpes simplex virus179, 195.  Longitudinal studies report infection with 
KSHV was already highly prevalent among MSM populations when the 
HIV epidemic began in San Francisco, and its prevalence was maintained 
at a nearly constant level through the nineteen eighties and nineties196.  
 
HIV is not associated with KSHV seropositivity in other (non-MSM) HIV 
infected groups; heterosexuals, hemophiliacs and IV drug users, these 
groups have a KSHV seroprevalence similar to levels reported in the 
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general population192, 193. Among men reporting to be exclusively 
heterosexual KSHV seroprevalence is low and risky sexual behaviour is 
not associated with KSHV infection193.  
 
Reports from North America and Europe consistently demonstrate that 
KSHV seroprevalence is lower among women than among men.  Risk of 
KSHV infection among women in North America has less clear cut and 
consistent associations with HIV and sexual risk factors. A study of 
women in San Francisco Bay area reported a KSHV seroprevalence of 4% 
in HIV infected women and 1% in women at high risk of HIV197.  Other 
studies of KSHV and HIV in women have reported no or borderline 
associations between the two infections179, 198.    
 
Self-reported markers of high-risk sexual activity in women, such as a 
high lifetime number of male partners, a history of commercial sex and 
young age at the time of first intercourse were found to be associated 
with KSHV seropositivity in one study198, but not in another179.  
 
In adolescents in North America antibodies to KSHV are associated with 
MSM, risky sexual behaviour in males and African-American descent199.  
Children in North America and Northern Europe are at very low risk of 
KSHV seropositivity200. 
 
Despite the consistent reports of relatively high KSHV prevalence among 
MSM, it remains unclear if KSHV is sexually transmitted in this population 
or if sexual risk factors are a surrogate marker for some other mode of 
KSHV transmission. The exact mechanism of KSHV transmission remains 
unclear.  KSHV DNA is found more commonly in saliva than in semen, 
prostate or nasal secretions201, 202 and salivary contact has been 
postulated as the most likely route of spread.  KSHV is not widely 
disseminated in urogenital tissue203.  KSHV DNA is present at very low 
concentrations in semen204 and is often undetectable in semen205 and the 
prostate gland206.  It has been postulated that MSM are more likely to 
have a large number of sexual partners and this may increase the chance 
of contact with infected saliva.  Exposure to KSHV in heterosexual 
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populations is likely low. Women reporting a relatively large number of 
lifetime sexual partners (greater than 50) remain at low risk of KSHV 
seropositivity. KSHV seroprevalence in heterosexual men and women is 
similarly low179 suggesting that heterosexual intercourse is inefficient at 
KSHV transmission.  This may be accounted for by the fact that KSHV is 
found infrequently in semen and prostatic secretions and it is rarely 
detected in cervico-vaginal secretions207.  MSM may be more likely to 
have anal intercourse than heterosexual individuals, but no significant 
correlation between KSHV serostatus and receptive or insertive 
unprotected anal sex or oral-anal contact in MSM has been shown.  
Furthermore women reporting anal intercourse did not have an increased 
risk of KSHV198.  However it is difficult to implicate specific sexual 
behaviours as they are correlated with each other.	  	  Why then MSM are at 
greater risk of KSHV seropositivity than heterosexual populations in the 
USA and Europe is unclear.  In a study of HIV negative MSM in San 
Francisco use of amyl nitrates was strongly associated in the adjusted 
analysis with KSHV195 and this has been reported in a number of 
studies208, 209.  Amyl nitrates increase sexual drive, cause relaxation of 
the anal sphincter and potentially alter T-cell function, increasing 
vulnerability to infectious agents such as KSHV210.  The increased 
seroprevalence of KSHV in MSM could also potentially be due to the fact 
that MSM more likely to come into contact with a HIV-positive partner195. 
HIV-positive MSM are more likely to be infected with KSHV129, 192-194 and 
may shed the virus at higher quantities in their saliva211.  
 
In conclusion, in North America and northern Europe, KSHV 
seroprevalence is generally low among both men and women, but is 
higher among MSM and among people whose ethnic origin is a country in 
which KSHV is more prevalent (such as those of African origin). Among 
MSM, HIV and other markers of risky sexual activity are associated with 
KSHV.  The mode of KSHV transmission remains undefined. 
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3.3.2 Kaposi’s sarcoma-associated herpesvirus sero-epidemiology 
in the Mediterranean 
 
Countries in the Mediterranean have moderate KSHV seroprevalence in 
general population studies (Table 3.1).  Sardinia has a KSHV 
seroprevalence of 28-35%28, 212 and one of the world’s highest incidence 
rates of the classical sub-type of KS54.  Regional differences of KSHV 
seropositivity within Mediterranean countries including Italy and Greece 
have been reported54.  Due to the location and presence of classic KS, 
Israel is often considered with Mediterranean epidemiology and has 
similar KSHV seroprevalence rates213.  KSHV seroprevalence in the 
Mediterranean increases with age214 and is more common in men than in 
women215.  This epidemiological pattern mirrors the observation that 
classic KS occurs more commonly in older men54.  
 
A high KSHV seroprevalence in the first-degree relatives of individuals 
with classic KS and familial clustering of KSHV seropositivity has been 
reported157, 215.  The specific relationship (spouse, offspring, sibling) has 
no effect on KSHV seroprevalence, which suggests a predominantly non-
sexual horizontal transmission route of the virus within families. A study 
of KSHV seroprevalence and sexual risk factors reported that antibodies 
to KSHV were higher in HIV-infected MSM214. There was no increased risk 
of KSHV seropositivity compared to the general population associated 
with risky heterosexual behaviour or intravenous drug use214.  This 
finding is similar to North American studies179.  
 
A series of publications on KSHV, KS and blood sucking arthropods from 
Italy will be discussed later in the section in Chapter 5.   
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3.3.3 Kaposi’s sarcoma-associated herpesvirus sero-epidemiology 
in Asia 
 
Studies of KSHV epidemiology in Asia are sparse and those reported 
often have low sample size. Seroprevalence to KSHV in populations of 
Asia is low to moderate (Table 3.1 and Figure 3.1), ranging from less 
than 1-24%20, 178, 188-190.  One study reported that seroprevalence in 
Northern Thailand amongst heterosexual couples with HIV or at high risk 
of HIV is about 25%216.  This is more than two-fold higher than in 
healthy, blood donor populations in the same region.  Most couples (with 
HIV or at high risk of HIV) in this study were discordant for KSHV 
suggesting that the KSHV transmission event did not take place between 
husband and wife. Seroprevalence of KSHV in South and North Xinjiang, 
China was 23% and 26%, respectively188. Older age was independently 
associated with higher KSHV seroprevalence188.  Seroprevalence of KSHV 
in Chinese patients with chronic hepatitis B, acquired through unsafe 
needle practices, is about 30%217.  This is higher than other studies 
based in China and raises the possibility of KSHV transmission via 
contaminated needles.  No studies in Asia of children or MSM populations 
could be identified.  
 
3.3.4 Kaposi’s sarcoma-associated herpesvirus sero-epidemiology 
in South America and the Caribbean  
 
KSHV seroprevalence data from South American cities range from 1-
19%, which is similar to rates from North America and Northern Europe 
(Table 3.1 and Figure 3.1)20, 94, 181, 182, 190.  Reported rates of KSHV 
seroprevalence in Brazilian urban areas were 18-19% in a study of 
healthy adult participants182. KSHV seroprevalence was not associated 
with age, reported sexual behaviour or with markers of socioeconomic 
status. Women in a female general population study in Argentina had a 
seroprevalence of 6%20; there was no association with HPV infection 
status, number of lifetime sexual partners or age of first sexual 
intercourse. The women tested were between 20 and 75 years and 
prevalence remained steady with age.   
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One might expect that South Americans of African descent and Afro-
Caribbean’s may have a high KSHV seroprevalence in keeping with that 
found in Africa.  However, KSHV seroprevalence in these populations 
appears moderate to low.  In a population-based sero-epidemiological 
survey in a village in French Guiana, among 1337 individuals of African 
origin aged 2-91 years, the overall KSHV seroprevalence was 13% with 
no difference according to sex218.  KSHV seropositivity increased with age 
and there was strong mother-child correlation but no correlation between 
spouses suggesting non-sexual transmission mainly between mother and 
child.  Studies of Caribbean populations with a high proportion of African 
origin descendants (Cuba, Jamaica, Trinidad) have reported a low KSHV 
seroprevalence of between 1-4%20, 181, 190.  This might suggest that 
removal from the African environment leads to a reduction in KSHV 
transmission. Indeed, in a STD clinic in London KSHV seroprevalence was 
high in individuals born in Africa but not in second generation Africans219.  
 
Amerindian populations have a high reported KSHV seroprevalence. 
Antibodies to KSHV have been reported in nearly 60% of Amerindian 
populations182, 220. Seroprevalence is not associated with gender or age94, 
182. In Brazil antibodies to KSHV were associated with indigenous 
descent182.  The high KSHV seroprevalence in Amerindian populations has 
not yet been explained.  In one study Amerindian and non-Amerindian 
people living in the same area had markedly different KSHV 
seroprevalence suggesting that environmental co-factors are not 
associated with detection of antibodies to KSHV220. There have been 
limited reports of classic KS (HIV uninfected individuals) in Amerindian 
populations in the Amazon basin91. This will be discussed in the section 
on disease below. 
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3.4 Kaposi’s sarcoma-associated herpesvirus sero-epidemiology 
in Africa 
 
KSHV seroprevalence varies markedly across Africa (Table 3.1 and Figure 
3.1)8, 11, 13, 14, 16, 18-21, 24, 25, 187, 191.  Great interest lies in this variation as it 
may suggest as yet un-identified co-factors for infection that vary across 
geographical regions.   In broad terms in Africa, KSHV seroprevalence 
increases over a wide age range and is higher in HIV-infected 
individuals8, 9, 13, 18, 191 and patients with KS16, 127-131.  A literature search 
was carried out of reports of KSHV seroprevalence in HIV negative adults 
without a diagnosis of KS.  These limits were placed to reduce variation 
in KSHV seroprevalence by age, HIV and KS status (Table 3.2 shows the 
studies used in Figure 3.2 ordered by the year of study publication). The 
general pattern that emerges is a high KSHV seroprevalence band across 
East and Central Africa and lower KSHV seroprevalence at Africa’s poles8, 
11, 13-17, 19, 21, 24, 25, 127, 129, 131, 183, 187, 190, 191, 221-230.  The methods and critique 
of the literature review is in the general methods chapter.  
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Figure 3.2: KSHV seroprevalence in HIV negative adults without KS for all studies 
identified through a comprehensive literature search. 
1KSHV-%: KSHV seroprevalence 
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3.4.1 Elimination of population and assay factors that may affect 
patterns of Kaposi’s sarcoma-associated herpesvirus 
seroprevalence 
 
There are potential issues in taking results from all published studies of 
KSHV epidemiology in Africa.  Variation in KSHV seroprevalence may 
represent differences in the population tested, assay, sample size and 
year of study rather than true geographical variation.   To try and 
eliminate some of these issues only studies of HIV negative women, 
tested using a KSHV ELISA developed by VOS, NCI231, 232 were selected 
from Table 3.2 (Table 3.3)8, 14, 18, 20, 24, 25, 191, 227.  KSHV seropositivity 
results from women were selected, as studies of men were sparse.  Four 
of the eight studies only recruited mothers or pregnant women8, 13, 25, 191.   
Results from HIV positive individuals were excluded due to the 
association between HIV and KSHV in some studies.  All studies were 
conducted between 2002 and 2012, using a similar testing strategy 
currently used by VOS, NCI.  Although the number of studies is now 
small, the pattern of a high equatorial band of KSHV seroprevalence 
remains.   
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Figure 3.3: KSHV seroprevalence in HIV negative women in studies conducted by the Viral Oncology 
Section, National Cancer Institute. Studies used in this figure are tabulated in Table 3.3. 
1KSHV-%: KSHV seroprevalence 
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A KSHV or KS “belt” across Africa has been hypothesized233.  Dollard et al 
used a standardized set of serological assays and a number of different 
algorithms to define KSHV seropositivity on samples collected from 
young adults in the “KS belt” (Uganda), and outside the “KS belt” 
(Zimbabwe and South Africa).  In an analysis restricted to HIV negative 
adults and adjusted for age individuals in Uganda had significantly higher 
odds of KSHV seropositivity than Zimbabwe and South Africa.  
 
Both the tables and figures produced for this thesis and the study by 
Dollard et al233 suffer from similar limitations: varied sampling methods 
of cohorts KSHV antibody tested and limited knowledge of potential 
confounders.  Furthermore, data is lacking for many countries.  
Nevertheless, conservative conclusions can be drawn that a geographic 
pattern of KSHV seroprevalence in Africa does seem to exist. 
 
 
3.5 Kaposi’s sarcoma-associated herpesvirus seroprevalence in 
Uganda 
 
Studies of populations in Uganda report a broad range of KSHV 
seroprevalence in HIV negative adults without KS: between 35 and 86%8, 
19, 127, 129, 190, 221, 222, 224, 225, 228.  Seven studies which state the region, 
district or town of the population the sample was taken from were 
identified (Table 3.4, Figure 3.4)8, 19, 127, 129, 190, 221, 222, 224, 225, 228.  The map 
(Figure 3.4) shows areas of high KSHV seroprevalence (≥60%) in the 
West Nile, Western Region bordering the Congo, and Entebbe, with lower 
KSHV seroprevalence in the Eastern and Southwest regions.  Studies 
from the capital Kampala have reported a wide range of KSHV 
seroprevalence.  
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Figure 3.4: KSHV seroprevalence in seven studies conducted in Uganda with location of 
sample collection documented.  Study participants HIV negative adults without KS.  
Studies used are tabulated in Table 3.4.  
1KSHV-%: KSHV seroprevalence 
 
 
Published reports have suggested that the variation of KSHV 
seroprevalence across narrow geographic regions in Uganda exist.  But in 
terms of the validity of results the major recurring problem for 
investigating potential variation in KSHV seroprevalence remain (a) 
details of the population studied in terms of key confounders (b) the 
diversity of assay types and definition of KSHV seropositivity (c) the 
sample size and (d) year sample collected.   Confounders may include 
age, HIV and after co-infections.  
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In conclusion, the in-depth study of KSHV seroprevalence in Uganda 
highlights the need for caution in interpretation of serological data in 
terms of populations tested, assay, sample size and the year conducted. 
It remains unclear as to whether geographical variation in KSHV 
seropositivity exists.  Further studies with large sample size and using a 
standardized assay and collection of extensive data on potential 
confounders for infection and local environmental factors are needed.  
 
 
3.6   Factors that could underlie geographical variation of 
Kaposi’s sarcoma-associated herpesvirus prevalence 
 
Taking account of issues that may bias KSHV seroprevalence results, 
broadly speaking three factors could influence the geographical variation 
of KSHV sero-epidemiology.  These factors are: 
1. KSHV viral actors 
2. Host factors 
3. Environmental factors 
 
3.6.1 Kaposi’s sarcoma-associated herpesvirus viral factors  
 
The majority of the KSHV genome is highly conserved, but both ends of 
the genome show marked variability.  At the far left of the KSHV 
genome, ORF K1 encodes for a lytic transmembrane glycoprotein, which 
has a sequence variation of up to 30%234, 235. Five major subtypes (A, B, 
C, D and E) of KSHV are classified on the basis of open reading frame 
(ORF K1)146, 236 and show some worldwide variation in geographic 
distribution147, 236, 237.  KSHV subtypes from North America, Europe and 
Asia tend to be A and C and those from Africa are predominantly the 
subtype B.  Subtype D is rare and is found only in the Pacific Islands.  
Subtype E has been identified Brazilian among Amerindians94.   
 
At the right hand side of the KSHV genome is ORF K15, which has two 
forms: P and M237. The P form accounts for the majority of isolates 
worldwide, while the M form has been found in KS patients in Taiwan, 
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China and Africa.  There are a number of hypotheses to explain the 
variability of ORF K1149, 238, 239.  The major consensus is that KSHV is an 
“ancient human virus”239, which has evolved with the human host to a 
point of equilibrium so that KSHV can persist as a latent infection without 
risk of either host clearance or overwhelming KSHV infection that may 
kill the host.  ORF K1 is thought to have evolved very slowly and sub-
types reflect human migration out of Africa over the past 60,000 years 
(for review see Hayward239).  KSHV ORF K1 nucleotide sequences have 
not been found to change over time within an individual or during 
oncogenesis238.  There is no evidence to support K1 variability correlating 
to KSHV seroprevalence, KSHV-related pathologies or regions that report 
endemic KS149.  
 
KSHV encodes microRNAs which may have a central function in viral 
infection and oncogenesis240.  MicroRNAs are small (approximately 22 
nucleotide) non-coding RNAs that post-transcriptionally regulate gene 
expression by degradation of messenger RNA and at translation through 
repression of protein synthesis.   MicroRNAs are found in virtually all 
cells.  KSHV microRNAs have been shown to play a critical role in KSHV 
cell entry, endothelial cell reprogramming, KSHV gene expression, 
cytokine production, immune evasion, cell survival and immortalization 
(For review see Qin240). MicroRNA-K12-1, 9, and 11 expression have 
been shown to be associated with macrophage and endothelial cell 
susceptibility to KSHV entry240.   Increased cell vulnerability to KSHV 
infection may increase infection persistence and allow entry of virus to 
neighboring cells.  MicroRNA and risk of oncogenesis have been 
discussed in the section on KS.  Whether KSHV microRNA expression 
could account for geographic differences in KSHV infection rates is 
currently unknown, but this is an area of extensive research.  
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3.6.2 Host genetics 
 
The migration of modern humans out of Africa resulted in a population 
bottleneck and concomitant loss of genetic diversity241.  Differences in 
diet, climate, and exposure to pathogens resulted in geographically 
distinct populations experiencing different selection pressures that 
resulted in genetic changes242.  African populations are generally older 
than non-Africans and exhibit a larger diversity of genetic material.   
Research has identified host variation in the risk of many infections.  In 
Africa host genetic associations with malaria, tuberculosis, 
schistosomiasis and leprosy have been characterized243.  
 
Studies of genetic polymorphisms and KSHV infection have been limited 
and disparate in their findings.  Research into host genetic risk of KSHV 
infection or seropositivity has focused mainly on human leukocyte 
antigen (HLA) polymorphism.  A study based in South Africa, found that 
carrying of HLA alleles HLA-A*6801, HLA-A*30, HLA-A*4301, and HLA-
DRB1*04 was associated with increased shedding of KSHV DNA in 
saliva244.   But no such associations were found in a study examining the 
same HLA types in children in Uganda245.  A study in a relatively high 
KSHV endemic area in Sardinia found no HLA association with 
susceptibility to KSHV infection246.  In Italy a study of killer cell 
immunoglobulin-like receptors to class I HLA found no association with 
50 alleles and KSHV infection247.  
 
The Amerindian population has a high reported KSHV seroprevalence94, 
182.  This ethnic group shows a very low genetic diversity compared to 
other populations.  The Amerindian indigenous people have gone through 
two tight genetic bottlenecks; the first during migration from central Asia 
and the second when descendants were devastated by smallpox, 
influenza and pneumonic plagues during the Spanish invasion in the 15th 
and 16th centuries248.  Genetic polymorphisms associated with a high 
propensity to diabetes249 and autoimmune diseases250 are recognized in 
the Amerindian population, but studies of infection risk could not be 
identified. A study of Amerindian and non-Amerindian populations living 
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in close proximity along the banks of the Amazon River in Brazil reported 
that Amerindians had a KSHV seroprevalence of nearly 80% compared to 
6% in non-Amerindians251. It is unclear why a marked disparity in 
detection of antibodies to KSHV exists, but genetic characteristics of the 
Amerindian population may be important.  
 
Current evidence is not overwhelming in support of genetic predisposition 
to KSHV infection or reactivation, but studies are limited and HLA may 
not be the correct genetic marker to study. 
 
3.6.3 Environmental factors 
 
A number of environmental co-factors for KSHV seropositivity including 
parasites7, 8 and oncoweeds252 have been hypothesized.  Regional maps 
of climate, topography and infectious diseases do not in broad terms 
match that of KSHV seropositivity making a single discrete environmental 
co-factor unlikely. It does however remain plausible that some 
environmental factor or factors contribute in part to conditions for 
primary KSHV infection or reactivation and hence worldwide patterns in 
epidemiology. 
 
A search for an environmental co-factor that facilitates transmission of 
KSHV either by affecting how infectious an individual is, or how 
susceptible (or both), has drawn parallels with research into endemic 
Burkitt lymphoma and this malignancy’s aetiological agents, Epstein-Bar 
Virus (EBV) and malaria. An epidemiologic link between malaria and 
Burkitt lymphoma infection is suggested by the number of endemic cases 
of Burkitt lymphoma that occur in discrete geographic climates along the 
malaria belt across sub-Saharan Africa253. Malaria and EBV infection are 
considered to be co-factors in the oncogenesis of Burkitt lymphoma253.  
Malaria may influence age of primary EBV infection254, and or control of 
EBV reactivation and replication253. The association between parasites 
and KSHV will be explored later in the thesis.  
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The ‘‘oncoweed’’ hypothesis is that certain extracts of natural plant 
products in KS endemic regions cause frequent reactivation in people 
leading to increased shedding, transmission and risk of KS252. It was 
proposed that this might provide a biological mechanism to explain 
geographic variations in KSHV reactivation rates. Higher reactivation 
rates may explain higher prevalence, viral loads and transmission 
frequency in KS endemic African regions.  
 
Markers of poverty are common to regions with high KSHV 
seroprevalence in Africa and the Amazonian basin.  The association is by 
no means perfect; low socioeconomic conditions are widespread in parts 
of Asia however and prevalence of KSHV is low, whereas in parts of Italy 
where socioeconomic condition are comparatively much higher KSHV is 
elevated.  However, poverty may be associated with one or more co-
factors that could drive an increased risk of KSHV seropositivity.  Poverty 
is associated with poor health, malnutrition, poor hygiene, environmental 
contamination and prevalent infections.  All of these factors could 
potentially create a muted or abnormal immune response that could 
make KSHV infection more likely. Or factors associated with low 
socioeconomic status in Africa may make “risky” KSHV infection more 
likely: infection during early childhood, high cumulative lifetime exposure 
or high viral activity. Within African and Amerindian populations factors 
associated with low socioeconomic status tend to have null associations 
with KSHV seroprevalence8, 13.  This may be explained by the fact that 
individuals taking part in studies, even with high socio-economic markers 
in Africa, tend to all live under conditions of relative poverty.  
 
It is plausible that some environmental factor or factors contribute in 
part to conditions for primary KSHV infection or reactivation and hence 
worldwide patterns in epidemiology.  But, in conclusion, a large-scale 
study across all continents and coordinated through a single laboratory 
collecting extensive data on known and potential risk factors for KSHV 
infection, along with environmental information will be required to clarify 
the world geographical variation in KSHV seroprevalence and the 
potential reasons underlying it. 
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3.7 Factors associated with Kaposi’s sarcoma-associated 
herpesvirus seropositivity in Africa. 
 
This section will review risk factors for KSHV seropositivity in African 
populations.  
 
3.7.1 Risk of Kaposi’s sarcoma-associated herpesvirus 
seropositivity in childhood 
 
Table 3.5 presents studies of risk of KSHV seropositivity in childhood in 
Africa.  A significant proportion of KSHV infection occurs during childhood 
in sub-Saharan Africa, with seroprevalence ranging from 7-58% (Table 
3.5)8-10, 13, 22, 25, 27, 230, 255-261. As discussed above, comparison between 
studies is hampered by differences in serological assay, sample size, and 
population factors (age, HIV status) since regional variations in KSHV 
seroprevalence may also exist. Butler et al tested children in Uganda 
aged 1 to 9 years and South Africa aged 2-8 years for KSHV antibodies 
and found that KSHV seroprevalence among Ugandan children was much 
higher than among South African children256.  Further, in Ugandan 
children KSHV seropositivity increased with age, but was static among 
children in South Africa.  The authors proposed that the difference in 
relationship between age and KSHV infection among children in Uganda 
and South Africa might suggest differences in KSHV transmission.  This is 
an interesting hypothesis and potentially fits with discrete geographical 
differences in KSHV infection.  But currently this is the only study to 
directly compare the prevalence of antibodies to KSHV in children in and 
outside the “KS belt”233.  Further the different age ranges and sample 
methods between the Ugandan and South African children could account 
for the differences. Other studies, which have investigated KSHV 
seropositivity among children in South Africa13, 25 or Uganda8, 258 have 
found KSHV seroprevalence comparable between the two countries 
(Table 3.5).  Although differences in age ranges, structure and power 
within age categories could have affected the results.  Despite potential 
assay, study and regional differences in KSHV transmission, patterns in 
risk of KSHV infection in childhood can be observed.  KSHV seropositivity 
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tends to increase with age in the vast majority of studies identified and 
tabulated in Table 3.58-10, 13, 22, 25, 27, 230, 255-261.  The young age of primary 
infection and age trend implies horizontal non-sexual transmission.  
There is no evidence to support the transfer of KSHV in breast milk23, 25, 
and KSHV infection in neonates is uncommon, making vertical 
transmission unlikely23. There is considerable evidence that KSHV 
transmission occurs via saliva 27, 262. In Africa, transmission from mothers 
and siblings is most likely the predominant route 10, 25.   Out of ten 
studies identified of mother-child transmission8, 10, 13, 25, 230, 257-261 eight 
found the maternal KSHV serostatus was a key determinant of childhood 
serostatus8, 10, 13, 25, 230, 259-261.  Two studies did not; both of these had a 
sample size of about 30 mother-child pairs, and were unlikely to have the 
power to investigate maternal KSHV serostatus as a risk factor for 
childhood seropositivity257, 258.   A family study in rural Tanzania10 found 
KSHV seropositivity in the child strongly related to serological status of 
the mother.  This finding was repeated in a study in South Africa; 
mothers with a high titre of antibodies to KSHV were more likely to shed 
KSHV virus in saliva and have a KSHV seropositive child25.  A study 
conducted in an endemic population from Cameroon reported that KSHV 
transmission mainly occurs from mother to child and between siblings.  
In this study transmission was independent of plasma antibody levels of 
KSHV in infected relatives260.  It has been proposed that exposure to 
maternal or sibling saliva may occur during close contact, sharing of 
eating implements or pre-mastication of food256. Two studies have 
investigated siblings as a source of KSHV transmission and in both the 
KSHV status of the sibling was associated with KSHV serostatus of the 
child10, 260.  Only two studies have investigated risk of infection from 
fathers10, 260; one reported a positive association although risk was less 
than that from mothers and siblings10, and one reported no 
association260.  
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Across studies gender has little or no effect on KSHV seroprevalence8-10, 
13, 22, 25, 27, 256, 258, 259.  Markers of childhood socioeconomic status 
(household density, maternal education, maternal occupation, maternal 
income) have no associations with childhood KSHV seropositivity (Table 
3.5).  Water source, a potential marker of socioeconomic status and 
exposure to water borne parasites is not associated with KSHV 
seroprevalence in the three studies that investigated it as a potential co-
factor8, 27, 259.   Having a blood transfusion as a child has been 
investigated in two studies22, 258, one found none and the other a positive 
association. The study with a positive association was conducted within a 
sickle cell anaemia clinic in Uganda and children were likely to have had 
multiple blood transfusions258.  It is common practice in Uganda to ask 
relatives to donate blood for the child, if a transfusion is required and this 
could account for transmission of KSHV if the donor was KSHV infected.  
	  	   70	  
	  	   71	  
 
	  	   72	  
As mothers are the key source of KSHV infection for children in Africa, 
studies investigating the risk of KSHV seropositivity in African mothers 
are shown in Table 3.68, 13, 22, 25, 191, 259.  Maternal age was not related to 
KSHV serostatus in any study of KSHV serostatus in mothers and 
pregnant women.  The age range of studies of mothers tends to be 
narrow, reflecting the age range of women’s fertility and possibly 
accounts for this.  HIV had positive associations with risk of maternal 
KSHV and this is discussed in detail in a later section of this thesis.  In 
the two most recent studies8, 191 higher socioeconomic status and 
increasing educational attainment were associated with decreased KSHV 
seroprevalence in mothers. 
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3.7.2 Heterosexual intercourse and risk of Kaposi’s sarcoma-
associated herpesvirus in sub-Saharan Africa 
 
Evidence to support sexual transmission mostly comes from studies of 
MSM in North America and findings in Africa are not consistent.   Trends 
of increasing KSHV seropositivity with age in sub-Saharan Africa, raise 
the possibility of the role of sexual transmission8, 13, 25. Table 3.714, 18, 228, 
263-267 shows studies of background and laboratory diagnosed sexually 
transmitted infections, self-reported markers of sexual risk and KSHV 
seropositivity in sub-Saharan Africa. 
 
Associations with markers of sexual activity are not consistent between 
studies. For example, syphilis was associated with KSHV seropositivity in 
three of six identified studies (Table 3.7)18, 263, 264.  Within one study, 
Eltom et al18 reported from Nigeria that syphilis was a potential co-factor 
for antibodies to KSHV among men attending an STD clinic but not in 
women attending the same STD clinic or in female sex workers.  
Differences in sexual behaviour could lead to differences in results.   In 
Western cohorts while specific sexual behaviours have not been 
identified, MSM appear overwhelmingly at more risk than heterosexual 
men193.  It has been suggested that sexual contact among MSM is a 
surrogate for exposure to saliva193. The same could be true in Africa.  In 
a study of KSHV shedding in commercial sex workers in Kenya the 
prevalence of detection of KSHV was about one third in saliva and mouth 
swab samples but only 4% in cervical swabs and 2% in vaginal swabs268.  
If saliva is the most likely source of transmitted KSHV, then anecdotal 
reports that kissing practices in Africa are uncommon may account for 
low or no levels of KSHV transmission through close contact during 
heterosexual sex.  In conclusion, heterosexual transmission of KSHV in 
Africa may occur but is likely to be at low levels.  
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3.7.3 HIV as a risk factor for KSHV seropositivity in high-risk 
heterosexual cohorts in sub-Saharan Africa.  
 
HIV is different from other STDs as it is not only a marker for sexual risk 
behaviour but is also immunosuppressive.  Individuals infected with HIV 
may be more susceptible to and/or may be more likely to transmit KSHV 
infection. Of the eight studies identified from sub-Saharan Africa 
investigating heterosexual transmission of KSHV (Table 3.7) only one 
study set in Nigeria found HIV to be associated with KSHV seropositivity 
and this result was from a sub-analysis restricted to a female-only small 
reference population recruited predominantly from office and factory 
workers18.  In Africa, cohorts studying HIV and sexual risk are all 
presumed to be heterosexual.  The lack of association between HIV and 
KSHV in studies of heterosexuals is unsurprising and mirrors reports from 
North America and Europe.  Here KSHV infection is predominately found 
in HIV infected MSM and not consistently in other HIV infected groups; 
male and female heterosexuals, female sex workers, hemophiliacs and IV 
drug users192, 193.  It could be that in Africa all individuals susceptible to 
KSHV have already been infected by early adulthood, thus reducing the 
effect of HIV as a risk factor for primary KSHV infection. Current data 
suggests that HIV is not a risk factor for KSHV seropositivity in high-risk 
heterosexual populations in Africa. 
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3.8  Chapter conclusion 
 
There is marked geographical variation in KSHV seroprevalence and this 
has a profound influence on worldwide incidence of KS.  Limitations in 
serological assays and study design reduce clarity in understanding 
causes of this variation.  Important risk factors for KSHV seroprevalence 
in Africa include having a KSHV seropositive mother, increasing age and 
HIV infection in mother-child pairs.	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Chapter 4: General methods   
 
4.1 Outline of chapter 
 
This chapter outlines the two study populations detailed in this thesis and 
the KSHV serology method.  Specifics of the design for individual studies 
will be given within the relevant chapters.  
 
4.2 Socio-demographic position of Uganda 
 
In the last Ugandan Population and Housing census in 2006 269, 270.  The 
population of Uganda was estimated to be 24.4 million with a sex ratio of 
95 males to 100 females.  Children below 15 years constituted 49% of 
the population.    
 
Figure 4.1: Population pyramid for Uganda (2002): A population pyramid is a pictorial 
representation of the age and sex distribution for the population of Uganda. Chart taken 
from Uganda Demographic and Health Survey, 2006270.  
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The Ugandan population has grown dramatically over the past 50 years.  
The high growth rate is a result of high fertility and declining mortality 
rates.  The annual population growth rate between 1969 and 1980 was 
2.7 and decreased to 2.5 between 1980 and 1991.  Instability in Uganda 
during the early 1980s may have contributed to this decline.  The annual 
population growth rate increased to 3.2% between the 1991 census and 
the 2002 census.  The level of urbanisation is still low but has been 
increasing over time.  In 2002, less than one fifth of the Ugandan 
population lived in urban areas and urbanisation was about 10% of the 
population per year.  
 
If the annual population growth continues at its current growth of about 
3% per year the population of Uganda will be over 130 million by 2050.  
For comparison, the United Kingdom’s population growth rate is 
0.60%271, and the predicted population in 2050 is 70 million.  The UK has 
a similar landmass to Uganda of about 90,000 square miles.  
 
 
 
 
Figure 4.2: Ugandan demographic statistics from population censuses of 1948 through to 
2002. In Uganda data was derived from population censuses, which started in 1948 and 
subsequently were held in 1959, 1969, 1980, 1991, and 2002. Over this period, the 
population has increased almost five-fold. Data taken from Uganda Demographic and 
Health Survey, 2006270.   
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Although mortality in Uganda is falling and a aging of the population is 
expected, mortality rates still remain relative high for key WHO 
indicators.  The infant mortality rate was 76 per 1000 live births with an 
under-five mortality rate, per 1,000 live births, of 137269.  Only about 
60% of children are immunised against measles270. The maternal 
mortality rate per 100,000 live births was 880269.  In 2006, the life 
expectancy in years at birth for men was 48 years and for women 51 
years 269.  The top five causes of death for all age groups were HIV 
(22%), malaria (11%), lower respiratory infections (not including TB) 
(11%), diarrheal diseases (8%) and perinatal conditions (5%) 269.  HIV 
prevalence among adults (15-49 years) was 4.1% 269.  The annual per 
capita total expenditure on health at an averaged exchange rate for 2006 
was $18 USD per year, and the annual per capita government 
expenditure on health at an averaged exchange rate for 2006 was $5 
USD per year 269.   
 
In terms of markers of socioeconomic status, about 10% of the 
population had access to a sanitation facility (flush toilet, pit latrine, 
compositing toilet) and only 8% of households had access to electricity.  
Almost all (97%), reported using firewood and charcoal for cooking.   
Safe access to drinking water was available in 61% of households.  Only 
4% of households had a television, while nearly 50% had a radio.  
 
In the last Uganda Demographic and Health Survey (2006)270 the literacy 
rate of individuals above 10 years was 68%.  About 50% of the urban 
population and 17% of the rural population attended secondary school.  
Employment in the 12 months preceding the 2006 survey was high and 
reported in about 85% of women and 95% of men.  Occupation was 
reported to be in agriculture in about 80% of adult Ugandans, with the 
vast majority being self-employed.  The percentage of the population 
living below the poverty line on less than 1.25 USD per day was 85% 269.  
Gross domestic product per capita 2011 was about $450 USD per year 
271.  
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4.3 Entebbe Mother and Baby Study 
 
4.3.1 Setting 
 
All women recruited in this study were resident in Entebbe Municipality 
and Katabi sub-county, beside Lake Victoria, Uganda.  Entebbe and 
Katabi are situated in Wakiso District, approximately 25 miles southwest 
of Kampala, Uganda's largest city and capital.  The residential area for 
the women covers rural, urban and fishing communities.  
 
 
 
Figure 4.3: Map of study location 
 
 
4.3.2 Entebbe Mother and Baby Study trial methods 
 
The analysis of KSHV in mother-child pairs was nested within an existing 
study in Uganda - the Entebbe Mother and Baby Study (EMaBS).  This is 
a large double-blind randomised placebo-controlled trial designed to 
  Entebbe, Uganda 
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determine the impact of helminth infections and their treatment on 
vaccine responses and infectious disease outcomes in children 
(International Standard Randomised Controlled Trials no. 32849447); the 
details have been reported elsewhere35.   
 
Consenting women were recruited between April 2003 and November 
2005 from the government funded antenatal clinic at Entebbe hospital.  
About two-thirds of women in the study area seek antenatal care 272.  At 
an initial screening visit, eligibility was assessed and a questionnaire and 
blood sample taken.  Inclusion criteria were: planned delivery in the 
hospital and being in the second or third trimester of pregnancy.  
Exclusion criteria for enrolment included a haemoglobin <8g/dL, 
abnormal pregnancy, clinically obvious liver disease, refusal to receive a 
HIV test result, and known adverse drug reaction to anti-helminth drugs.  
At enrolment, sociodemographic data were collected and blood samples 
were obtained by venepuncture, and processed for syphilis, HIV serology, 
CD4 count and for examination for malaria parasites and Mansonella 
perstans.  A stool sample was obtained for examination for intestinal 
helminths.  Participants were then randomised to receive albendazole 
(400mg) and placebo, praziquantel (40mg/kg) and placebo, both 
albendazole and praziquantel, or two placebos, in a 2 by 2 factorial 
design.  During antenatal follow-up, ferrous sulphate (200mg; 60mg 
elemental iron) and folic acid (0.25mg) were given daily and 
sulfadoxine/pyrimethamine treatment for malaria was given twice in the 
second and third trimester.  Women found to be infected with HIV were 
offered single-dose nevirapine to prevent vertical HIV transmission and 
treated for syphilis if indicated.  In the early post-partum period, repeat 
stool and blood samples were taken and all women received a single 
dose of albendazole and praziquantel six weeks after delivery.  
 
The mother, father or guardian gave consent for study participation for 
the child, and children were then followed from birth.  At routine yearly 
visits, clinical data, blood for full blood count, blood slides for malaria and 
M. perstans and stool samples were collected from well children.  Any 
helminth infections were treated.  Children were seen for routine 
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vaccinations at 6, 10, 14 weeks and nine months.  Vitamin A was given 
at six months and at one year.  Children received routine twice-monthly 
visits by field workers.  If unwell, attendance to the study clinic for 
medical treatment was encouraged.  At approximately six weeks and 18 
months of age blood samples were obtained from children of HIV infected 
mothers to ascertain the child’s HIV status.  At 15 months children were 
randomised to receive three-monthly albendazole or placebo.  Visits and 
intervention continued quarterly from 15 months to five years.  The 
primary outcomes were: immunological responses to BCG and tetanus 
immunisation, and the incidence of infectious and atopic disease events 
in childhood (pneumonia, diarrhoea, malaria, measles, tuberculosis and 
vertical HIV transmission and atopic eczema).  
 
4.3.3 Diagnosis and treatment of infections in EMABS 
 
Stool was prepared using the Kato-Katz273, 274 method for identification of 
Hookworm, Schistosoma mansoni, Trichuris trichiura, Ascaris 
lumbricoides and Trichostrongylus species, and by charcoal culture for 
Strongyloides stercoralis274.  Two slides from a single stool sample were 
examined for each individual, within 30 minutes for hookworm, and the 
next day for other ova and parasites.  Egg counts were measured.  Blood 
was examined for M. perstans by a modified Knott's method275.  
Plasmodium falciparum was diagnosed by examination of thick blood 
films and asymptomatic malaria parasitaemia defined as the presence of 
parasites without fever.  A P. falciparum parasite count per 200 white 
blood cells was recorded.  In 6-week-old children HIV was indicated by 
plasma viral load.  In mothers, and children 18 months of age, HIV was 
identified using a triple rapid test serial testing algorithm276.  Women 
were screened for syphilis on a Rapid Plasma Reagin (RPR) test, with 
positive results being further tested for active syphilis, based on a 
definition of RPR titer ≥1:4 and a positive Treponema Pallidum 
Haemagglutination Assay (TPHA) result (both kits supplied by BIOTEC 
Laboratories Ltd., UK).  Helminth infections were treated according to 
study protocol, either during pregnancy (the trial intervention) or after 
delivery. In accordance with recommendations from the Ugandan 
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Ministry of Health: all women received intermittent presumptive 
treatment for malaria with sulphadoxine-pyrimethamine; HIV-positive 
women received nevirapine for prevention of mother-to-child HIV 
transmission, and, if they had a low CD4-count, were referred for 
treatment; RPR-positive women received benzathine penicillin. 
 
 
4.4 Rural Clinical Cohort 
 
4.4.1 Setting  
 
The study population was resident in Kyamulibwa sub-county, Masaka 
district in South West Uganda.  The study area is about 250km from the 
capital of Uganda, Kampala.  Kyamulibwa is a rural area, the nearest 
large town, Masaka, is about a one hour drive away.  The MRC/UVRI 
have a field station in Kyamulibwa, which consists of research clinics, 
laboratories, a surveillance field office, a data section, offices and a 
guesthouse.  The MRC/UVRI Unit is the major provider of general health 
care for the study population in the area.  
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Figure 4.4: Map of rural clinical cohort study area. 
 
 
4.4.2 Rural Clinical Cohort Methods 
 
The Rural Clinical Cohort (RCC)277-279 consists of HIV infected individuals 
identified through the General Population Cohort (GPC).  A small number 
of HIV seronegative individuals are also followed through the RCC to 
prevent potential prejudice against people living with HIV/AIDS.  The 
GPC was established by the MRC in 1989, to study the dynamics and 
natural history of HIV disease in a typical rural Ugandan community280-
282.  A population of approximately 10,000 in a cluster of 15 villages was 
studied from 1989 to 1999.  In 2000, the GPC was expanded to cover a 
further 10 villages.  The cohort is open and dynamic with new births, 
deaths and migrations reported at each round of follow-up; the current 
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population under survey includes approximately 20,000 people.  An 
annual census of the resident population collects data on births, deaths, 
in-migration and out-migration, age, sex, education, and relationship to 
household head.  This is followed by an annual household survey in 
which, all willing residents aged 13 and above are individually recruited 
and includes collection of blood specimens for HIV testing and a brief 
behavioural questionnaire.  Children (birth to 12 years) are included 
every third year.  Every four years, starting at baseline, information is 
collected on socio-economic status using a list of household assets.  The 
annual surveys have coverage of 60–70% of the resident census 
population in any given year.  The blood specimens are obtained at each 
annual survey.  Serum is tested for HIV-1 and the remainder is stored at 
-80 degrees in freezers in Entebbe.  The 23rd annual survey is currently 
underway.  The RCC consists of people living with HIV in 1989/1990 
(round 1) and HIV incident cases after that.  About 40% of HIV infected 
individuals from the GPC opt to join the RCC. 
 
4.4.3 HIV prevalence and incidence 
 
The Ugandan national prevalence of HIV infection reached a peak of 18% 
in 1992, before declining through the 1990s to about 6%283, 284.  HIV 
prevalence in the GPC has varied from 6.7 to 8.7% with an incidence, 
per 1000 person-years, of about 5.0285-287. While all participants of the 
serosurvey have a HIV test, uptake  for receipt of the HIV test results 
from the annual serosurvey never exceeded 10% prior to 2004.  An 
intervention including offering counselling and giving HIV test results in 
the home increased it to nearly 50% 288.   The date of HIV 
seroconversion is assigned to the middle of the interval between the last 
negative test and the first positive test.  The GPC used two independent 
enzyme immunoassays to establish HIV-1 status (Wellcozyme HIV-1 
recombinant VK 56/57, Murex Biotech, Dartford, UK; and Recombigen 
HIV 1/2, Trinity Biotech, Galway, Ireland).  Samples discordant on 
enzyme immunoassay and all first time positive samples were tested by 
western blot (Cambridge Biotech HIV-1 western blot, Calypte Biomedical, 
Rockville, MA, USA). 
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4.4.4 HIV care within the RCC 
 
RCC participants were reviewed in the study clinic at regular 
appointments.  A clinical questionnaire was filled in at each visit and a 
full physical examination carried out and documented.  CD4 cell counts 
were measured (FACSCount, Becton Dickinson, San Jose, USA) at 
baseline and every clinic visit and a serum sample was collected and 
stored at -80 degrees at MRC/UVRI in Entebbe.  Anti-retroviral therapy 
(ART), available from 2004, commenced in accordance with Ugandan 
Ministry of Health criteria; CD4 count of 200 cells⁄µL or below; or WHO 
clinical stage 4; or advanced WHO clinical stage 3 with persistent or 
recurrent oral thrush and invasive bacterial infections; or CD4 count of 
250 cells⁄µL or below during pregnancy.  First-line ART regime was 
zidovudine (AZT), lamivudine (3TC) and nevirapine (NVP), with the 
possibility of switching to stavudine for AZT toxicity and to efavirenz for 
NVP toxicity or concurrent tuberculosis treatment.  Patients on ART had a 
HIV viral load measurement (Amplicor MONITOR 1.5, Roche Molecular 
Systems, NJ, USA) at drug commencement and about every six months.  
HIV viral load of 400 copies/ml and above was considered detectable.    
 
4.5 Overview of serological assays for Kaposi’s sarcoma-
associated herpes virus 
 
A number of serological assays have been developed to investigate KSHV 
related pathology and epidemiology.  KSHV encodes for multiple proteins 
that are classified broadly by whether they are produced during lytic and 
latent cycle.  The most common antigens used in assays, due to 
relatively high immunogenicity, are latency associated nuclear antigen 
(LANA) encoded by ORF 73175, 192, 231, 232, 289, K8.1125, 175, 192, 231, 232, 289 and 
ORF 65125, 129, 172.  LANA or ORF 73 is a protein expressed during latency 
and inhibits p53 function. ORF 65 or small viral capsid antigen (sVCA) is 
a lytic phase protein thought to function in virion formation and 
structure.  ORF K8.1 is a lytic phase glycoprotein expressed on the cell 
surface.  The presence of antibodies to KSHV is normally used to define 
exposure to infection rather than protective immunity.  
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A “gold standard” clinical reference test for KSHV is currently lacking.  
The reasons for this are: (1) KSHV viral DNA in biological fluids is often 
of low copy number125, 290 and cannot be used as a marker of infection; 
(2) not all patients with KS, who are taken to be infected with KSHV, are 
found to be positive on serological assays127, 129, 172, 231; (3) populations 
taken as negative (healthy blood donors in North America or neonates) 
often have a seroprevalence of between 0-20%172, 174, 291; (4) host 
responses to antigens are highly variable98, 116; (5) the  performance of 
assays tends to vary across populations, making comparative 
interpretations difficult176, 231 and (6) kinetics of appearance of KSHV 
antibodies are not well known and diagnosis of evidence of KSHV 
infection using both latent and lytic class antibodies may be necessary to 
achieve adequate sensitivity for detection of KSHV in individuals with and 
without clinical KSHV-associated disease176.  The concordance between 
single antigen assays tends to be moderate or low125, 171-173, 175, 231, 292.  
This is a particular problem in low prevalence populations were the use of 
one KSHV antigen may underestimate KSHV seroprevalence.  The 
combination of the results of several assays or the use of a combination 
of several peptides or proteins in a single assay has been proposed to 
increase sensitivity175, 293 of assays. 
 
First generation KSHV serological assays were based on KSHV infected 
PEL cell lines and immunofluorescence assays (IFA).  These techniques 
have major disadvantages in terms of cost, labour, low reproducibility 
and difficulties in automation for testing a large number of samples175.  
Enzyme linked immunosorbent assays (ELISA) for KSHV antibodies have 
been developed to immunogenic recombinant proteins and peptides171, 
175, 231.  High throughput testing can be achieved with ELISAs and they 
tend to be of relatively low cost and maintain high sensitivity and 
specificity in a large number of settings.  
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4.6 KSHV serology in this analysis 
 
The KSHV assay used in this thesis is a recombinant ELISA to K8.1 and 
ORF 73 proteins developed by the Viral Oncology Section (VOS), National 
Cancer Institute (NCI), USA231, 232. Both their K8.1 and ORF 73 assays 
have a high performance accuracy with a sensitivity of 98.78% and 
89.02% respectively and specificity of 98.79% and 97.57% 
respectively175. All ELISAs in this analysis were transferred from VOS, 
NCI and performed at the Uganda Virus Research Institute (UVRI).  
 
4.6.1 K8.1 ELISA 
 
Recombinant K8.1 protein was diluted 1/5000 in 0.05M Sodium 
Carbonate / 0.05M Sodium Bicarbonate, pH 10.0 (Invitrogen, Carlsbad, 
CA) and 100 µl of diluted protein was added to each well of a flat–
bottom, 96-well, non-sterile Dynex Immulon 4 HBX microtitre plate 
(VWR, Bridgeport,NJ). Each plate was covered with a plate sealer and 
incubated overnight at 4 °C.  The wells were then washed 3 times with 
350 µl of in-house ELISA wash (300ml PBS Ph7.4 10x, 0.005% Tween 20 
(Sigma Aldrich), 2700ml distilled water) using an automated plate 
washer (model ELx405 Bio-Tek Instruments).  Assay buffer of a volume 
of 280 µl was used to block each well (2.5% BSA [Sigma-Aldrich], 2.5% 
normal goat serum [Equitech-Bio, Kerrville, TX], 0.005% Tween 20 
[Sigma-Aldrich] and 0.005% Triton-X 100 [Sigma-Aldrich] in dulbeccos 
PBS]) for 3h at 37 °C. 
 
Plates containing assay buffer were stored at -80 °C for transport and 
before use.  Plates were defrosted for two hours at room temperature.  
Plates were washed 3 times in 350 µl in in-house ELISA wash using an 
automated plate washer.  Diluted test and control sera (final volume of 
100 µl at 1/20 dilution in assay buffer) were pipetted into the wells and 
incubated at 37 °C for 90min.  In order to provide an internal control, 
samples from patients with KS and samples from an American blood 
donor population were run in triplicate as positive and negative controls, 
respectively.  Two blank wells containing assay buffer were included (see 
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plate layout below). Unbound antibodies were removed by washing five 
times with in-house ELISA wash using an automated plate washer and 
then tapped dry.  The conjugate was prepared by diluting Goat anti-
human IgG (g) alkaline phosphatase (ReserveAP™, KPL, Gaithersburg, 
MD) at 1:7500 in assay buffer and adding 100 µl to each well.  Plates 
were covered and incubated at 37 °C for 30 min.  After 5 washes, 100 µl 
of substrate, 1 step p-nitrophenyl phosphate, disodium salt (Pierce, 
Rockport, IL) was added to detect antigen–antibody complexes.  The 
plates were allowed to develop at room temperature, uncovered in the 
dark for 25min.  Absorbance was read at 405 nm using a model EL 808IU 
automated plate reader (Bio-Tek Instruments).  
 
4.6.2 ORF 73 ELISA 
 
Recombinant ORF 73 protein (0.5 mg/mL) was diluted 1/500 in 
phosphate buffer saline (PBS) (Invitrogen, Carlsbad, CA) and 100 µl of 
diluted protein was added to each well of a flat-bottom, 96-well, non-
sterile Dynex Immulon 4 HBX microtitre plate (VWR, Bridgeport, NJ). 
Each plate was covered with a plate sealer and incubated overnight at 4 
°C.  The wells were then washed 3 times with 350 µl of in-house ELISA 
wash (300ml PBS Ph7.4 10x, 0.005% Tween 20 (Sigma Aldrich), 2700ml 
distilled water) using an automated plate washer (model ELx405 Bio-Tek 
Instruments).  Assay buffer of a volume of 280 µl was used to block each 
well (2.5% BSA [Sigma-Aldrich], 2.5% normal goat serum [Equitech-Bio, 
Kerrville, TX], 0.005% Tween 20 [Sigma-Aldrich] and 0.005% Triton-X 
100 [Sigma-Aldrich] in Dulbecco’s PBS]) for 3h at 37 °C. 
 
Plates containing assay buffer were stored at -80 °C for transport and 
before use.  Plates were defrosted fir two hours at room temperature.  
Plates were washed 3 times in 350 µl with in-house ELISA wash using an 
automated plate washer.  Diluted test and control sera (final volume 100 
µl at 1/100 dilution in assay buffer) were pipetted into the wells and 
incubated at 37 °C for 90min.  In order to provide an internal control, 
samples from patients with KS, and samples from an American blood 
donor population were run in triplicate as positive and negative controls, 
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respectively.  Two blank wells containing assay buffer were included (see 
plate layout below).  Unbound antibodies were removed by washing five 
times with in-house ELISA wash using an automated plate washer and 
then tapped dry.  The conjugate was prepared by diluting Goat anti-
human IgG(g) alkaline phosphatase (ReserveAP™, KPL, Gaithersburg, 
MD) at 1:5000 in assay buffer and adding 100 µl to each well.  Plates 
were covered and incubated at 37 °C for 30 min.  After 5 washes in 350 
µl in in-house ELISA wash, 100 µl of substrate 1 step p-nitrophenyl 
phosphate, disodium salt (Pierce, Rockport, IL) was added to every well 
to detect antigen–antibody complexes.  The plates were allowed to 
develop at room temperature, uncovered in the dark for 30min.  
Absorbance was read at 405 nm using a model EL 808IU automated 
plate reader (Bio-Tek Instruments).  
 
4.6.3 Assay intra-plate quality control  
 
For the assay results to be considered valid, the mean of the two 
blanking wells was calculated and required to be between -0.05 and 
0.05.  The mean of the blank wells was subtracted in turn from each 
negative and positive control value.  For K8.1, each negative control 
value needed to have an optical density value between 0 and 0.2, after 
subtracting the mean of the two blanking well's OD value. For ORF 73, 
each negative control value needed to have an optical density value 
between 0 and 0.1, after subtracting the mean of the blanking well OD 
values. For both K8.1 and ORF 73, each positive control value needed to 
have an optical density value greater than 1.5, after subtracting the 
mean of the two blanking well's OD value. 
 
4.6.4 Calculation of cut-off 
 
For the K8.1 ELISA the cut off was set as the mean of the negative 
controls plus 0.75 for each plate.  For the ORF 73 assay, a cut-off was 
empirically set at the mean of the negative controls plus 0.35 for each 
plate.  
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4.6.5 Titres 
Plasma or serum samples that were KSHV seropositive (optical density 
above cut-off) were identified.  These samples were then selected for a 
titre ELISA.  The assay protocol for titres was identical to those above.  
For K8.1, samples were titrated in 2-fold serial dilutions from 1:20 to 
1:20480 across the plate.  For ORF 73, samples were titrated in 2-fold 
serial dilutions from 1:100 to 1:102400.  The titre value is the dilution 
before which the sample loses positive signal, when the optical density 
falls below the cut off.  A negative sample was negative at the first 
dilution and was given a titre value of zero.  A high titre positive sample 
may still be positive at the last dilution and was given a titre value of 
1:20480 for K8.1 and 1:102400 for ORF 73.  
4.7 Validation of assay transfer 
 
The assays were transferred to the Ugandan Virus Research Institute 
(UVRI) from the Viral Oncology Section (VOS), National Cancer Institute 
(NCI), USA and analysis of the positive and negative controls showed 
comparable performance at NCI and UVRI (Table 4.1).  Each plate was 
checked and passed assay intra-plate quality control as above.  Each 
plate was set up with three positive controls and three negative controls 
and the mean of positive controls and negative controls was calculated.  
This resulted in 114 mean positive and 114 mean negative control results 
from VOS, NCI, and 48 mean positive and 48 mean negative control 
results from UVRI, Uganda.  The number of samples testin in Uganda 
were limited by the number sent from VOS, NCI.  Each plate tested (114 
at VOS, NCI and 48 at UVRI) had a cut-off value calculated.  For the ORF 
73 assay, the cut-off was the mean of the negative controls plus 0.35 for 
each plate. For the K8.1 ELISA the cut off was the mean of the negative 
controls plus 0.75 for each plate.  The results for the mean of the 
positive controls, the mean of the negative controls and the cut-offs were 
imported into StataSE11 and median and 95% confidence intervals 
calculated (Table 1).  The performance of the assay at VOS, NCI and 
UVRI, Uganda was considered comparable.  
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4.8 Assay quality control 
 
For the first run of study samples at MRC Uganda, two hundred samples 
were repeated randomly across both K8.1 and ORF 73 plates to check for 
consistency of ELISA results.  All 25 K8.1 ELISA plates and 25 ORF 73 
ELISA plates included in the analysis passed quality control.  For K8.1, 
the mean optical density of the negative controls was 0.04, range 0.01-
0.06, SD 0.02.  For ORF 73, the mean optical density of the negative 
controls was 0.02, range 0.01 to 0.05, SD 0.01. For K8.1, all blank 
optical density values were less than 0.19, and for ORF 73, all blank 
optical density values were less than 0.11.  The mean cut-off for K8.1 
Table 4.1: Comparison of median optical density results for positive and negative 
controls and plate cut-offs tested at Viral oncology Section (VOS), National Cancer 
Institute (NCI) and at UVRI, Uganda.  
 
 
K8.1 Positive 
controls K8.1 Negative controls K8.1 Cut-off 
 VOS Uganda VOS Uganda VOS Uganda 
Median 2.28 2.18 0.09 0.06 0.85 0.82 
95% CI 
1.70-
2.82 
1.86-
2.83 
0.06-
0.15 0.05-0.08 
0.81-
0.86 
0.80-
0.83 
       
       
 
ORF 73 Positive 
controls 
ORF 73 Negative 
controls ORF 73 Cut-off 
 VOS Uganda VOS Uganda VOS Uganda 
Median 2.47 2.61 0.04 0.06 0.39 0.41 
95% CI 
2.03-
3.09 
2.25-
3.14 
0.02-
0.07 0.04-0.09 
0.37-
0.42 
0.40-
0.44 
       
Each positive or negative control tested in triplicate. The mean of the three positive 
or three negative controls used in the analysis.  
Analysis based on 114 positive and 114 negative control means tested at VOS, NCI 
and 48 positive and 48 negative control means tested at UVRI, Uganda.  
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(mean negative controls plus 0.75) was 0.81, 95% CI 0.81-0.82 and for 
ORF 73 the mean cut-off (mean negative controls plus 0.35) was 0.41, 
95% CI 0.40-0.41.  The Kappa score for agreement for the 200 duplicate 
samples for positive/negative outcome for K8.1 was 0.82 and for ORF 73 
was 0.91.  These scores represent almost perfect agreement294, 295.  After 
this run it was standard practice to run 10% of samples tested in 
duplicate.  No issues were identified with quality control. 
 
 
4.9 Methods for literature reviews 
 
4.9.1 The epidemiology of Kaposi’s sarcoma among individuals 
without overt immune suppression; methods for section 2.4.3 
 
To aid description of the potential geographical variation in endemic and 
classic KS a critical literature search was undertaken of this cancers 
occurrence. First, data available from GLOBOCAN 2008, but the required 
information was not available296. A Google search was then carried out 
for online cancer registry databases available in English on the 11th June 
2012.  Search terms “cancer registry” or “cancer data” and each “country 
name” as listed by the Centers for Disease Control and Prevention, 
Atlanta, USA,  (http://wwwnc.cdc.gov/travel/destinations/list.htm/) were 
used.  Two were identified: United States Surveillance Epidemiology and 
End Results (SEER)82 and the United Kingdom’s Office for National 
Statistics (ONS)83, 84.  Next, a PubMed search was made for “cancer 
registry” or “cancer” or “classic Kaposi’s sarcoma” or “endemic Kaposi’s 
sarcoma” or “Kaposi’s sarcoma”.  Review articles were searched for 
relevant publications. Only articles published in English were considered.  
Due to the influence of age on crude incident rate, publications were first 
searched for age-standardised incidence rates in a population of a million 
in men, for “classic” KS or “endemic” KS.  After the initial results, data 
was sparse and the search was widened to include age-standardised 
incidence rates per million population for any sub-type of KS in men 
diagnosed either over the age of 60 or prior to the HIV epidemic (1980).  
A date prior to 1984 was accepted for the Faroe Islands. The results of 
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this search are tabulated in Table 2 in Chapter 2 by continent and in 
alphabetical order.  The results from Table 2 were plotted on a world 
map (Figure 2.2, Chapter 2)8, 13, 14, 16-21, 24, 25, 28, 94, 129, 178-191.  
 
This search has many limitations in the quality and quantity of data 
available in the public domain.  Indeed, there was not a great amount of 
cancer registry data in the public domain.  Although, limiting the search 
to publications in English may have affected this.   Only two countries 
(Israel and Italy) had available data specifically about KS without overt 
immune suppression.  An age cut-off of 65 or 60 years and a calendar 
cut-off of 1980 may not be sufficient to exclude HIV-related KS.  KS, 
compared to other cancers tends to be easier to diagnose on visual 
inspection but misclassification cannot be ruled out.  Information on 
diagnosis made by histology was not available in the majority of 
publications. The population at risk used in the calculation of incidence 
may be unreliable for census data from older time periods (1970’s) and 
from Africa. Reports from sub-Saharan Africa all suffered from limited 
population coverage of cancer registration and it is difficult to ascertain 
how representative the cancer data is of true population risk.  A numbers 
of studies identified from Africa only presented prevalence data, 
representing burden and were not included in this review.   
 
 
4.9.2 Antibodies to Kaposi’s sarcoma-associated herpesvirus 
among individuals with HIV-associated KS; methods for section 
2.6.4 
 
In order to present available evidence of the association between the 
presence of antibodies to KSHV and risk of HIV-associated KS in sub-
Saharan Africa, a literature search was undertaken in PubMed up to an 
including 24th October 2012.  Terms searched for were “Africa” and 
“Kaposi’s sarcoma” or “KSHV” or “HHV-8”.  The tables published by the 
International Agency for Research On Cancer were cross-referenced.  
Inclusion criteria were (1) study population in sub-Saharan Africa, (2) 
KSHV serological technique (rather than viral load assessment), (3) 
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study subjects or cases were HIV-positive individual with KS, (4) 
comparison or control group were HIV-positive persons without KS.  
Studies measuring KSHV viraemia or investigating endemic (HIV-
negative KS) or transplant-associated KS were excluded.   
 
Thirteen studies of antibodies to KSHV and HIV-associated KS from sub-
Saharan Africa were identified. Five studies were excluded as they 
measured KSHV DNA by a polymerase chain reaction technique122, 297-300.  
One study was excluded as it investigated endemic KS301. One was 
excluded as the comparison group was described as a “general 
population” and HIV status was not given302.   
 
Studies investigating the presence of KSHV antibodies and KS in sub-
Saharan Africa are tabulated in Table 2.3, Chapter 2 in order of 
publication date16, 127-131.  All studies were cross-sectional or case-control 
in design. Only one study included children16. In all studies the 
prevalence of antibodies was higher in individuals with HIV-associated KS 
than in HIV-positive individuals without KS.  Two studies estimated the 
risk of HIV-associated KS by increasing fluorescent intensity signal to 
KSHV antigens128, 131; in one the comparison group included both HIV 
positive and HIV negative individuals131. The majority of studies (five of 
six) had small study size, particularly in respect to the number of 
samples from HIV-positive individuals with KS.  Five of six studies solely 
used an IFA technique to estimate antibodies to KSHV, which is potential 
prone to poor sensitivity and specificity.  No study reported repeat 
testing of samples or using a range of cut-off for definition of KSHV 
seropositivity. No study presented formal titres to KSHV antigens.  
Information of the whether HIV-associated KS was diagnosed clinically 
and/or confirmed histologically was limited in all studies. No study 
presented results by age; given that KSHV seroprevalence in sub-
Saharan Africa increases with age this may be important.  
 
 
 
 
	  	   97	  
4.9.3 Antibodies to Kaposi’s sarcoma-associated herpesvirus 
predating the development of HIV-associated Kaposi’s sarcoma; 
methods for section 2.6.4 
 
A PubMed search was carried out for longitudinal studies using KSHV 
antibody titre to determine risk of HIV-associated KS prior to diagnosis.  
Due to a prior knowledge of the literature the search included studies 
conducted worldwide and was not restricted to Africa.  The search 
included all listed studies on PubMed up to and including the 12th October 
2012.  Terms searched for in PubMed were “Kaposi’s sarcoma” or “KSHV” 
or “HHV-8”.  Tables published by IARC were cross-referenced126.  
Inclusion criteria included (1) presenting data on prevalence or titre of 
antibodies to KSHV prior to a diagnosis of KS, and (2) control of 
comparison group that were HIV-positive and without KS. Studies 
investigating KS among transplant recipients or HIV-negative KS 
(endemic or classic) and studies of MCD and primary effusion lymphoma 
were excluded.  
 
Twenty-eight studies were identified. Studies were excluded on the basis 
of investigating KSHV viraemia (3)113, 114, 118, KS among transplant 
recipients (9)106, 303-310 and individuals with MCD or primary effusion 
lymphoma (5)311-315.  Eleven studies were included investigating the 
presence of antibodies to KSHV and risk of KS prior to KS diagnosis, and 
are tabulated in Table 2.4, Chapter 2 in order of year of publication33, 115-
117, 127, 132-137.  Four studies were case-control in design and the remaining 
seven were cohort studies.  No studies were found that included children.  
 
Only one study had more than 100 cases of HIV-associated KS, the 
remainder had relative small sample sizes117.  Three of eleven studies 
used only an IFA assay, which may be prone to false positives and false 
negatives115, 134, 136.  No longitudinal studies were identified for HIV-
associated KS in sub-Saharan Africa or any country considered endemic 
for KSHV infection.  This may be important if repeated exposure to the 
virus affects KSHV viral reactivation and antibody titre. Five of the eleven 
studies did not adjust for any potential confounders33, 116, 132, 133, 137; age 
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and sexual risk factors may be important.  Only two of eleven studies 
reported a quantitative analysis of risk of KS33, 117; one study by titre and 
one by fluorescent intensity to KSHV antigens.  
 
4.9.4 Worldwide seroprevalence of Kaposi’s sarcoma-associated 
herpesvirus, methods for section 3.3 	  
To aid description of worldwide patterns of KSHV seroprevalence a review 
of published literature was carried out.  The critical review had two 
phases: first a literature search of studies conducted by the VOS, NCI 
was conducted. This restriction was placed to limit issues with directly 
comparing seroprevalence results between IFA and ELISA and between 
assays from different laboratories.  Next, countries without a VOS, NCI 
study were added.    
 
PubMed was searched up to and including 31st July 2012. The search 
terms used were “KSHV” or “HHV8” each “country name” as listed by the 
Centers for Disease Control and Protection, Atlanta, USA.  
(http://wwwnc.cdc.gov/travel/destinations/list.htm/).  Articles displayed 
in PubMed were reviewed and links to related articles and reference lists 
were checked. All published literature investigating KSHV seroprevalence 
were eligible for identification and screening. The first screening process 
consisted of removing duplicates and selecting studies published by VOS, 
NCI.   Once a list of studies by VOS, NCI was complied the all identified 
publications were re-screened to identify KSHV seroprevalence data in 
countries without a VOS, NCI study.  If more than one publication 
available the most recent in terms of publication date was included.  
Inclusion criteria were; (1) KSHV seroprevalence data estimated using 
ELISA, Western Blot or IFA, and (2) report had to state that the 
populations tested were without KS, “healthy”, “blood donors” and/or 
HIV negative.  These limits were chosen to limit the potential impact of 
KS, HIV and sexual risk group on KSHV seroprevalence.  Due to the 
potential increased risk of KSHV seropositivity and KS in HIV infected 
individuals in sub-Saharan Africa, studies for this region had to present 
data on laboratory defined HIV negative individuals.  The major exclusion 
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criteria were (1) reviews, tutorials, letters, and editorials; (2) duplicate 
data; and (3) publications that were not written in English.  
 
Twenty-eight publications were identified (Table 3.1, Chapter 3) 
containing results from 36 countries8, 13, 14, 16-21, 24, 25, 28, 94, 129, 178-191.   Two 
studies were included for Brazil as KSHV infection rates may significantly 
differ between Amerindian communities and other Brazilian populations94, 
182, 251.  Study populations were varied and methodological details of 
selection and enrolment of study participants were largely absent.   Five 
of the studies had a small sample size with 100 of fewer participants. 
These studies tended to have been published prior to the year 2000 and 
used an IFA tool.  No general population studies that fitted criteria for 
this search could be identified for Ireland, Canada, Russia, Pakistan, 
Indonesia, Australia, New Zealand or any country in Central Asia.  The 
only country in Western Asia with KSHV seroprevalence data was Israel.   
 
4.9.5 Kaposi’s sarcoma-associated herpesvirus sero-epidemiology 
in Africa, methods for section 3.4 
 
To allow a description of potential regional variation in KSHV infection 
across Africa a comprehensive literature search of studies presenting 
KSHV seroprevalence in HIV negative adults without a diagnosis of KS 
was conducted (Table 3.2, Figure 3.2, Chapter 3)8, 13-17, 19, 21, 24, 25, 127, 129, 
131, 183, 187, 190, 191, 221-230.   The search was conducted in PubMed using 
“KSHV” or “HHV8” and “Africa” and Google Scholar using “KSHV” and 
“Africa” up to and including 6th July 2012.  Links were then followed to 
related articles and reference lists in identified articles and reviews were 
also checked for KSHV seroprevalence data. To be included; (1) the 
study had to use a IFA, ELISA or Western blot assay for KSHV serology, 
(2) test and state that the population was HIV negative, and (3) be 
conducted among individuals described as adults, “childbearing” or over 
the age of 12 years.  Only articles published in English were assessed for 
inclusion and conference proceedings, abstracts, theses, dissertations or 
national or local vital statistics data not published as peer reviewed 
articles were not included.  
	  	   100	  
 
All studies were cross-sectional.   Study design was variable.  Selection 
of study populations and limited reporting of methods makes assessment 
of comparability between studies difficult.  The majority used the 
antibody results of more than one KSHV antigen to define KSHV 
seropositivity.  As discussed above comparison of assay results between 
laboratories may be problematic.  Studies conducted prior to 2000 (Table 
3.2, Chapter 3) had small samples size (≤100) and used an IFA, which 
may be prone to false positives and false negatives.  Age ranges in the 
studies were wide and may have confounded the KSHV seroprevalence 
results. Studies have been conducted in relatively few countries and 
prevalence is unknown for most countries.	  	   
 
The use of different serological assays and testing populations of 
different age, HIV and KS status has made accurate mapping of potential 
variation of KSHV occurrence problematic. Previous descriptions of KSHV 
seroprevalence in Africa have not taken these factors into account5, 227.  
To eliminate issues that may cause variation in KSHV seropositivity only 
studies conducted using an assay originating from VOS, NCI among HIV 
negative women were selected (Table 3.3, Chapter 3).  KSHV 
seropositivity results from women were selected, as studies of men were 
sparse.  Four of the eight studies only recruited mothers or pregnant 
women8, 13, 25, 191.   Results from HIV positive individuals were excluded 
due to the association between HIV and KSHV in some studies (Table 3, 
Chapter 3, included odds ratio of association between antibodies to KSHV 
and women HIV infection compared to HIV negative).  
 
4.9.6 Kaposi’s sarcoma-associated herpesvirus seroprevalence in 
Uganda; methods for section 3.5  
 
Reports of KSHV seropositivity among HIV negative adult populations in 
Uganda vary widely between 35 and 86%8, 19, 127, 129, 190, 221, 222, 224, 225, 228.  
To investigate potential reasons for these wide-ranging results, studies 
conducted in Uganda were tabulated (Table 3.4, Chapter 3)8, 19, 127, 129, 190, 
221, 222, 224, 225, 228.  Eleven studies of KSHV seroprevalence in HIV negative 
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adults without KS conducted in Uganda were identified (Table 4, Chapter 
3) from the search in the section above.  Figure 3.4, Chapter 3 pictorially 
represents KSHV seroprevalence of the seven studies shown in Table 3.4, 
which state the region, district or town of the population the sample was 
taken from were resident.   
 
Only one identified study222 reports an analysis of samples from defined 
geographical regions across Uganda and these found moderate regional 
KSHV variation. This study utilized archival plasma samples from the 
Uganda HIV-AIDS sero-behavioural survey (UHSBS) conducted in 2004–
2005.  The UHSBS is reported to be a nationally representative 
population-based sample of people in Uganda. It has important potential 
limitations in that the sample size from each district was small and no 
clinical information on KS was collected.  There is marked variation in 
KSHV seroprevalence in the Ugandan capital Kampala.  Each of the four 
studies based in Kampala used a different assay and definition of KSHV 
seropositivity.  Two studies222, 224 were based on a relatively small sample 
size.  Two of the four studies conducted in Kampala use samples from 
the blood bank221, 222 and one used samples collected at the main 
hospital225.  Kampala hosts the only tertiary referral Unit in Uganda and 
hospital and blood bank based studies in Kampala likely contain samples 
from individuals resident across the country.  Neither source is likely to 
represent the general population.  
 
Sample size is important for precision of an estimate.  To pictorially 
represent this, KSHV seroprevalence was plotted against decade in which 
the samples were collected with dot size proportional to the study sample 
size (Figure 4.5 below).  It can be more clearly seen in that the older 
studies had low sample sizes and low power.  
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Figure 4.5: KSHV seroprevalence in HIV negative adults without KS in eleven studies 
identified through a comprehensive PubMed search.  KSHV seroprevalence results from 
each study were plotted against the decade the samples were collected.  The size of dot 
for each study represents the study sample size.  Studies included in this figure are 
tabulated in Table 3.4, Chapter 3.  
 
For the study conducted by Biryahwaho et al222 KSHV seroprevalence for 
all regions combined was plotted.  In addition to sample size, the decade 
the sample was collected may effect KSHV seroprevalence in a number of 
ways: (1) all serological assays were conducted between 1996 and 2011, 
samples collected in the 1960’s and 1970’s may have undergone a 
number of freeze thaw cycles which can degrade protein and hence 
antibody levels, (2) first generation KSHV immunofluorescence assays 
(IFA) tend to have issues with reproducibility and cross reactivity with 
other herpesviruses171, 175, 292, they are labor intensive and so prevent 
high through-put of samples and (3) the AIDS epidemic commonly taken 
to have commenced in the 1980’s may have effected KSHV 
seroprevalence in some way (cohort effect). In terms of the most valid 
estimate of KSHV seroprevalence in Uganda, the two most recent studies 
which both use two ELISAs (one to a lytic protein and one to a latent 
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protein) and have study sizes over 1500 are probably the most reliable 
estimates.  
 
4.10 Ethics 	  
Approval was given by the Science and Ethics Committee, Uganda Virus 
Research Institute; the Uganda National Council for Science & 
Technology; the London School of Hygiene & Tropical Medicine and the 
University of York.	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   104	  
Chapter 5: Risk factors for Kaposi’s sarcoma associated 
herpesvirus seropositivity in mother-child pairs in Uganda 
 
5.1 Chapter abstract 
 
Background: Studies from Uganda report high Kaposi’s sarcoma 
associated herpesvirus (KSHV) seroprevalence.  In sub-Saharan Africa, 
primary KSHV infection often occurs in childhood.  Transmission from 
mothers during childhood is likely a predominant route.  This study 
investigates common infectious agents including HIV and parasites as 
potential co-factors for KSHV transmission.   
Methods: We measured antibodies against KSHV, by ELISA, in 1823 
paired plasma samples from pregnant women and their subsequent 
children in Uganda. We examined the association KSHV antibody 
positivity and exposures including between HIV, current parasite 
infections, and sociodemographic markers. and antibodies against KSHV, 
measured by ELISA.  
Results: KSHV seroprevalence was 61 % in mothers and 11 % among 
their children.   The risk of KSHV seropositivity was marginally higher in 
children of KSHV seropositive mothers compared with those of KSHV-
seronegative mothers (OR 1.4, 95% CI 1.1-2.0, p=0.04). In both 
mothers and children seroprevalence of KSHV was higher among 
individuals with malaria parasitaemia compared to those without 
(mothers; OR 1.9, 95% CI 1.4-2.7, p<0.0001 and children; OR 4.1, 95% 
CI 2.4-7.0, p<0.0001).  Children of HIV infected mothers had a higher 
prevalence of antibodies to KSHV than children of HIV negative mothers 
(p=0.03).  This was so whether or not the child was HIV infected.  These 
effects were not explained by age or socioeconomic status. 
Conclusion: HIV infection was associated with a higher KSHV 
seroprevalence among children.  Malaria in both pregnant women and 
their children is associated with the presence of antibodies against KSHV, 
perhaps mediated via effects on immune function. 
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5.2 Background 
 
Studies from sub-Saharan Africa report high Kaposi’s sarcoma 
associated-herpesvirus (KSHV) seroprevalence.  KSHV seroprevalence 
exhibits a marked worldwide variation 20.  Risk factors for seropositivity 
appear to vary depending upon the population192, 193, 233, 256. This may 
reflect regional differences in modes of transmission, or suggest local co-
factors for KSHV reactivation.  Studies suggest that multiple 
characteristics and exposures in a population are important222.  
 
In sub-Saharan Africa, primary KSHV infection often occurs in childhood 
and KSHV seroprevalence increases with age 25. KSHV infection among 
newborns is uncommon, suggesting vertical transmission is unlikely22, 23.  
There is evidence that transmission occurs via saliva 27, 262 and in sub-
Saharan Africa transmission during childhood, from mothers and siblings, 
is likely the predominant route 10, 25.  A key component of this study was 
to investigate potential associations between KSHV serostatus and 
common infectious agents in a typical community in Uganda.  The 
influence of HIV on KSHV transmission in sub-Saharan Africa is unclear.  
Among mothers and pregnant women in sub-Saharan Africa, HIV 
seropositivity is associated with a small increase in KSHV 
seroprevalence8, 13, 22, 25.  Studies of the impact of HIV infection on KSHV 
seroprevalence in children reveal conflicting results, with HIV having a 
protective256, null22, or positive effect7, 13, 25.  Parasites are potential co-
factors for KSHV infection and disease because they modulate the 
immune system316 and are endemic in regions where high seroprevalence 
of KSHV is also found317, 318.  While ecological associations between 
malaria and KSHV or KS have been reported in Italy, studies in Africa are 
inconclusive 40.  One study from sub-Saharan Africa has attempted to 
measure helminth burden among cases with KS and controls; KS patients 
had a higher carriage of certain intestinal helminths than controls 319.  
Studies of KSHV in Africa have identified risk factors for KS that might be 
common to being at risk of certain parasites, such as exposure to surface 
water, high rainfall and walking barefoot 40, 41, 301, 320.  The depth of data 
collected through the Entebbe Mother and Baby Study (EMaBS) allows 
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other key risk factors identified in the literature to also be investigated.  
These include the following for mothers: markers of socioeconomic status 
and sexual risk. And in children in markers of socioeconomic status and 
maternal KSHV serostatus.  
 
5.3 Aims of chapter 
 
This chapter describes the association between antibodies against KSHV 
in pregnant women in Uganda and their children with common local 
exposures. The primary aims are to: 
(1) Investigate the association between common infectious 
agents including HIV and parasites with antibodies to KSHV 
in mothers and their children 
(2) To investigate maternal socioeconomic factors associated 
with maternal and childhood KSHV seropositivity 
 
5.4 Methods 
 
The investigation was conducted within an existing study in Uganda - the 
Entebbe Mother and Baby Study (EMaBS) - a large double blind 
randomised placebo controlled trial designed to determine the impact of 
helminth infections and their treatment on vaccine responses and 
infectious disease outcomes35.  Detailed information about the study 
design has been reported in the general methods chapter.  The mothers’ 
enrolment plasma sample was selected for testing.  Of the samples 
collected from children at each annual visit, the sample from the oldest 
available age was selected.  KSHV serologic testing was based on ELISA 
for recombinant proteins to K8.1, a KSHV structural glycoprotein 
expressed during lytic infection, and for ORF 73, a nuclear antigen 
expressed during latency 13, 175.  Details of the assay protocol and the 
quality assurance from the assay transfer and set-up are given in the 
general methods chapter.  Randomised lists of samples were created 
using Stata11SE (StataCorp LP, College Station, Texas, USA).  The 
ELISAs were performed at the Uganda Virus Research Institute (UVRI) by 
the PhD student and two technicians, all of whom were blinded to patient 
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clinical and sociodemographic details at the time of testing.  Each plate 
was checked for internal validity as described in the general methods 
section.  
 
5.4.1 Statistical analysis  
 
Data were analysed using Stata11SE (StataCorp LP, College Station, 
Texas, USA).  Since individual responses to KSHV antigens are complex 
and no gold standard assay exists, to simplify the presentation, the 
results for K8.1 and ORF 73 were combined to define evidence of KSHV 
infection as “positive” if either of the two assays were positive and 
“negative” if both assays were negative.  The agreement between K8.1 
and ORF 73 ELISA assays was assessed by calculating Kappa statistic 
values.  The interpretation of the Kappa values was set as follows: less 
than zero as indicating no agreement and zero to 0.20 as slight, 0.21-
0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial, and 0.81-
1 as almost perfect agreement294, 295.  Twenty sets of twins were 
excluded from all analyses.   
 
5.4.2 Analysis of risk factors for maternal KSHV seropositivity 
 
A composite variable for socioeconomic status was derived based on 
home building materials, number of rooms and items collectively owned 
at the mothers home 276.  Anaemia was categorised in accordance to 
WHO criteria into three groups: normal (haemoglobin ≥11.3 g/dl), mild 
anaemia (haemoglobin 9.3-11.2 g/dl) and moderate anaemia 
(haemoglobin ≤9.2 g/dl)321.  CD4 counts in HIV seropositive women were 
categorised into three groups: ≤200cells/μL, 201-499cells/μL and 
≥500cells/μL.  A high eosinophil count was defined as above the normal 
range cut-off value ≥0.45x109/L.  For parasite intensities, hookworm was 
measured by egg counts in stool and categorised as negative, light (limit 
of detection to <1,000 egg per gram [epg] of stool), moderate (1,000 to 
3,999 epg) and heavy infection (≥4,000 epg) 35, 322, 323.  The intensity of 
malaria infection was categorised as being uninfected (negative), below 
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(“low”) or above (“high”) the median parasite count (of positive slides), 
per 200 white blood cells.  For microfilariae, tertiles of the number of 
filaria per millilitre of blood were used to categorise into low, medium 
and high infection intensity.  
 
Risk factors considered for maternal KSHV seropositivity were (a) 
background and sociodemographic variables: age, marital status, 
maternal education, occupation, household socioeconomic status, 
number of people living in the home and number of times pregnant 
including current pregnancy, (b) laboratory factors: anaemia, (c) HIV, 
sexual and non-sexual risk factors for HIV: HIV serostatus, active syphilis 
infection, reporting having ever had a sexually transmitted disease, 
having ever had a partner known to be HIV positive, having ever 
received a blood transfusion and CD4 count in HIV infected women, (d) 
parasite infections and risk factors for malaria and helminth infections: 
walking distance to Lake Victoria, type of toilet, use of mosquito nets in 
the home, spraying home for mosquitoes, water collection source (lake, 
well, bore hole, stand pipe, tap), walking barefoot, wading, swimming, 
fishing or washing in Lake Victoria, having ever taken worm medication 
and received treatment for malaria in this pregnancy and eosinophil 
count. The outcome of interest was KSHV serostatus of the mother.  
 
5.4.3 Analysis of risk factors for KSHV seropositivity in children 
 
Children were categorised into three HIV status groups: HIV unexposed, 
HIV exposed to maternal HIV but not infected and HIV infected.  As the 
prevalence of helminth infections in children was low, a variable for 
current infection with any helminth was created indicating infection with 
Trichostrongylus sp., A. lumbricoides, hookworm, M. perstans, S. 
mansoni, S. stercoralis or T. trichiura.  The intensity of malaria infection 
was divided at the median value and categorised into three groups: 
uninfected (negative), below (“low”) or above (“high”) the median 
parasite count, per 200 white blood cells.    
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Risk factors for childhood KSHV seropositivity considered were (a) age 
and sex, (b) laboratory diagnosed infections: HIV, asymptomatic malaria 
parasitaemia, number of previous symptomatic malaria episodes and the 
composite variable for helminth infection, (c) maternal and household 
factors: KSHV serostatus of mother, maternal age at birth of child, 
maternal educational attainment, marital status, household 
socioeconomic status and number of people or children living in the 
home, (d) HIV exposure, (e) risk factors for malaria and helminth 
infections: walking distance to Lake Victoria, type of toilet, use of 
mosquito nets, spraying home for mosquitoes and water collection source 
(lake, well, bore hole, stand pipe, tap). The outcome of interest was 
KSHV serostatus of the child.  
 
Potential bias in the sample of mother-child pairs was investigated by 
comparing the covariate distributions of mother-child pairs included, to 
the distributions of those in the cohort who had no samples available for 
inclusion.  Furthermore, mother-child pairs where the child was lost to 
follow-up at an early age were compared to pairs with longer child 
follow-up.  
 
Separately for mothers and children, potential associations between 
KSHV seropositivity and each potential risk factor were estimated using 
the Pearson chi-squared test or Fisher’s exact test, where expected 
numbers were small.  For analysis of outcome in both mothers and 
children, odds ratios (ORs) and 95% confidence intervals (CIs) were 
calculated using logistic regression modeling and statistical significance 
was assessed using the likelihood-ratio test.  It is of note that, for 
children, the initial analysis was based on a prior hypothesis that the age 
of the child would be a major determinant of risk of infection.  Therefore 
two models were generated.  In model 1 all ORs were adjusted for age of 
child.  In model 2 all risk factors that were associated with the outcome 
at the 5% significance level in model 1 were included in a multivariable 
logistic model to calculate ORs.  Departure from linear trend was 
considered for all ordered categorical exposure variables by calculation of 
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a likelihood-ratio test.  No adjustment was made for multiple 
comparisons.  All p-values were 2-sided and we considered a p-value of 
less than or equal to 0.05 to be statistically significant.    
 
To assess factors that potentially modify the risk of KSHV in pregnant 
women, interactions between HIV, helminth infections and asymptomatic 
malaria parasitaemia were added to the regression model.  To assess 
factors that potentially modify the risk of a KSHV seropositive mother 
having a KSHV seropositive child, interactions between maternal KSHV 
serostatus and HIV status or asymptomatic malaria parasitaemia in the 
child were added to the regression model.   
 
5.5 Results  
 
5.5.1 Background of study participants 
 
Plasma samples were identified for 78% (1823/2345) live-born children 
in the cohort.  The median age of women in the study was 23 years (IQR 
19-27).  At enrolment to the study, most were in the third trimester of 
pregnancy (54%) with 46% in the second.  The seroprevalence of HIV 
among pregnant women was 10% and the median CD4 count among 
those who were HIV seropositive was 551 (IQR 368-796).  Active syphilis 
was identified in 4% of women.  The highest level of educational 
attainment reached by the majority of women was primary (50%) with 
22% stating they were not able to read.  The majority of women (62%) 
described themselves as unemployed or housewives and 85% reported a 
monthly income below the World Bank poverty line of 1.25 USD per day.  
At the time of sampling, 30% (524/1772) of the pregnant women were 
parasite free, 37% had one parasite, 22% had two parasites, 9% had 
three parasites, 2% had four parasites and <1% had five parasites.  
Parasite infections among the pregnant female participants were 
hookworm (44%), M. perstans (21%), S. mansoni (18%), S. stercoralis  
(12%), asymptomatic P. falciparum parasitaemia (10%), T. trichiura 
(9%), A. lumbricoides (3%) and Trichostrongylus sp. (1%).  
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In children, the prevalence of asymptomatic malaria parasitaemia was 
5% and HIV prevalence was 1%.  Helminth infections were rare among 
children compared to mothers: 3% prevalence of Trichostrongylus sp. 
and 1% prevalence of A. lumbricoides infection, hookworm, M. perstans, 
S. mansoni, S. stercoralis and T. trichiura were all detected in less than 
1%.  The majority of children (91% [1250/1375]) had no parasite 
infections.  
 
Mother-child pairs with no samples available for inclusion were more 
likely to be from a HIV seropositive mother, a mother with malaria and 
less education.  Mothers of children whose last available sample was at 
one year were younger and more likely to be HIV seropositive, compared 
to mothers of children who were followed for a longer period.   
 
5.5.2 Determination of KSHV seropositivity in mother-child pairs 
 
In pregnant women the prevalence of antibodies to K8.1, ORF 73, both 
antigens and either antigen was 41%, 52%, 32% and 61% respectively.  
There was moderate concordance between K8.1 and ORF 73 ELISA 
assays in detecting KSHV seropositivity (κ=0.43).  The seroprevalence of 
KSHV among children was 9% to K8.1, 6% to ORF 73, 4% to both 
antigens and 11% to either K8.1 or ORF 73.  There was moderate 
concordance between lytic K8.1 and latent ORF 73 and assays in 
detecting KSHV seropositivity in children (κ=0.46).   
 
5.5.3 Risk factors for KSHV seropositivity in pregnant women in 
Uganda 
 
KSHV seroprevalence, crude and adjusted odds ratios between KSHV 
seropositivity, sociodemographic factors and anaemia are presented in 
Table 5.1.  Factors significant at the 5% level and included in the 
multivariate model were maternal age, maternal educational attainment, 
household socioeconomic status, anaemia, HIV status, asymptomatic 
malaria parasitaemia, hookworm, M. perstans, use of spray in the home 
to kill mosquitoes, water source and having ever taken worm medication.  
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In antenatal maternal samples KSHV seroprevalence decreased with 
increasing maternal age, educational attainment and socioeconomic 
status in the crude, but not in the adjusted analysis.  Antibodies to KSHV 
were more prevalent in women with anaemia (haemoglobin <9.2g/dl) 
compared to women with haemoglobin above 11.3g/dl, before but not 
after adjusting for relevant factors. Marital status, occupation, number of 
people living at home and number of times pregnant were not associated 
with KSHV seroprevalence.  
 
In pregnant women HIV seropositivity was associated with a marginal 
increase in prevalence of antibodies to KSHV, but this association was 
lost in the adjusted analysis (Table 5.2).  There was no association 
between sexual and non-sexual behavioural risk factors for HIV 
acquisition and KSHV seroprevalence.  There was no association between 
antibodies to KSHV and CD4 count in HIV seropositive women.  
 
In pregnant women current infection with asymptomatic malaria, 
hookworm and M. perstans were associated with antibodies to KSHV in 
the crude analysis (Table 5.2).  In the adjusted model the association 
between asymptomatic malaria parasitaemia and KSHV seropositivity 
was marginally strengthened.  The results for five other parasites were 
null.  Use of mosquito spray to kill mosquitoes in the home was 
associated with a lower KSHV seroprevalence in the crude but not in the 
adjusted analysis.  Having ever taken worm medication was associated 
with a decreased prevalence of antibodies to KSHV in pregnant women in 
both unadjusted and adjusted models, although in the adjusted model 
the confidence limits included one.  Reporting water source directly from 
Lake Victoria had a marginal positive association with risk of maternal 
KSHV compared to use of water from a well bore hole, stand pipe or tap.  
The adjusted ORs for the presence of antibodies to KSHV in women who 
reported using water from Lake Victoria compared to water from another 
source (well, bore hole, standpipe and tap) was 1.7 (95% CI 1.0-2.7, 
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p=0.04).  Other factors associated with contact with surface water 
(distance walk from Lake Victoria, wading, swimming, fishing or washing 
in the Lake) were not associated with KSHV seroprevalence.  Potential 
surrogate markers for helminth infections (walking barefoot and type of 
toilet at home) were also not associated with KSHV seropositivity in 
pregnant women.  
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In pregnant women the prevalence of antibodies to KSHV increased with 
increasing intensity of hookworm infection in the crude (p < 0.001 
[trend]) and adjusted analysis (p=0.03 [trend]) as measured by egg 
counts in stool; from 56% in those with no infection to 67% in those with 
light/moderate infection (limit of detection - 3,999 eggs per gram (epg) 
of stool) to 72% in those with heavy infection (≥ 4,000 epg), although 
confidence limits were wide in the adjusted analysis. No consistent trends 
were observed for malaria parasite density or M. perstans intensity, but 
most infections were light (Table 5.3). 
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5.5.4 Risk factors for Kaposi’s sarcoma-associated herpesvirus 
seropositivity in children in Uganda 	  
KSHV seroprevalence and associations between KSHV serostatus and 
factors in Ugandan children aged one to five years are shown in Table 
5.4.  In children there was no association between antibodies to KSHV 
and male or female sex.  Increasing age of the child had a statistically 
significant association with increasing seroprevalence of KSHV from 4% 
in one year olds to 14% in five year olds in the adjusted analysis (model 
2).  
 
In the model adjusted for age of the child, KSHV seroprevalence was 
increased in children exposed to but uninfected with maternal HIV 
compared to children not exposed to maternal HIV.  Children infected 
with HIV had an even greater risk of KSHV seropositivity, compared to 
children not exposed to maternal HIV.  Adjustment for potential 
confounders reduced but did not negate the increased odds of KSHV 
seropositivity in children exposed to HIV and children infected with HIV 
compared to children not exposed to HIV.  In a sub-group analysis 
restricted to HIV seropositive mothers, being a HIV seropositive child was 
associated with a two and a half-fold increase in being KSHV seropositive 
compared to being a HIV negative child on model 1 (OR 2.6, 95% CI 1.0-
6.9, p=0.05), and in model 2 (OR 2.4, 95% CI 0.8-9.3, p=0.09).  
 
In both model 1 and 2, antibodies to KSHV were associated with infection 
with asymptomatic malaria in children (Table 5.4).  High malaria 
intensity was associated with antibodies to KSHV in children, compared 
to children with no malaria infection (Table 5.5).  In Ugandan children, 
there was no association with number of previous episodes of malaria or 
with current helminth infection (Table 5.4).  Children born to KSHV 
seropositive mothers had an increased prevalence of antibodies to KSHV; 
adjusting for potential confounders in model 2 marginally weakened the 
association.  KSHV seropositivity in the child decreased with increasing 
maternal educational attainment, although the association lost statistical 
significance in the adjusted analysis (model 2).  In the analysis, use of a 
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mosquito net in the home was associated with a decreased 
seroprevalence of antibodies to KSHV in children in model 1 (adjusted for 
age of child) but not in model 2.  None of the other factors examined 
(Table 5.4) were associated with antibodies to KSHV in children.  
 
 
 
 
 
 
 
 
 
 
	  	   119	   
	  	   120	  
 
 
 
 
 
Table 6 shows the relationship between KSHV serostatus in mothers and 
children by child’s age.  The point estimate for odds of infection in 
children peaked three-fold at two years, but power was small.  At three 
years of age, KSHV seropositivity in children of KSHV seropositive versus 
KSHV seronegative mothers was two-fold higher and statistically 
significant.  If a difference in the association between mother and child 
KSHV status by age exists, it is not strong (p value for interaction=0.7). 
 
 
 
 
	  	   121	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5.5.5 Associations between parasites and socioeconomic status 
 
For pregnant women, associations between household socioeconomic 
status and eight parasite infections and HIV serostatus were examined.  
Higher household socioeconomic status was associated with a reduced 
prevalence of infection with hookworm and M. perstans.  No association 
with socioeconomic status was seen for HIV, malaria parasitaemia or any 
of the five other parasites examined. The association between hookworm 
and antibodies to KSHV was observed when each household 
socioeconomic stratum was examined separately.  For M. perstans, the 
association between infection and antibodies to KSHV also held when 
each household socioeconomic stratum was examined in turn (Figure 
5.1). Among children, household SES was not associated with any of the 
infectious exposures examined (malaria, helminth or HIV infection).  
	  	   123	  
 
 
 
 
 
 
	  	   124	  
5.5.6 Associations between infectious agents and reported risk of 
parasite exposure  
 
For mothers, all parasite infections were examined for associations with 
reported risk factors for parasite exposure.  The following significant 
associations between the factor and parasite (outcome) were identified: 
use of mosquito net (OR 1.5, 95% CI 1.1-2.1, p=0.008) was associated 
with increased odds of asymptomatic malaria parasitaemia; wading, 
swimming, washing or fishing in Lake Victoria was associated with 
increased odds of S. mansoni (OR 3.3, 2.4-4.6, p=0.0001) compared to 
pregnant women who never or only sometimes swam, fished, waded or 
washed in the lake; having ever taken worm medication was associated 
with a decreased odds of hookworm (OR 0.4, 95% CI 0.4-0.5, 
p>0.0001), T. trichiura (OR 0.7, 95% CI 0.5-0.9, p=0.02), S. stercoralis 
(OR 0.6, 95% CI 0.4-0.8, p=0.001) and M. perstans (OR 0.6, 95% CI 
0.5-0.8, p<0.0001); use of Lake Victoria as the main water source was 
associated with infection with S. mansoni (OR 2.6, 95% CI 1.6-4.2, 
p<0.0001), hookworm (OR 2.0, 95% CI 1.2-3.0, p=0.005), A. 
lumbricoides (OR 4.2, 95% CI 1.8-9.7, p=0.001) and T. trichiura (OR 
0.3, 95% CI 1.3-4.2, p=0.007).  In pregnant women there was a 
borderline association between asymptomatic malaria parasitaemia and 
HIV serostatus (OR 1.7, 95% CI 1.0-2.6, p=0.03).  All associations 
remained significant with no material difference after adjustment for 
household socioeconomic status.  Among children, malaria and current 
helminth infection were examined for associations.  No associations were 
found.   
 
5.5.7 Effect modification 
 
No modifiers of the relationship between KSHV serostatus of the mother 
and child were detected.  In pregnant women no interaction was found 
between HIV, malaria parasitaemia, hookworm, M. perstans and KSHV 
infection.  
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5.6 Discussion 
 
The findings reported here provide evidence of an association between 
antibodies to KSHV and asymptomatic malaria parasitaemia in pregnant 
women in Uganda.  Borderline associations in pregnant women between 
KSHV seroprevalence and using water directly from Lake Victoria as well 
as having ever taken worm medication were also identified; but for both 
these variables the confidence limits included one. The risk of KSHV 
seropositivity was marginally higher in children of KSHV seropositive 
mothers compared with those of KSHV-seronegative mothers.  Among 
children detection of antibodies to KSHV was higher among individuals 
with malaria parasitaemia compared to those without.  In children, HIV 
exposure and infection status was associated with antibodies to KSHV 
compared to children unexposed and not infected with HIV. Increasing 
age in children was confirmed as a significant risk factor for antibodies to 
KSHV. 
 
5.6.1 Kaposi’s sarcoma-associated herpesvirus seropositivity in 
mother-child pairs 
 
KSHV seroprevalence in both mothers and their children in this study is 
consistent with published reports from sub-Saharan Africa8-10, 13, 22, 25, 27, 
258-260.  The moderate concordance between latent K8.1 and ORF 73 
assays in detecting KSHV seropositivity was consistent with previous 
studies 13, 324. 
 
In pregnant women, the prevalence of antibodies to KSHV did not change 
significantly with age in the adjusted analysis, but the age range of study 
participants was relatively narrow.  Previous studies of women in a 
similar age range in Africa have shown little or no association with age 13, 
25, 259, 324.  In sub-Saharan Africa, KSHV is endemic and prevalence of 
infection in children increases with age, suggesting non-sexual horizontal 
transmission 14.  The seroprevalence of KSHV in this study increased 
from 4% in children aged one year to 15% in five-year-old children.  The 
mode of KSHV transmission is not fully understood.  There is little 
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evidence for vertical KSHV transmission22, 23.  Antibodies to KSHV that 
are detected in infants less than one year tend to decrease in prevalence, 
possibly indicating decay in maternal antibodies acquired in-utero22, 23, 25.  
Transmission of KSHV via breast milk has been studied.  One study 
identified the KSHV genome in about 30% of 43 breast milk samples 
from mothers with high titres of antibodies against a lytic KSHV 
antigen25.  In contrast, in a longitudinal study of KSHV seropositive 
women in Zambia, breast milk samples did not contain KSHV DNA in any 
sample collected in the first six months after delivery23.  Identifying 
antibodies to KSHV in infants (one to twelve months) during the period 
they are most likely to be breastfed is uncommon.  If transmission of 
KSHV via breast milk occurs, then it is likely rare.  The majority of 
evidence suggests that KSHV is transmitted through saliva 27, 262.  
 
Differences in the prevalence of antibodies to KSHV in men and women 
have been subject to some interest as endemic KS (or KS in HIV-
negative individuals) is a cancer predominantly in men.  In Uganda 
children aged one to five years were investigated in this study; there was 
no association between antibodies to KSHV and the sex of the child. This 
is consistent with other studies from this region8, 22, 25 and suggests that 
infection with KSHV per se does not account for the male predominance 
of endemic KS.  
 
5.6.2 Maternal Kaposi’s sarcoma-associated herpesvirus 
serostatus as a risk factor for antibodies to Kaposi’s sarcoma-
associated herpesvirus among children 
 
KSHV infection status of mothers was positively associated with evidence 
of infection risk in children consistent with other studies from sub-
Saharan Africa, 13, 25.  Adjustment for potential confounders reduced the 
strength of association but it remained statistically significant.  The 
analysis of odds of childhood KSHV seropositivity by maternal KSHV 
serostatus and child’s age may suggest that the younger children are at 
higher risk of acquiring KSHV infection from their mothers than older 
children.  Unfortunately the power in this analysis was too low to draw 
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firm conclusions, but one might expect that younger children have closer 
contact with their mothers than older children and are thus more likely to 
be exposed to maternal KSHV.  In older children KSHV infection from 
other sources may dilute the effect of the mothers KSHV serostatus.  It is 
of note that, of the KSHV seropositive children, nearly a third had a 
KSHV antibody negative mother and this figure is in keeping with 
published literature13, 25.  It is possible in the study presented in this 
thesis, that these mothers became infected with KSHV after the 
antenatal enrolment sample or that the child was infected from another 
source.	   	   This may reduce the effect of maternal KSHV serostatus on 
childhood KSHV seropositivity.  KSHV transmission within families in sub-
Saharan Africa has been documented with infection risk for the child 
showing associations, in decreasing order of importance, with infection in 
the mother, father and next oldest sibling 10.  
 
5.6.3 The relationship between Kaposi’s sarcoma-associated 
herpesvirus serostatus and socioeconomic factors 
 
The association between antibodies to KSHV in mothers and their 
children and marital status was null, consistent with other published 
reports22, 191.  In samples from pregnant women, potential markers of 
socioeconomic status, namely household socioeconomic status, maternal 
education, maternal occupation, number of people living at home and 
number of times pregnant, were not associated with antibodies to KSHV 
in the adjusted analysis.  The composite variable and other markers of 
socioeconomic status were similar among women in this study, which 
may have made a difference difficult to detect.  Other studies from sub-
Saharan Africa also report an absence of an association between 
maternal KSHV seropositivity and socioeconomic markers including 
maternal educational attainment and occupation22, 259.  In contrast, in a 
report from Uganda of socioeconomic factors in mothers, the risk of 
being KSHV seropositive was low in the high-income group, although the 
trend in risk with increasing income was not linear 259.  Among children in 
this study, markers of socioeconomic status were not associated with 
antibodies to KSHV.  The absence of an association between childhood 
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KSHV seropositivity and maternal educational attainment and markers of 
social status is similar to other studies from Africa 22, 259.  Given this 
general lack of association with markers of socioeconomic status, the key 
factor for seropositivity to KSHV in mother-child pairs may potentially be 
an aspect of behaviour or exposure not strongly related to socioeconomic 
status.  
 
5.6.4 The impact of HIV on Kaposi’s sarcoma-associated 
herpesvirus seropositivity 
 
HIV is an important candidate for influencing KSHV transmission rates 
between KSHV infected mothers and their children.  HIV infected 
subjects may be more likely to shed KSHV in saliva and HIV-associated 
immune deficiency may increase susceptibility to KSHV infection.  In 
studies of women in sub-Saharan Africa 13, 22, 25, the impact of HIV on 
KSHV seropositivity in mothers has been shown to be positive13, 22, 25, 191.  
Although in one study there was a positive association between lytic K8.1 
antibodies and maternal HIV, but a null association with antibodies to the 
latent antigen ORF 7325.  In the analysis for this thesis a borderline 
association between HIV and KSHV seropositivity in pregnant women was 
observed in the unadjusted analysis, but was lost when potential 
confounders were adjusted for.  Women in this study were relatively 
immune competent with high CD4 counts.  This could reduce the 
detection of antibodies to KSHV and could limit the chance of finding an 
association with HIV.  There was no association between KSHV 
seropositivity and CD4 count in HIV infected women, but the numbers in 
each CD4 group category was small, the range was narrow and counts 
high.     
 
Among children this study found some evidence that having an HIV-
infected mother was a risk factor for KSHV seropositivity if the child was 
HIV negative, and stronger evidence that if the child was HIV positive the 
odds of KSHV seropositivity were increased compared to HIV unexposed, 
uninfected children and to HIV exposed uninfected children.  Among HIV 
seropositive mothers the impact of the child being HIV infected compared 
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to HIV negative was about a two and a half-fold increase in odds of 
having antibodies to KSHV.  This was a sub-group analysis and power 
was small, but may suggest that HIV infected children are at increased 
risk of having antibodies to KSHV.  This study confirms the findings of 
others 13, 22, 25, that HIV infection is associated with an increased 
seroprevalence of KSHV in children, although this finding has been 
challenged in one study 256.  The marginal association when the child is 
exposed to maternal HIV but is not infected is also consistent with 
published literature 13, 22, 25.  Whether HIV is acting to increase 
vulnerability to infection or causing reactivation in children infected with 
KSHV in the past, is unclear.  
 
5.6.5 maternal sexual and non-sexual behavioural risk factors for 
HIV acquisition 
 
The lack of association with syphilis and reporting having ever had a 
sexually transmitted disease is consistent with previous studies reporting 
no association between KSHV and markers of sexual behaviour in studies 
of mothers in Africa 13, 14, 20, 225.  Mode of KSHV transmission is yet to be 
fully elucidated, but high acquisition rates during childhood imply a non-
sexual route 13-15, 25, 27, 131, 226, 228, 256, 259, 325-327.  Acquiring KSHV infection 
through a blood transfusion in Uganda has been reported328.  This was 
not the case in this study, but the number of women who had had a 
transfusion was small and re-call bias may be a contributing factor.  
 
5.6.6  Kaposi’s sarcoma-associated herpesvirus seroprevalence 
and association with anaemia 
 
The association with anaemia was lost in the adjusted model, but the 
number of women with severe or moderate anaemia was small due to 
trial entry criteria.  Pregnant women were excluded from enrolment into 
EMaBS if they had a haemoglobin level <8g/dl.  Hypoxia has been shown 
to cause KSHV reactivation162, 164.  As discussed in the introduction 
section, anaemia may potentially be associated with tissue hypoxia. 
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5.6.7 Antibodies to Kaposi’s sarcoma-associated herpesvirus and 
parasites 
 
5.6.7.1 Kaposi’s sarcoma-associated herpesvirus and laboratory 
diagnosed parasite infections 
 
In both mothers and their children asymptomatic malaria parasitaemia 
was significantly associated with antibodies to KSHV in the crude and 
adjusted analysis.  The point estimate for odds of KSHV infection in both 
mothers and children increased in the multiple logistic models when 
potential confounders were included.  Concurrent malaria appeared more 
important than previous episodes.  But data on previous episodes of 
malaria was not available for mothers and was limited for children,	  	    
 
Factors associated with potential prevention of malaria infection were not 
protective for KSHV, but this is not surprising given that the use of 
mosquito spray and nets, did not prevent malaria among mothers and 
children.  Among pregnant women, statistically significant associations 
with the presence or absence of hookworm or M. perstans and antibodies 
to KSHV were presented in the crude analysis.  In the adjusted analysis, 
increasing intensity of hookworm infection was associated with the 
detection of antibodies to KSHV, driven by a difference between women 
uninfected with hookworm and women with heavy hookworm infection.  
 
Parasites are a potential co-factor for primary KSHV infection or KSHV 
pathogenesis.   Areas of high KSHV seroprevalence tend, in broad terms, 
to have a climate suitable for high parasitic burden and transmission317, 
318.  Biologically, parasites rely on immunomodulation of the host for 
survival329, and it is conceivable that this could affect an individual’s 
immune response to KSHV.  Immune perturbations associated with 
parasite infections may impede viral control during KSHV infection, and 
affect the transmission events or immune surveillance required for 
eliminating abnormal cells with oncogenic potential.   
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5.6.7.2 A review of parasites as co-factors for Kaposi’s sarcoma-
associated herpesvirus infection and pathogenesis 
 
In the era prior to the HIV epidemic and the discovery of KSHV in 1994, 
a link between parasites and KS was first suggested by Williams and 
published in 1966 as an observation of the occurrence of both endemic 
KS and onchocerciasis in the West Nile region of Uganda47.  
Onchocerciasis, or river blindness, is caused by the infection, Onchocerca 
volvulus, a roundworm that is transmitted through the bite of a black fly 
of the genus Simulium.  Williams proposed that the Simulium fly might 
transmit a yet unidentified infectious agent that might act as a co-factor 
for KS.  In a follow-up paper examining the same cohort of individuals 
with endemic KS330, an association was observed between KS and 
reported bites from blood sucking insects or drinking water directly from 
rivers.  The author’s conclusion was that a microorganism may cause KS 
or that an arthropod vector may spread the aetiological agent. Still in the 
era prior to the discovery of KSHV, geographical restriction of classic KS 
in the Mediterranean was reported79, 331, with high incidence rates, 
compared to surrounding areas of classic KS, in the island of Sardinia (2 
per 100,000 males) and Southern Italy (3 per 100,000 men).  Geddes et 
al, used cancer registry data and reported that individuals with Classic 
KS resident in Italy were more likely to be born in areas that were 
endemic for malaria332.  Agricultural occupations with potential exposure 
to environmental toxins or infectious agents were also reported to be 
association with classic KS in the Mediterranean region333. 
 
After the recognition of KSHV as the aetiological agent for KS in 1994, 
there was keen interest in the geographical variation in KSHV infection 
and differing incidence of KS across narrow regions in the Mediterranean 
and potential associations with parasites.  In Italy, a marked reduction in 
KSHV seroprevalence was observed in subjects born after the peak of 
DDT house-spraying to kill the malaria vector Anopheles labranchiae334.  
Subsequently, as numbers of Anopheles larvae rose again, parallel 
increases in KSHV seroprevalence were reported334. Ascoli et al have 
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published the “promoter-arthropod” hypothesis, which postulates that 
exposure to the bites of certain species of haematophagous arthropods 
may be a co-factor linked to KSHV infection and/or development of 
classic KS in the Mediterranean335.  This theory hypothesised that certain 
species of arthropod may “promote” viral reactivation in the biting 
process; during blood feeding, piercing the skin and injecting insect 
saliva reactivates KSHV, leading to increased viral shedding in human 
saliva and an increased risk of KS development336-338.  The incidence of 
classic KS in the Po Valley in Italy339 and Sardinia340 was reported to 
correlate with density of “promotors”, predominantly Aedes vexans 
(Meigen) and Aedes caspius (Pallas).  One Mediterranean study reported 
a null association between classic KS and malaria; this study was 
conducted in Sardinia and examined a correlation between malaria 
prevalence in 1934, and the standardized KS morbidity ratio from 1977 
to 2003 in eight historical sub-areas79.   
 
In HIV infected populations reports investigating potential associations 
between KSHV, KS and parasites are sparse; an AIDS cohort of MSM in 
North America reported an increase in gastrointestinal amoebiasis in 
individuals with KS341.  In sub-Saharan Africa an association with KS and 
certain helminth infections as been reported319.  
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5.6.7.3 Kaposi’s sarcoma-associated herpesvirus and self-
reported or surrogate markers of parasite exposure 
 
Reports of the associations between KSHV, KS and potential surrogate 
markers of parasite exposure have also been published, such as 
residence in areas of high rainfall and walking barefoot 40, 41, 301, 320. 
Previously reported risk factors for KSHV, such as use of surface rather 
than piped water, may also be consistent with increased exposure to 
parasites 259.  In this study, pregnant women reporting using surface 
water from Lake Victoria rather than water from a borehole, stand-pipe 
or tap was marginally associated with antibodies to KSHV in the adjusted 
analysis.  While use of water from Lake Victoria is linked to 
socioeconomic status, adjustment for markers of socioeconomic status in 
this analysis did not fully explain this association. In Italy “closeness to 
rivers”342 has been associated with risk of classic KS.  KSHV seropositivity 
has also been reported to be higher in people living in areas surrounded 
by several rivers343.  In Africa “drinking water from rivers” has been 
associated with risk of endemic KS330.  Fast flowing rivers are not typical 
breeding grounds for mosquitoes or other parasites but are often 
associated with surrounding areas of still water and swampland that may 
be.  Water masses may also be outlets for human sewage, which convey 
a risk of certain helminth infections.  
 
Soil types that are potentially the most suitable for arthropod and sand-
fly breeding344 have been associated with KS.  Areas with high incidence 
of classic KS in Italy have landscapes on limestone, acid volcanic rocks 
and alluvial deposits340. Soil type has also been implicated in the 
pathogenesis of endemic KS in Africa.  The “soil” hypothesis put forward 
by Zeigler to explain the pattern of endemic KS in Africa implicates highly 
absorptive volcanic kaolin clays laden with iron as the cause of local 
inflammation and immunologic disturbance leading to development of 
KS345. Walking barefoot was associated with endemic KS in Uganda301, a 
region rich in iron-laden soils.  In the study walking barefoot had a 
borderline association with the presence of antibodies to KSHV among 
pregnant women. Whether soil types may impact insect or parasite 
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diversity in Africa has not been reported, but would be of interest.  
 
In this study, having ever taken worm medication was associated with a 
reduced KSHV seroprevalence in pregnant women.  If helminth infections 
increase the risk of detection of antibodies to KSHV then eliminating 
parasite infections may be associated with a decrease. Drug effect on the 
detection of antibodies to KSHV cannot be ruled out, nor can an 
unmeasured confounder.  
 
Eosinophilia was of interest due to its association with parasitic infection, 
but no association with KSHV seropositivity was found. 
 
5.6.7.4 Biological plausibility for an association between 
parasites and Kaposi’s sarcoma-associated herpesvirus 
 
Helminths have adapted through evolution to overcome the host immune 
environment and as a consequence many infections are asymptomatic.  
Immunological consequences of helminth infections are recognized.  In a 
simplified model of immunological response to helminth infection, helper 
T cell responses are described as predominantly TH1 or TH2.  TH1 
responses are associated with production of interferon-gamma, which 
activates cell-mediated immunity to kill intracellular pathogens.  TH2 
responses are associated with the production of interleukin-4, which 
activates B cell and humoral immunity.  Host responses to helminth 
infections are complex but broadly biased towards TH2 and regulatory 
responses346 with the activation of eosinophils and mast cells and 
production of immunoglobulin E.  Chronic helminth infection may lead to 
down-regulation of TH1 activity and the associated dampening of cell-
mediated immunity may impair immune responses to co-infections with 
bacterial, viral, and protozoal pathogens347.  Co-infections with helminths 
and viruses are common, especially in Africa, but the clinical and 
biological consequences are largely unknown.  No biological research on 
the immunological impact of co-infection with KSHV and helminth 
infections could be identified in the literature.  Co-infection with hepatitis 
B or hepatitis C and S. mansoni suggests that the outcome of viral 
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infection may be influenced by the balance between Th1 and Th2 
responses348.  Studies on the impact of helminths on HIV acquisition and 
progression have proved conflicting349.  Loss of KSHV-specific T cells 
allows KSHV infected cells to proliferate and KSHV related cancers to 
develop102; if helminth infections dampen T-cell mediated immunity it is 
reasonable to hypothesize that they may affect KSHV control and disease 
outcome. 
 
Hookworm has attracted interest as a co-factor for endemic KS due to 
the observation that endemic KS often begins on the lower limbs in a 
similar location to the place where hookworm larvae enter human skin.  
Upon dermal penetration, hookworm secretes enzymes that facilitate 
migration through tissues and a multitude of immune-stimulating 
molecules are released leading to inflammation (for review see Loukas 
and Prociv350).  Chronic hookworm infections are associated with 
diminished hypersensitivity reactions in the skin351 and this type of 
immune reaction has also been reported in the lower limbs of people with 
classic KS352 and in endemic KS in Africa353.  It is pure speculation 
whether larval penetration or the immune perturbation associated with 
loss of hypersensitivity reactions in hookworm infections may have a role 
in KS development in KSHV infected individuals.    
  
In malaria endemic regions, repeated infections lead residents to develop 
immunity that improves clearance of parasites and limits the 
inflammatory response to malaria that causes acute symptoms.  Young 
children who have yet to develop protective immunity are at greatest risk 
of clinical symptoms, severe disease and death354.  Presumed 
mechanisms for host immune response to malaria include the production 
of interferon-gamma, and activation of both TH1 and TH2 effector 
responses (For review see Stevenson and Riley355).   
 
The impact of P. falciparum malaria on EBV, a herpesvirus closely related 
to KSHV is recognised.  EBV is an oncovirus linked to a number of 
malignancies356 including Burkitt lymphoma which accounts for 30 to 
50% of all childhood cancer in equatorial Africa357.  There are a number 
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of theories to explain the interaction of EBV and malaria in the 
pathogenesis of Burkitt lymphoma:  
(1) P. falciparum may provide a chronic stimulus for poly-clonal B-cell 
expansion thereby increasing the chance of genetic translocations 
that immortalise cells253.  
(2) P. falciparum may impair EBV-specific T-cell immunity, which leads 
to a loss of viral control253. 
(3) P. falciparum may facilitate EBV infection early in childhood and 
lead to subsequent poor viral immune control, potentially due to 
an immature immune system.  More than 95% of African children 
are infected with EBV by age three, whereas, in affluent countries, 
primary infection is often delayed until adolescence358.  
 
Many parallels can be drawn between the effects of malaria and EBV 
outcome.  Like EBV, KSHV latently infects B cells and can cause clonal 
expansion and two B cell malignancies – primary effusion lymphoma and 
MCD.  T-cell immunity is important in the control not only of EBV but also 
of KSHV infection and KS disease102.  Losses of KSHV-specific T-cells are 
associated with high replication of KSHV and KS pathogenesis and/or 
disease progression.  Restoration of KSHV-specific T-cells is associated 
with KS regression.  Age is also a key factor in KSHV epidemiology.  
Countries where classic or endemic KS occurs have a high prevalence of 
childhood infection with KSHV, associated with mother to child 
transmission8, 13, 22, 25, 359, compared with countries where classic and 
endemic KS are rare.  It is very tempting to hypothesis a similar role for 
malaria in KSHV disease.   
 
Acute P. falciparum is also associated with another herpesvirus; herpes 
simplex virus-1360.  The mechanism by which acute malaria infection 
triggers the reactivation of latent herpes simplex infection is not clear, 
but it has been proposed that interleukin-6 (IL-6), produced by 
sequestered malaria parasites, may result in viral reactivation361, 362.  IL-
6 is also implicated in driving KSHV reactivation and pathogenesis of 
MCD.  (Review see Polizzotto363).  This invites the speculative question as 
to whether IL-6 produced in response to malaria could affect KSHV 
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control.  
 
In conclusion, if parasites impact the control and pathogenesis of KSHV, 
the mechanism is likely to be complex.  The immunological interactions 
between parasites and KSHV are likely to be governed by the timing of 
the infections in relation to each other, the intensity of duration of the 
infections, host genetics and environmental factors.  Biological 
plausibility does exist but research is required to investigate potential 
mechanisms.   
 
5.7 Conclusion 
 
Co-factors for KSHV transmission and disease have been sought to 
explain the elevated prevalence of KSHV and incidence of KS in Uganda.  
Exposure to HIV infection and having a KSHV seropositive mother in 
childhood is associated with an increased risk of KSHV seropositivity.  
Data presented here also suggests that parasites such as malaria may 
constitute one such co-factor.  Further epidemiological and laboratory 
studies are needed to fully understand the role of parasites as a risk 
factor for infection with KSHV. 
 
5.8  Study comments, strengths and limitations 
 
This is the first study of KSHV seroprevalence in sub-Saharan Africa that 
investigates direct measures of parasite burden, rather than surrogate 
markers of potential infection.  This study benefited from being 
conducted within the context of a randomised control trial.  The data 
collected was of high quality and the datasets had been extensively 
cleaned.  Many of the associations identified in this study do not rely on 
human judgment or recall and use automated laboratory data.  The 
nursing and field teams were highly trained and followed standard 
protocols.  Lost to follow up rates were low.  Stringent steps were taken 
to ensure ELISA assay quality control.  The ELISA samples were run blind 
and agreement in the ELISA results for control and duplicated samples 
was consistently high.  Given the novel finding of an association between 
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malaria, helminths and KSHV seropositivity a study recruiting more cases 
would increase confidence.  To investigate an exposure-response 
relationship a sample with a higher number if individuals with high 
intensity parasite infections is needed.  It would be most ideal to 
prospectively calculate a power-based estimate of the sample size 
needed.  A sample containing more cases of HIV and parasite infections 
would reduce sampling error. 
 
5.8.1 Generalisibility 
 
Investigations have been carried out by EMaBS to ascertain if women 
recruited were representative of the general population of Entebbe and 
Katabi and that trial enrolment was not linked to health status.   Results   
showed biases towards higher socioeconomic status.  This may mean 
that some of the women and children most vulnerable to parasites and 
KSHV infection were not included.  The potential importance of the 
findings of this thesis may be conservative.  The study was conducted 
retrospectively on stored samples collected by the EMaBS trial.  It was 
not design prospectively to investigate exposures on KSHV seropositivity.  
The sample size was overall relatively large, but the number of same 
exposures including HIV and some parasites was small and this increased 
sampling error.  The wide confidence intervals surrounding the point 
estimates for childhood HIV and KSHV seropositivity shows the lack of 
precision.  All of the women included in the study were pregnant. 	  
 
5.8.2  Bias, confounding and other reasons for caution 
 
Pregnant women were recruited through a government antenatal clinic 
after extensive community education about the EMaBS study.  
Differences between women who chose to participate in the study and 
those who did not may have impacted the results.  Selection bias 
occurred as HIV seropositive mothers, or mothers with malaria and less 
education had no plasma samples available for KSHV serology.  This may 
have led to an underestimation of the effect of HIV or malaria on 
antibodies to KSHV.  
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Misclassification of KSHV serostatus could have affected cases and 
controls.  Limitations in the KSHV ELISA assay used have been discussed 
in Chapters 3 and 4.  The repeatability of KSHV ELISA results as tested 
by a Kappa statistic was good and using a range of cut-off values for 
KSHV seropositivity did not materially change the main results.  The 
diagnosis of intestinal helminths may have been affected when only one 
stool sample was used.  In the main EMaBS trial the sensitivity for 
diagnosis of parasites by stool samples was greater when three samples 
were used compared to one364. Malaria blood slides have been shown to 
under-estimate malaria prevalence by about 10%365, and this may have 
led to a underestimate of the strength of association between malaria 
and KSHV.  
 
Recall and reporting bias, as with all studies, may have been a potential 
issue with markers of socioeconomic status and surrogate markers for 
parasite infections.  It is difficult to predict, but depending on the 
situation, individuals may over or under report an exposure.  It is 
perhaps reassuring that many of the “soft” surrogate markers for 
parasites are associated with actual parasite burden as measured in the 
laboratory.  Although this was not the case in use of mosquito nets and 
use of spray to kill mosquitoes in the home, which were both associated 
with an increased risk of malaria.  It is possible this could represent 
reverse causality in that individuals with multiple episodes of malaria 
illness start using preventative measures.  Or individuals are living within 
areas with many mosquitos.  It is of further reassurance that markers of 
socioeconomic status show consistency of direction with, for example, 
increasing household socioeconomic groups being associated with 
increasing wage groups366.  
 
Adjustment for markers of socioeconomic status had little material effect 
on associations between factors and antibodies to KSHV.  One cannot 
rule out the possibility of residual confounding by unmeasured factors.  
Known confounders that may explain the association between the 
exposure and KSHV seroprevalence have been considered.  Age as a 
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confounder to children’s KSHV status was a prior hypothesis and all 
analysis for children was adjusted for age.  Socioeconomic status is 
probably the leading candidate for confounding a relationship between 
HIV and parasites.  Socioeconomic status was associated with hookworm 
and M. perstans infection.  Attempts were made to control for potential 
confounders by including them as covariates in the multivariate analysis. 	  
The cross-sectional design makes it difficult to differentiate between risk 
factors for primary infection and reactivation, leading to a boost in 
antibody titres.  The mothers had relatively high CD4 counts and this 
may have impacted on our ability to assess the role of HIV.  The 
mother’s plasma sample was collected remotely in time from the child’s 
sample.  Power to detect potential associations between antibodies to 
KSHV in children and helminth infections or HIV was small. The analysis 
was cross-sectional and associations identified should be confirmed in 
longitudinal studies.   
 
The study participants were pregnant and pregnancy itself may modulate 
immune function.  However, since all comparisons were internal within 
the study (i.e. comparing one group of pregnant women with another), it 
is difficult to see how this could have impacted on the comparisons.   
 
5.9 Further directions 
 
The novel finding in the analysis for this thesis is a potential association 
between antibodies to KSHV and malaria.  Evidence from HIV-infected 
and renal transplant cohorts suggests that KSHV-specific T-cell function 
is key to control of KSHV viral replication.  A birth cohort is an ideal 
setting because age is a determinant of immune function, risk of malaria 
and primary infection with KSHV.  This type of study would allow the 
exploration of the impact of concurrent versus previous episodes of 
malaria to be investigated.  It has been reported that poor viral immune 
control of EBV may be facilitated by P. falciparum early in childhood254.  
In addition to samples for KSHV serology, it would be advantageous to 
collect suitable material to study KSHV viral load in PBMCs and KSHV 
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shedding in saliva.  KSHV viral load may be a better marker of KSHV 
control than antibody responses.  PBMCs would also be required for an 
ELIspot or FACS assay to determine KSHV-specific T-cell function.  If an 
association were identified between malaria and poor control of KSHV 
viral load it would be of interest to investigate the impact of malaria 
treatment.  A prospective powered study could be designed to compare 
KSHV DNA loads in PBMCs and saliva in individuals with falciparum 
parasitaemia at the time of malaria diagnosis and after anti-malarial 
treatment.  If KSHV were cleared from PBMCs or saliva after anti-malaria 
treatment a relationship between the viral control and malaria may be 
suggested.  
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Chapter 6.  A meta-analysis of the association between HIV and 
Kaposi’s sarcoma associated herpesvirus among mothers and 
children in sub-Saharan Africa 
 
6.1 Chapter abstract 
 
Background: The results presented in Chapter 5 of this thesis suggest 
an association between HIV and KSHV seropositivity in mother-child pairs 
in sub-Saharan Africa.  To explore current literature a systematic review 
and meta-analysis was conducted.  
Methods: A comprehensive search was conducted in PubMed, Medline, 
Web of Science and EMBASE.  Relevant material was evaluated.  
Published adjusted odds ratios and 95% confidence intervals were 
transferred into Stata SE11.  Due to anticipated heterogeneity between 
studies, a random-effects model was used for all analyses.   
Results: The summary analysis suggests that: (1) HIV infection in 
mothers and pregnant women is associated with an increased risk of 
KSHV seropositivity compared to HIV-negative individuals; (2) HIV-
negative children of KSHV-HIV seropositive mothers are not at increased 
risk of detection of antibodies to KSHV compared to HIV negative 
children of mothers with antibodies to KSHV alone, and (3) childhood HIV 
infection is associated with increased KSHV seroprevalence when 
compared to HIV negative children.  
Conclusion: HIV infection is associated with an increased prevalence of 
antibodies to KSHV in pregnant women, mothers and children.    
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6.2  Rationale 
 
In sub-Saharan Africa KSHV is a common infection in children and adults.  
Mother to child transmission of KSHV is thought to be important in the 
spread of infection.  In this region, HIV is endemic, increasing the risk of 
KSHV-HIV co-infection.  HIV-associated immunosuppression can cause 
KSHV reactivation367 and increase KSHV viral load in bodily fluids113.  
HIV-infected individuals may therefore act as highly infectious reservoirs, 
facilitating KSHV transmission.  Furthermore, people with HIV are 
potentially more susceptible to infection due to the associated immune 
suppression. Despite this, the effect of HIV infection on KSHV 
transmission in mothers and their children is not well understood. 
 
Some challenges in the interpretation of the current literature potentially 
stem from the HIV testing strategy employed; in particular the way the 
HIV status of the child is determined and the definition of the child’s HIV 
status – HIV unexposed and uninfected, HIV exposed but uninfected, and 
HIV infected.  A child’s HIV status is not necessary the same as maternal 
status and a further problem is that HIV status in children can change 
due to breast-feeding.	   	   In an attempt to bring clarity to the literature, a 
meta-analysis of epidemiological studies that determined KSHV and HIV 
status of mothers and their children living in sub-Saharan Africa was 
carried out.  
 
6.3 Objectives 
 
In this meta-analysis the aim was to pool results from all relevant studies 
to test the following hypotheses:  
(1) HIV infected mothers and pregnant women will have a higher KSHV 
prevalence compared to mothers and pregnant women without HIV 
infection,  
(2) HIV negative children of KSHV-HIV co-infected mothers will be more 
likely to have KSHV compared to children whose mothers are infected 
with KSHV alone, and  
(3) HIV infected children will have a higher KSHV prevalence compared 
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to children who are not infected with HIV.  
 
6.4 Methods 
 
Research methods and reporting are in accordance with the Cochrane 
Collaboration and PRISMA (Preferred Reporting Items for Systematic 
reviews and Meta-Analyses)368 guidelines.  
 
6.4.1 Eligibility criteria 
 
All studies of KSHV seropositivity in mothers and/or children in sub-
Saharan Africa were considered.  Publications did not have to contain 
results for both mothers and children.   KSHV infection could be defined 
by the presence of antibodies to KSHV proteins in plasma or serum or by 
detection of the KSHV genome in saliva, plasma, serum or PBMCs. 
Childhood was defined as ≥1 year (to avoid detection of maternal 
antibodies) and ≤12 years.  Mothers and children had to have had a HIV 
test; a child’s HIV status could not be defined by maternal HIV status).  
Studies could be cross sectional or longitudinal in design.  
 
6.4.2 Exclusion criteria 
 
The exclusion criteria were designed to keep between study 
heterogeneity to a minimum and were as follows: 
1. Individuals with KS, 
2. Women part of sex-worker cohorts,  
3. Studies of heterosexual transmission of KSHV,  
4. Studies were recruitment took place within a hospital setting, 
5. Studies set outside of sub-Saharan Africa, 
6. All individuals HIV infected, 
7. HIV status of participants not reported and 
8. Duplicate published datasets.  
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6.4.3 Information source and search 
 
PubMed was electronically searched up to and including the 17th April 
2012 and the search updated on the 9th May 2013.  Initial searches were 
conducted using “KSHV” or “HHV8” and “HIV”.  Due to the large number 
of publication returned a search using “KSHV” or “HHV8” and “Africa” in 
all fields of the PubMed advanced search builder was used.  Followed by 
“KSHV” or “HHV8” and “children”, and then “KSHV” or “HHV8” and 
“mother”/“women”.  Medical subject headings (MESH) and terms of 
relevant articles were reviewed and searches carried out using 
("herpesvirus 8, human" [MeSH Terms] OR "human herpesvirus 8" [All 
Fields] OR "kshv"[All Fields]) AND ("hiv"[MeSH Terms] OR "hiv"[All 
Fields]) AND ("africa"[MeSH Terms] OR "africa"[All Fields]) AND 
("child"[MeSH Terms] OR "child"[All Fields] OR "children"[All Fields]) OR 
("mother"[MeSH Terms] OR "child"[All Fields] OR "mother-child"[All 
Fields]).  Links were followed to related articles and reference lists in 
identified articles and reviews were also checked.  For completeness, 
searches were run in Medline, Web of Science and EMBASE, up to and 
including the 9th May 2013.  Only articles published in English were used.  
Conference proceedings, abstracts, theses, dissertations and national or 
local vital statistics data not published as peer reviewed articles were not 
included.  
 
6.4.4 Data collection process 
 
Articles were reviewed and the following variables recorded: first author; 
year of publication; location; cohort description; age; study size; method 
of determination of HIV status; HIV prevalence in mothers and/or 
children; KSHV prevalence in mothers and/or children; type of assay 
used to determine KSHV status; definition used to define KSHV 
positivity; if analysis was restricted to KSHV positive mothers, prevalence 
of KSHV-HIV co-infection, HIV alone, KSHV alone and neither KSHV or 
HIV; unadjusted odds ratios (OR) and 95% confidence intervals (CI) for 
KSHV; adjusted OR and 95% CI for KSHV; adjustment factors.  
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When published datasets were duplicated or overlapped, only the latest 
study was included.  All first authors were contacted to provide 
information on missing information, including HIV testing protocol, 
whether analysis was restricted or not restricted to KSHV positive 
mothers, adjusted OR and adjustment factors.  No additional information 
was returned.  
 
6.4.5 Statistical analysis 
 
Adjusted ORs and 95% CI were extracted.  If a publication did not 
provide an adjusted OR, an unadjusted OR was sought or an OR was 
estimated from the raw data. ORs and 95% CI were recorded to one 
decimal place. Due to anticipated heterogeneity between studies, a 
random-effects model was used for all analyses.  The OR calculated in 
the random effects model provides an estimate of average effect. 
Statistical heterogeneity was inspected graphically with a forest plot and 
assessed by calculating the degree of heterogeneity between study 
estimates using the I2 statistic.  The interpretation of I2 was 0%, no 
heterogeneity, 25% low heterogeneity, 50% moderate heterogeneity, 
75% high heterogeneity, where an I2 value of 50% indicates that half the 
total variability is caused by true heterogeneity between studies, and not 
by sampling error369.  Prediction intervals set at 95% were also 
calculated.  Funnel plots were examined for bias and the Beggs and 
Eggers test conducted370.  CIs were set at 95% and two-sized P values of 
less than 0.05 were considered statistically significant.  All statistical 
analyses were performed using the StataSe version 11.0 software (Stata 
Corporation, College Station, TX).  
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6.5 Results 
 
In PubMed the search terms yielded in English the following results: 268 
articles for “KSHV” or “HHV8” and “Africa”, 275 articles for “KSHV” or 
“HHV8” and “children” and 178 articles for “KSHV” or “HHV8”.  Searching 
Medline, Web of Science and EMBASE did not yield any additional 
publications.  The search results for 721 articles were exported into 
Microsoft Excel.  Duplicates were deleted leaving 529 unique records for 
screening.  The published articles were screened for relevance and 247 
were dropped from further analysis.  The abstracts of 282 articles were 
read and the full text of 71 articles was read (Appendix 1).  
 
 
Figure 61: Flow of information through phases of systematic review and meta-analysis.   
 
 
Seven studies were identified that satisfied eligibility criteria8, 9, 13, 22, 25, 
191, 256,7. All studies determined KSHV status by detection of antibodies to 
KSHV in serum or plasma.  No study used KSHV viral load.  
Iden%ﬁca%on*
• Number'of'records'iden/ﬁed'through'database'searching'=721'
• Number'of'addi/onal'records'iden/ﬁed'through'other'databases=0'
Screening*
• Number'of'duplicates'records'removed=192'
• Number'of'records'excluded'through'screening'=247'
• Number'remaining'and'abstracts'reviewed=282'
Eligibility*
• Number'of'full'text'ar/cles'assessed'for'eligibility=71'
• Number'of'full'text'ar/cles'excluded'(reasons)=631'(duplicate*dataset*published*[6],*not*based*in*
sub>Saharan*Africa*[14],*all*par%cipants*HIV*infected*[5]*,*individuals*with*KS*[8],*adolescents*[2],*
hospital*cohort*[3],*sex>worker*cohort*[8],*HIV*not*tested*for*(17).**
• 1*See*appendix*1*
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• Number'of'studies'included=8'
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6.5.1 Objective 1:  Kaposi’s sarcoma-associated herpesvirus 
seroprevalence in HIV infected mothers and pregnant women 
compared to mothers and pregnant women without HIV 
 
Four cross-sectional studies conducted in Zambia, South Africa and 
Uganda met eligibility criteria (Table 6.1)8, 22, 25, 191.  HIV seropositivity 
among women was between 10 and 30%.  HIV testing strategy varied 
between studies.  KSHV seroprevalence ranged from 40 to 61%.  
Malope191 and Wakeham8 used the same KSHV serological assay.  All four 
studies reported that HIV co-infection was associated with an increased 
point estimate in the odds of KSHV seropositivity, compared to HIV-
negative mothers and pregnant women.  
 
 
 
Figure 6.2: Random effect forest plot of studies identified that investigated the odds of 
KSHV seropositivity among HIV seropositive mothers compared to HIV seronegative 
mothers.  Studies ordered by year of publication. Studies included are shown in Table 
6.1. 
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The random effects summary OR for KSHV seropositivity in HIV 
seropositive mothers, compared to seronegative mothers was 2.0 (95% 
CI 1.3-3.2).  The proportion of the total variation between study 
estimates that was due to heterogeneity (I2 statistic) was 94.0%.  The 
95% prediction interval (the range within which future observations 
might be expected to fall) was 0.2-18.6.      
 
A funnel plot was constructed.  A large amount of heterogeneity was 
suggested but no conclusion could be drawn due to the small number of 
published studies (results not shown).  The Beggs and Egger test did not 
indicate any evidence of bias but power to demonstrate a relationship 
was very low due to data only being available from four studies (results 
not shown).  
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6.5.2 Objective 2: The odds of Kaposi’s sarcoma-associated 
herpesvirus seropositivity among HIV negative children of KSHV-
HIV co-infected mothers compared to children of mothers with 
Kaposi’s sarcoma-associated herpesvirus alone 
 
Four publications were included (Table 6.2)7, 9, 13, 25.  All studies were 
cross-sectional and conducted in South Africa, Zambia and Uganda and 
had samples sizes between 677 and 1823.  The HIV testing strategy, 
KSHV assay and definition of KSHV seropositivity varied (Table 6.2).  
Malope et al. presented an adjusted OR that was not restricted to KSHV 
seropositive mothers13; exclusion or inclusion of this study did not 
materially change the summary OR (results not shown).  Dedicoat et al. 
presented results for antibodies to both K8.1 and ORF 7325; the forest 
plot and summary OR below are for K8.1 results, in order to keep the 
analysis comparable with objective 1 (where only K8.1 results were 
available).  
 
 
 
Figure 6.2: Random effect forest plot of studies identified that investigated the odds of 
KSHV seropositivity among HIV negative children of KSHV-HIV co-infected mothers 
compared to children of mothers with KSHV alone 
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Three of the four studies reported no increased risk of antibodies to 
KSHV among HIV negative children of KSHV-HIV co-infected mothers 
(Table 6.2).  
 
The random effects summary OR for KSHV seropositivity in HIV negative 
children of HIV-KSHV seropositive mothers compared to KSHV 
seropositive HIV negative mothers was 1.2 (95% CI 0.80-1.9). Between 
studies, heterogeneity was 56% (I2 statistic).  The 95% prediction 
interval was 0.2-6.6.       
 
Funnel plots, and the Beggs and Egger test, did not indicate any evidence 
of publication bias (results not shown).  But due to the small number of 
studies conclusions could not confidently be drawn.  
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6.5.3 Objective 3: Kaposi’s sarcoma-associated herpesvirus 
seroprevalence among children infected with HIV compared to 
HIV negative children  
 
Five cross-sectional studies containing seven sets of results were 
eligible7, 9, 13, 25, 256 and they were conducted in South Africa, Zambia and 
Uganda.  The sample sizes ranged from 427 to 1823 (Table 6.3)7, 9, 13, 25, 
256.  The definition of KSHV seropositivity varied and antibodies to KSHV 
were detected among 7 to 20% of children.  The results for Malope et al. 
are an unadjusted OR13.  The study by Butler and co-workers contained 
results from a population in Uganda and a population in South Africa256.  
One study (Dedicoat) contained results for two KSHV antigens separately 
25.  Butler et al. did not report the HIV testing strategy and it could not 
be obtained from other related publications.  Among the Ugandan and 
South African populations presented by Butler et al., HIV was associated 
with a reduced prevalence of antibodies to KSHV256.  In the other studies 
HIV was associated with increased odds of detection of antibodies to 
KSHV.  
 
First, all seven populations were included in the estimation of the 
summary OR (Figure 6.3).  Next, the analysis was repeated dropping the 
ORF 73 results from the Dedicoat et al. study (Figure 6.4) and one or 
both of the results for the Butler et al. study (Figure 6.5 and 6.6).  The 
decision to omit the Butler et al. study results was because selection bias 
within the study was potentially high (see below). The Dedicoat ORF 73 
results were omitted to keep the analysis in keeping with objectives 1 
(where only K8.1 outcome data was available) and 2.  
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Figure 6.3: Random effect forest plot of studies identified that investigated the odds of 
KSHV seropositivity among HIV-infected children, compared to HIV negative children.  
Studies are ordered by year of publication.  
 
 
The random effects summary OR for KSHV seropositivity among HIV-
infected children compared to HIV-negative children was 1.9 (95% CI 
1.1-3.4).  The total variation in study estimates due to heterogeneity (I2 
statistic) was 62.0%.  The 95% prediction interval was 0.4-9.7.      
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Figure 6.4: Random effect forest plot of studies identified that investigated the odds of 
KSHV seropositivity among HIV-infected children, compared to HIV negative children.  
ORF 73 results from the Dedicoat et al. paper have been omitted.  Studies are ordered by 
year of publication.  
 
 
The random effects summary OR (with the ORF 73 results from the 
Dedicoat et al. study omitted) for KSHV seropositivity among HIV-
infected children compared to HIV-negative children was 1.9 (95% CI 
1.0-3.6).  The total variation in study estimates due to heterogeneity (I2 
statistic) was 67.8%.   
 
The summary OR results for the association between HIV and KSHV in 
children, in turn omitting the Butler et al. South African population, the 
Butler et al. Ugandan population, or both, were OR 2.0 (95% CI 1.0-3.9), 
I2 statistic=73.0% and 2.6 (95% CI 2.0-3.6) I2 statistic=0%, and 2.7 
(95% CI 2.0-3.7) I2 statistic=0% (Figure 6.5), respectively.  
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Figure 6.5: Random effect forest plot of studies identified that investigated the odds of 
KSHV seropositivity among HIV-infected children, compared to HIV negative children.  
ORF 73 results from the Dedicoat et al. study and both populations are presented but 
Butler et al. have been omitted.  Studies are ordered by year of publication.  
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Figure 6.6: Funnel plot, using data from six studies of the association between antibodies 
to KSHV and HIV infection in children.  Both the Ugandan and South African populations 
from Butler et al. are included.  Only the K8.1 results from the Dedicoat el at study are 
included.   Eggers regression line for funnel plot asymmetry is shown in orange.  
 
 
 
The funnel plot (Figure 6.6) for examining the risk of bias in studies to 
investigate KSHV seroprevalence among children infected with HIV 
compared to HIV negative children, suggest possible publication bias.  
But the small number of published studies makes a firm conclusion 
impossible to draw.  Neither Beggs’ nor Egger’s test suggested any 
evidence of small study effect, but the small number of studies means 
there is very low power to detect a relationship. 
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6.6 Risk of bias within and across studies 
 
The author’s judgment of risk of bias in the studies including in the meta-
analysis is presented in Table 6.47-9, 13, 22, 191, 256.  All studies were 
considered to have moderate to high selection bias.  Five of the studies 
rated with moderate selection bias were recruited through government 
run maternal-child health services (four antenatal wards and one 
vaccination clinic).  Women attending local government services may 
differ in sociodemographic or clinical factors, including health status and 
income, from the general population.   Malope et al. was rated as having 
high risk of selection bias13.  This study used left over blood samples 
from paternity suits in South Africa.  Butler et al. was also rated as high 
for selection bias; information on the selection of the South African 
population was limited and results for the Butler’s Ugandan population 
were pooled from a household survey and a study conducted in a 
transfusion clinic.  Children attending a transfusion clinic may be a biased 
population, either because they are unwell or because they are worried 
about a particular medical issue256.  Attrition of individuals and/or loss of 
samples was judged as high in one study (Minus)9 because over half of 
the children did not return for a HIV test and no information was 
available on the children who did not re-attend.   
 
The laboratory exposure (HIV) and outcome (KSHV) measures were 
judged to be at low and moderate risk of measurement bias respectively.  
Butler at al could not be judged on measurement of HIV status as neither 
the paper or associated publications described the HIV testing 
strategy256.  KSHV serological assays have potential problems with 
misclassification due to false positive and false negative rates.  One 
study (Butler) sent samples for independent verification of KSHV 
antibody results256.  Only one study (Malope) described the KSHV 
serology quality control steps and adjustment of cut-off values13.  Two 
studies (Wakeham, Malope) stated that the KSHV serological assay was 
run blind7, 13.  No study presented analysis from a range of cut-offs or 
checked assay repeatability.  
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Confounding was deemed high in two studies (Bulter and Brayfield)22, 256.  
In one, Butler et al., no prior hypothesis was stated but results from both 
South African and Ugandan populations were adjusted for age, sex and 
study site.  The odds of KSHV seropositivity in HIV-infected children 
compared to HIV-negative children in Butler et al. are not in keeping with 
the other published literature.  The papers authors do not explore the 
reasons behind this.  Brayfield et al. and Malope et al. only presented an 
unadjusted OR13, 22.  A criticism of all studies was the limited data on 
potential confounders.  
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6.7 Between study heterogeneity and publication bias 
 
Heterogeneity in the summary estimate random effects models was 
moderate to high.  Clinical and statistical heterogeneity between studies 
investigating potential associations between HIV and KSHV could account 
for this.  Participants differed in age, a known risk factor for KSHV 
seropositivity in Africa.  KSHV assay type varied, and false positive or 
false negative results could lead to differences in KSHV seroprevalence 
between studies.  Misclassification of HIV test results are unlikely as 
studies used validated clinical assays.  Studies varied in the prevalence 
of HIV-KSHV positive participants, and hence the power to detect a 
relationship.  Studies differed in the factors used to adjust the 
multivariate analysis; some studies had a prior hypothesis and others 
adjusted for all factors significant at the 5% level in the multivariate 
analysis.  Two studies only presented un-adjusted ORs.  Study location 
also varied; epidemiological patterns of KSHV transmission may vary 
across Africa233, 256.  Geographical differences that may affect KSHV 
transmission include KSHV viral factors, host genetic susceptibility, 
environmental co-factors and human bahaviours.  It is notable that 
Uganda has a relatively high prevalence of endemic KS compared to 
South Africa, which may suggest underlying differences in population 
baseline risk for KSHV infection or KS development.  Due to the small 
number of studies identified, formal statistical investigation of 
heterogeneity was not carried out.  Unmeasured factors could also 
account for heterogeneity.  
 
The prediction interval width depends on the heterogeneity or 
uncertainty between studies.    Its advantage over calculating a summary 
estimate and 95% CI is that it indicates effect in an individual setting and 
may make the analysis more useful in clinical practice and for policy 
making371.  The prediction intervals calculated in this study were wide 
and in all cases crossed one, indicating that in some settings HIV may 
have no (or even a protective) effect on KSHV seroprevalence outcome.  
The large width is in part due to the small number of studies and large 
heterogeneity in this meta-analysis.  A larger number of studies and 
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better knowledge of causes of bias are needed to calculate more robust 
prediction intervals.  
 
Funnel plots to investigate publication bias were created for each 
objective, but the small number of studies made interpretation difficult.  
The Beggs and the Egger test for each outcome did not indicate any 
evidence of publication bias, but due to the relatively small number of 
studies, power was very small.  Begg and colleagues propose that 25 
studies or more are required for moderate power372.  
 
6.8 Within study limitations  
 
KSHV serological assays are potentially prone to issues of 
misclassification and poor repeatability.  No study presented data using a 
range of KSHV assay cut-offs or repeated measures to test robustness of 
associations.  The studies were cross-sectional in design, and changes in 
associations with time were not investigated.  Longitudinal data could 
potentially be important given the limitations of the KSHV serological 
assays and the potential for antibody titres to change biologically over 
time.  Little or no data was available for length of time individuals had 
HIV or KSHV infection and immune status (CD4 count and HIV viral load) 
or ART status.  One cross sectional study reported that KSHV saliva viral 
load is increased at higher CD4 counts in HIV positive individuals373, 
raising the possibility that KSHV may be more easily transmitted early in 
HIV disease.  Long-term ART is associated immune reconstitution is 
associated with reduced KSHV viral activity, and lower KSHV antibody 
titres102, 104.  While all the studies were relatively large in overall size, the 
number of HIV-KSHV co-infected individuals for each of the three 
analyses was small.  This can be noted in the relatively wide confidence 
of intervals for each study.  In particular, Wakeham et al. had a small 
population of HIV infected children7. 
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6.9 Discussion 
 
HIV is potentially an important co-factor for KSHV transmission.  High 
prevalence areas of KSHV seropositivity in sub-Saharan Africa overlap 
with areas were HIV is endemic.  In these regions dual infection with HIV 
and KSHV occurs, making the role of co-infection in transmission an 
important issue. 
 
Within the context of the limitations of this analysis:  
 
1. HIV seropositivity in mothers and pregnant women is associated 
with an increased prevalence of antibodies to KSHV, 
2. Maternal HIV seropositivity was not associated with increased risk 
of detection of antibodies to KSHV among HIV-negative children, 
and 
3. Children with HIV infection had an increased seroprevalence of 
antibodies to KSHV 
 
HIV is implicated in the transmission of viral co-infections.  Some viral 
co-infections such as HCV and HBV have common routes of transmission 
with HIV, increasing the risk of dual infection.  Others, such as herpes 
simplex virus, increase the risk of acquiring HIV, and may also increase 
the risk of transmitting HIV374{Celum, 2004 #3746.  There is no current 
evidence to suggest that KSHV may impact HIV transmission.  It is more 
plausible that HIV infection may increase an individual’s risk of being 
infectious or vulnerable to KSHV.  In this analysis HIV infection in 
mothers and children was associated with increased odds of detection of 
antibodies to KSHV compared to individuals without HIV.  The 
progressive immunological decline associated with HIV infection makes 
individuals more vulnerable to infections.  HIV could potentially cause an 
increase in antibodies to KSHV by increasing the risk of primary KSHV 
infection.  But HIV infection may make antibodies to KSHV simply easier 
to detect by causing KSHV reactivation and a subsequent boost in 
antibody titre in a latently infected individual.  The cross-sectional design 
of the studies makes it impossible to differentiate between these two 
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possible explanations of the observed association.   
 
In this analysis, HIV infection did not appear to increase maternal 
transmission of KSHV.   This is not in keeping with the original 
hypothesis.  HIV infection is associated with KSHV reactivation and 
replication and increased oral, cervical and vaginal shedding of KSHV268, 
375, 376, which could increase the infectiousness of an individual.  The 
small number of studies used in the calculation of the summary estimate 
makes conclusions difficult to draw with any degree of certainty.  
 
6.10 Conclusion 
 
There are clear limitations in the summary estimates for this meta-
analysis but all relevant published studies have been included.  With 
these limitations in mind this analysis suggests that HIV infection is 
associated with increased detection of antibodies to KSHV in mothers and 
children in sub-Saharan Africa.  Large longitudinal studies are required to 
investigate KSHV transmission in mother-child pairs.  Collection of KSHV 
viral load data may help investigate is HIV is facilitating transmission of 
KSHV either by effects on infectiousness or susceptibility, or both. 	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Chapter 7: Antibodies against Kaposi’s sarcoma associated 
herpesvirus and the risk of developing HIV-associated Kaposi’s 
sarcoma in a rural population cohort in Uganda 
  
7.1 Chapter abstract 
 
Background: In Uganda, KSHV is endemic and the HIV epidemic has 
resulted in marked increases in incidence of KS.  No prospective studies 
of the evolution of KSHV antibody titres in relation to risk of HIV-
associated KS have previously been conducted in this population.  
Consequently we conducted a case-control study nested within an 
existing longstanding population-based cohort to investigate whether the 
pattern of KSHV antibody titres in individuals who subsequently develop 
KS, differs over time, when compared to individuals who do not.    
Methods: We identified 30 individuals who developed KS, from a cohort 
of HIV-infected people in rural Uganda.  For each case, four individually 
matched controls were selected from among HIV and KSHV seropositive 
individuals not diagnosed with KS.  Matching factors were sex, age band, 
and CD4 count at time of (pseudo)diagnosis. Serum samples were tested 
for antibodies against KSHV using two quantitative ELISAs: one to lytic 
phase K8.1 and the other to latent phase ORF 73.  Antibodies measured 
in samples from two time periods were considered: after HIV 
seroconversion in the six years before KS diagnosis (using a pseudo date 
of diagnosis for controls), and prior to HIV seroconversion. Antibody 
titres were converted to doubling dilutions for the analysis. Data were 
analysed using linear regression with generalized estimating equations 
(GEE) to allow for repeated measures.  
Results: In the six years prior to KS (pseudo)diagnosis, both K8.1 and 
ORF 73 antibody levels were higher in cases than in controls: the GEE 
regression estimate for the difference in K8.1 doubling dilutions between 
cases and controls was about four doubling dilutions (p<0.0001);  the 
estimated difference of ORF 73 antibody between cases and controls was 
about 3 doubling dilutions (p<0.0001).  Levels of antibodies for both 
K8.1 and ORF 73 in KS cases increased over time towards KS diagnosis, 
compared with controls (p<0.0001). Prior to HIV seroconversion, the 
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level of K8.1 antibody was already higher in KS cases compared to 
controls.  
Conclusion: In this nested case-control study of HIV-infected individuals 
from rural Uganda: (1) individuals who develop KS have a higher K8.1 
and ORF 73 antibody titre, which is evident for years prior to diagnosis 
compared to those without KS; (2) K8.1 and ORF 73 antibody titre in KS 
cases tend to increase towards diagnosis and (3) K8.1 antibody titre was 
higher in those who went on to develop KS compared to those who did 
not, even prior seroconversion to HIV.    
 
7.2 Background 
 
KSHV is the aetiological agent responsible for KS4.  HIV infection is the 
strongest predictor of risk for KS among KSHV infected individuals29, 136.  
Worldwide, HIV-associated KS is the most common tumour arising in 
HIV-infected persons.  The risk of developing KS in HIV-KSHV co-infected 
individuals in the USA, approaches 50 % in ten years193.  However, not 
all HIV-KSHV co-infected individuals develop KS33.  Understanding the 
evolution of biomarkers such as KSHV viral load or antibodies in 
asymptomatic KSHV-HIV co-infected individuals may be key to 
identifying individuals at highest risk of KS.  Anti-retroviral therapy (ART) 
is associated with a decreased incidence of KS138.  Individuals who 
develop KS while receiving ART tend to have less extensive disease124.  
Identifying those at greatest risk of KS may be particularly important for 
prioritizing ART treatment and cancer treatments in resource limited 
settings.  
 
The detection of the KSHV genome in peripheral blood mononuclear cell 
(PBMC) samples taken prior to KS diagnosis has been associated with as 
much as a 10-fold increase in the risk of developing KS113, but viral DNA 
in biological fluids is often of low copy number, particularly in pre-clinical 
or early stage clinical disease125, 262.  Consequently the use of viral DNA 
as a predictive marker for development of KS is limited.  Serological 
assays may offer an alternative marker for the risk of developing KS. 
Serology also has added benefits in being substantially cheaper than 
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techniques to detect DNA, such as the polymerase chain reaction (PCR), 
and is, relatively speaking, more easily transferable to a variety of 
environments.  KSHV antibody tests could be simplified into a point-of-
care test using lateral flow technology.      
 
In studies from South Africa and Uganda, increasing antibody titres 
against KSHV were associated with an increased risk of developing KS128, 
131.  There is some evidence, from longitudinal cohorts in North America 
and Northern Europe, that antibody titres against KSHV are increased 
preceding or at the onset of clinically evident KS33, 115-117, 127, 132-137.  Data 
from longitudinal studies of serological markers of KS risk in sub-Saharan 
Africa are lacking, and there remains substantial uncertainty about 
patterns of antibodies prior to diagnosis.  It is unclear whether antibody 
patterns may differ in KSHV-HIV co-infected individuals in sub-Saharan 
African compared to North America and Northern Europe.  In sub-
Saharan Africa, KSHV is endemic in the general population16, 127-131; it is 
often an infection in healthy children7, 9, 10, 13, 22, 256, 259, 260 and repeated 
exposure to KSHV is presumably a common occurrence.  By contrast, in 
North America and Northern Europe, KSHV is rare in the general 
population and occurs predominantly in MSM193, often at the time of or 
after HIV seroconversion116.  Titres to antibodies to KSHV in an endemic 
setting, such as in Uganda, may be higher and patterns more evident. 
 
7.3 Aims of chapter 
 
In Uganda, KSHV is endemic8, 19, 222, 228 and the HIV epidemic has resulted 
in KS being the commonest reported cancer32.  No longitudinal study of 
the evolution of KSHV antibody titres as a predictor of the risk of KS has 
been carried out in this population.  Therefore, this study investigates:  
(1) whether, prior to diagnosis of HIV-associated KS, antibody titres to 
KSHV are higher in those who develop KS compared to HIV-infected 
individuals who do not develop KS;  
(2) whether the pattern of antibody titres in individuals who develop KS 
differs over time when compared to individuals who do not; and  
(3) whether the titre and pattern of antibody titres prior to HIV 
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seroconversion differs between those who become KS cases compared to 
those who do not.  
 
7.4 Methods 
 
Data from the RCC277, 279, 377, based in Kyamulibwa, South-West Uganda, 
was used to identify 30 individuals with HIV-associated KS diagnosed 
between 2nd October 1990 and 5th July 2010.  All cases were confirmed 
by a review of clinic notes by two clinicians.  Five cases had histological 
verification of diagnosis and the remainder had clinical documentation 
only.  Controls were selected using the following procedure: each case 
was classified by sex, age band (≤37 years or >38 years), and CD4 
count band (≤200cells⁄µL, 201-500cells⁄µL, ≥501cells⁄µL) at the time of 
their KS diagnosis.  Potential controls were then examined to find the 
time points at which their characteristics (sex, age and CD4 count band) 
matched those of the case.  This time point was then taken as the 
pseudo-diagnosis date for that control and they were included in the 
dataset as matched to the corresponding case.  Serum samples taken at 
the (pseudo)diagnosis time point, along with all available serum samples 
prior to (pseudo)diagnosis for cases and controls, were tested for 
antibodies against KSHV using a quantitative lytic K8.1 ELISA and latent 
ORF 73 ELISA as previously described in the general methods section13, 
175.  Initially, 222 controls fulfilling the inclusion criteria were tested and 
149 were found to be KSHV seropositive to either K8.1 and/or ORF 73 on 
the KS pseudo-diagnosis serum sample.  For each case four individually 
matched controls were selected from HIV and KSHV seropositive people 
without a diagnosis of KS during the study period.   
 
In a sub-study of patterns of K8.1 and ORF 73 antibodies prior to HIV 
seroconversion, 12 KS cases and 29 controls with a date of HIV 
seroconversion and available serum samples, were identified.  All 
samples available prior to HIV seroconversion were selected for K8.1 and 
ORF 73 serology.  
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The K8.1 and ORF 73 ELISAs were performed at the Uganda Virus 
Research Institute (UVRI) by the study lead and a technician, both of 
whom were blinded to patient details.  Randomised lists of samples were 
produced.  Serum samples positive to antibodies against K8.1 at a 1:10 
dilution were subsequently tested at doubling dilutions from 1:20 to 
1:20,480 to measure titre.  Serum samples positive to antibodies to ORF 
73 at a 1:10 dilution were tested at doubling dilutions from 1:100 to 
1:102,400.  The titre value was the dilution before which the sample lost 
positive signal.  
 
7.4.1 Statistical analysis 
 
Data were analysed using Stata11SE (StataCorp LP, College Station, 
Texas, USA).  Two time periods were of interest in this study.  The main 
study analysed data from a time period up to 6 years prior to KS 
(pseudo)diagnosis when all study participants were HIV seropositive.  
The sub-study investigated a time period around and prior to HIV 
seroconversion.   
 
The distribution of K8.1 and ORF 73 titres was skewed.  To simplify the 
analysis and presentation of results, titres were converted to the number 
of dilutions.  This number, from 0-10 for K8.1 and 0-11 for ORF 73, was 
used for all analyses and will be referred to throughout as “K8.1 doubling 
dilution” or “ORF 73 doubling dilution” (Table 7.1).  Samples KSHV 
seronegative were coded zero.  
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Table 7.1: Antibody titres to KSHV and doubling dilution equivalents 
 
Panel a: K8.1 titre and doubling dilutions 
K8.1  
Titre 
Doubling 
dilutions 
Negative 0 
1:20 1 
1:40 2 
1:80 3 
1:160 4 
1:320 5 
1:640 6 
1:1280 7 
1:2560 8 
1:5120 9 
1:10240 10 
 
Panel b: ORF 73 titre and doubling dilutions 
ORF 73 
Titre 
Doubling  
dilutions  
Negative 0 
1:100 1 
1:200 2 
1:400 3 
1:800 4 
1:1600 5 
1:3200 6 
1:6400 7 
1:12800 8 
1:25600 9 
1:51200 10 
1:102400 11 
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Results for HIV viral load were considered a suitable representation of an 
individual’s viral load at KS diagnosis if within 100 days of 
(pseudo)diagnosis date.  The characteristics of cases and controls were 
compared using the Mann-Whitney test, t-test and chi-squared test.  
 
Data from the time period in the six years prior to (pseudo)diagnosis 
were analysed in two ways.  Firstly, Odds Ratios (ORs) and 95% 
confidence intervals (CI) were calculated using conditional logistic 
regression, maintaining the case-control matching.  For each individual, 
their mean doubling dilution, based on data from all time points within 
the six years, was calculated.  These were then considered separately as 
predictors for case-control status in conditional logistic regression 
models.  In order to investigate whether change in doubling dilution was 
associated with a subsequent diagnosis of KS, the rates of change 
(gradient) in each individual’s doubling dilution over the time preceding 
(pseudo)diagnosis date were estimated using linear regression modeling 
of samples from all time points.  These gradients were then included, 
along with the mean doubling dilution for each individual, in conditional 
logistic regression models.  Secondly, linear regression models corrected 
using a generalized estimating equation (GEE) that ignores matching and 
fits a population averaged regression line correcting within individual 
correlations, were used.  In the GEE analysis repeated measures of 
doubling dilution and time elapsed were modeled with an exchangeable 
correlation structure.  Interaction terms between time elapsed and case 
control status were examined in order to assess whether doubling 
dilution changed across time differently in cases and in controls.  
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Figure 7.1: Time periods for study 
 
 
For the sub-study of data from the period prior to HIV seroconversion, 
three time periods were considered (Figure 7.1): 
 
Time point 1 - The mean doubling dilution for K8.1 and ORF 73 was 
estimated for the time period prior to HIV seroconversion when all 
individuals were HIV-negative (blue band from study entry).   
 
Time point 2 - The mean doubling dilution for both antibodies was 
estimated at HIV seroconversion (orange band).  The HIV seroconversion 
time period was defined as being within 6 months of the first HIV 
seropositive sample.  Time points just before and just after 
seroconversion were included. 
 
Time point 3 - In order to investigate any potential impact HIV 
seroconversion may have on antibodies to KSHV, the mean doubling 
dilution for samples taken at HIV seroconversion for cases and controls 
was compared to the mean doubling dilution of samples collected at least 
two years prior to HIV seroconversion (furthest from HIV seroconversion, 
green band).	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Finally, the analysis was restricted to only those cases and controls K8.1 
or ORF 73 seropositive at the (pseudo)diagnosis time point.  Tests for 
statistical significance were derived from likelihood ratio test statistics.  
All p values were 2 sided and significance was considered at the 5% 
level.  
 
7.5 Results 
 
Results were available for 30 cases and 108 matched controls. All cases 
and controls were seropositive to either K8.1 or to ORF 73 at KS 
(pseudo) diagnosis, but not necessarily to both.  At the KS diagnosis time 
point 93% (28/30) of the cases were seropositive to K8.1, as were 69% 
(74/108) of the controls at the pseudo-diagnosis time point.  For ORF 73, 
at the KS (pseudo)diagnosis time point, 100% (30/30) of the cases were 
seropositive, as were 88% (95/108) of the controls.  The median number 
of samples available from each individual was 6 (range 2-12). ART 
regimes for the KS cases were as follows: 
zidovudine(AZT)/lamivudine(3TC)/nevirapine(NVP) – five cases, 
stavudine/3TC/NVP - two cases; and for the controls: AZT/3TC/NVP - 16 
controls, stavudine/3TC/NVP – two controls, AZT/3TC/efavirenz- two 
controls and unknown-one control.  
 
7.5.1 Results from the basic analysis 
 
Table 7.2 presents the characteristics of the study population.  K8.1 and 
ORF 73 titre was higher in KS cases compared to controls at the 
(pseudo)diagnosis time point. Figure 7.3 and Figure 7.2 depict the 
distribution of titres and doubling dilutions in cases and controls at the 
(pseudo)diagnosis time point.  
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Figure 7.2: Distribution of titres of antibodies to K8.1 and doubling dilution equivalents in 
30 HIV-positive individuals with Kaposi’s sarcoma (KS) and 108 matched controls, at time 
of (pseudo)diagnosis.  For each patient with KS, four matched controls without KS were 
selected and matched for sex, CD4 count group and age.  The median titre in each group 
is indicated by a horizontal red line.  
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Figure 7.3: Distribution of titres of antibodies to ORF 73 and doubling dilution equivalents 
in 30 HIV-positive individuals with Kaposi’s sarcoma (KS) and 108 matched controls at 
time of (pseudo)diagnosis.  For each patient with KS, four matched controls without KS 
were selected and matched for sex, CD4 count group and age.  The median titre in each 
group is indicated by a horizontal red line.  
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7.5.2 Results from conditional logistic models 
 
The conditional logistic models investigating whether K8.1 or ORF 73 titre 
dilution was predictive of KS status are presented in Table 7.3, showing 
the odds of having KS approximately doubled for each additional 
doubling dilution (OR 2.2, 95% CI 1.5-3.1, p<0.0001).  Adjusting for 
ART status at the time of KS (pseudo)diagnosis did not materially change 
the results.  The rate of change of K8.1 antibody level between the first 
and last time points for a case was approximately double the rate for a 
control (OR 2.1, 95% CI 1.0-4.3, p=0.04).  For ORF 73, each additional 
doubling dilution was associated with a one and a half-fold increase in 
the odds of developing KS (OR 1.5 95% CI 1.2-1.8, p<0.0001).  As with 
K8.1, adjusting for ART status did not change the results.  The rate of 
change in ORF 73 antibody titre between the first and last time points 
was borderline (OR 1.0, 95% CI 0.6-1.9, p=0.9).  
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7.5.3 Linear regression model corrected using a generalized 
estimating equation  
 
The GEE model accounts for the lack of independence in the repeated 
measurements by assuming within-patient correlation.  For K8.1 doubling 
dilution the GEE crude estimate for the difference in cases and controls 
was four doubling dilutions, or a 16-fold increase (4.1, 95% CI 3.3-5.0, 
p<0.0001).  The interaction term for time was significant (p<0.0001), 
indicating that K8.1 doubling dilution changes across time differently in 
cases and in controls.  This is illustrated in Figure 7.4.  For cases K8.1 
increases with time towards KS diagnosis, but no time trend is apparent 
for controls.  The difference in estimated K8.1 doubling dilution between 
cases and controls is greater nearer to the time of (pseudo)diagnosis.  
Adjusting for ART status at time of (pseudo)diagnosis did not materially 
change the results (3.9, 95% CI 2.8-5.0, p<0.0001).  
 
The estimated difference of ORF 73 doubling dilution from the GEE model 
between cases and controls was about 3 doubling dilutions or 8-fold (2.8 
95% CI 1.5-3.9, p<0.0001).  The interaction term for the time was 
significant (p<0.0001), signifying that ORF 73 doubling dilution changes 
across time differently in cases compared to controls (Figure 7.5).  For 
cases titre increases with time towards KS diagnosis, but no time trend is 
present for controls.  The estimated difference in ORF 73 doubling 
dilution is greater nearer to the time of (pseudo)diagnosis between cases 
and controls.  Adjusting for ART status at time of (pseudo)diagnosis did 
not materially change the results (2.7, 95% CI 1.5-3.9, p<0.0001).  
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Figure 7.4: Graphical representation of the difference between K8.1 doubling dilution for 
KS cases and non-KS controls using a linear regression model corrected by a generalized 
estimating equation (GEE).  Red, KS cases.  Blue, KS controls.  Dashed lines represent 
95% CI.  
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Figure 7.5: Graphical representation of the difference between ORF 73 doubling dilution 
for KS cases and non-KS controls using a linear regression model corrected by a 
generalized estimating equation (GEE).  Red, KS cases.  Blue, KS controls.  Dashed lines 
represent 95% CI.  
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7.5.4  Antibodies to K8.1 and ORF 73 prior to HIV seroconversion 
 
The median number of days from HIV seroconversion to KS was 1956 
(range 432-5454) [or 5.4 years, range 1.2-15.0 years].  All except four 
cases (13 % [4/30]) were K8.1 seropositive at HIV seroconversion and 
all seroconverted prior to KS diagnosis.  All cases were ORF 73 
seropositive at the serum sample closest to HIV seroconversion.  The 
characteristics of the 12 cases and 29 controls analysed to investigate 
the impact of HIV seroconversion on antibodies to KSHV are presented in 
Table 7.4. 
 
The mean K8.1 doubling dilution was higher in KS cases compared to 
controls in both the time period furthest from HIV seroconversion and in 
the HIV-negative period (Table 7.5).  In the peri-HIV time period (within 
6 months of HIV seroconversion) samples from individuals who went on 
to develop KS had a higher point estimate of K8.1 mean doubling dilution 
when compared to those who did not develop KS, but the difference did 
not reach statistical significance.  The mean doubling dilution for ORF 73 
for cases compared to controls was not statistically different at the period 
furthest from HIV seroconversion, in the HIV-negative period or at HIV 
seroconversion.  There was no statistical difference in mean doubling 
dilutions for KS cases between samples furthest from HIV seroconversion 
and samples at HIV seroconversion for either K8.1 (p=0.5) or ORF 73 
(p=0.3). 
 
 
	  	   186	  
	  	   187	  
	  	   188	  
Restricting the results to K8.1 or ORF 73 seropositive individuals at 
(pseudo)diagnosis did not change the results (data not shown).  
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7.6 Discussion 
 
7.6.1 K8.1 and ORF 73 antibody titre in individuals with HIV-
associated Kaposi’s sarcoma 
 
In this nested case-control study of HIV-infected individuals from rural 
Uganda, doubling dilutions have been used to investigate potential 
differences in K8.1 and ORF 73 antibody titre between individuals who 
develop HIV-related KS and HIV seropositive individuals who do not.  The 
study has shown that individuals who develop KS: (1) have a higher K8.1 
and ORF 73 antibody titre compared to those without KS up to six years 
prior to (pseudo)diagnosis; and (2) that K8.1 and ORF 73 antibody titre 
tends to increase with time towards KS diagnosis.  Individuals who did 
not develop KS had relatively stable titres over time.  
 
Increasing antibody titres against KSHV have been associated with an 
increased risk of developing KS both in HIV infected and uninfected 
people117, 128, 131, although the absolute risk for a given median KSHV 
antibody titre was much greater in HIV-infected patients compared to 
HIV-negative patients; the respective risk ratios for HIV-associated 
versus HIV-negative KS compared to KSHV seronegative individuals were 
48 versus 2 at titres of 1:200, 62 versus 6 at titres of 1:51,200, and 
1683 versus 12 at titres of 1:204,800131.  The results presented in this 
study are also in keeping with studies of KSHV antibodies prior to KS 
diagnosis from North America and Northern Europe.  In these regions 
high titre to KSHV antibodies are associated with risk of development of 
KS in renal transplant recipients and in HIV-infected individuals117.  A 
study from Italy investigated the risk of KS in a HIV-KSHV co-infected 
cohort using an immunofluorescence assay; bright cytoplasmic staining 
at a dilution of 1:5 or more were considered positive and further dilutions 
for titres of 1:25 and 1:125 were carried out.  The risk of KS increased 
with increasing anti-K8.1 KSHV antibody titres, reaching more than 40% 
10 years after HIV seroconversion for individuals with an antibody titre of 
1:125136.  A Swiss study determined change in proportion of samples 
seropositive to KSHV between KS cases and controls: the reactivity in KS 
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cases steadily increased throughout the observation time of about five 
years compared to controls33.  
 
Due to the paucity of longitudinal studies and the variation in serological 
techniques it is not possible to compare antibody titres to KSHV between 
sub-Saharan Africa, North American and Northern European cohorts.  Yet 
difference in titre and patterns of titres between KS cases and controls in 
this HIV seropositive Ugandan cohort were certainly evident and are 
consistent with data from elsewhere.  
 
7.6.2 K8.1 antibody titres and HIV seroconversion 
 
The median time from the point of infection with both HIV and KSHV, to 
development of KS, was similar in this cohort to Western cohort studies.  
In an Italian cohort, predominantly comprising men who have sex with 
men, the median time to develop KS was 5.6 years (range, 2.2–9.9 
years) from the time of HIV seroconversion and 4.2 years (range, 1.4–
7.6 years) from the diagnosis point of KSHV-HIV co-infection136.  In 
Western cohorts, KSHV seroconversion is reported to be more common 
at the same time as HIV infection or in individuals who are already HIV-
positive115, 116, 378.  In the study reported here all cases were ORF 73 
seropositive at or before HIV seroconversion.  All but four KS cases in 
this study were K8.1 seropositive at or before HIV seroconversion and all 
seroconverted prior to KS diagnosis. This may be because in the West 
the at-risk group for KSHV-HIV co-infection is men who have sex with 
men, and risk bahaviours for KSHV are closely related to those of HIV; 
whereas in this study the majority of individuals were KSHV infected 
prior to HIV seroconversion and non-sexual factors including those in 
early childhood are likely the important determinants of primary KSHV 
infection.  
 
In the smaller sub-set of samples analysed prior to HIV seroconversion, 
KS cases had higher antibodies to K8.1 prior to contracting HIV and at 
HIV seroconversion, compared to controls.  For ORF 73 there was no 
difference between cases and controls mean doubling dilutions at HIV 
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seroconversion, or at the two HIV-negative time periods (“HIV-negative” 
and “period furthest from HIV seroconversion”).  However, the small 
number of individuals in this sub-set analysis limits the power of the 
study.  But the results suggest that HIV seroconversion has little if any 
impact on KSHV antibody titre, since the results at the time period 
furthest from HIV seroconversion and the time period around HIV 
seroconversion are similar.  In contrast, a cohort study from Amsterdam 
reported that HIV seroconversion was associated with a significant boost 
in antibody titre378.  KS cases had a higher antibody titre to K8.1 prior to 
HIV seroconversion than controls.  The KSHV glycoprotein K8.1 is 
expressed during the lytic cycle379.  In the lytic phase KSHV is reactivated 
with the initiation of extensive viral DNA replication and gene expression, 
resulting in production of new viral particles380. Viral reactivation is 
crucial for KSHV pathogenesis and contributes to the progression of 
KS381, 382. Risk of tumour development is associated with increasing KSHV 
antibody titres to the lytic protein K8.1225, 33.  High antibody titres to 
K8.1, are evident in this cohort prior to HIV seroconversion.  A potential 
explanation for high antibodies to K8.1 and the limited impact on this of 
HIV is that in KSHV endemic countries such as Uganda viral reactivation 
is being driven by other co-factors.  Viral reactivation and lytic activity of 
KSHV could also be due to repeated exposure to the virus in this 
prevalent setting.  Alternatively, antibody titres may be an inadequate 
indicator of KSHV viral activity; a marker such as KSHV viral load may be 
required.  
 
7.6.3  Methods of statistical analysis 
 
A number of statistical techniques were used in the analysis of this study.  
It is reassuring to consider that whether using simple methods, for 
example comparing median K8.1 antibody titres, or more complex 
techniques such as conditional logistic regression or linear regression 
adjusted for correlation with individuals, the results remain consistent 
with each other.   The potential advantage of the conditional logistic 
regression (CLR) model is that it explicitly allows for the individual case-
control matching.  It may also be more biologically intuitive model 
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because in this model case/control status is the outcome, which is a 
consequence of antibody level.   The disadvantage of the CLR approach 
(compared to linear regression adjusted using GEE) used in this thesis is 
that fitted changes in antibody level over time only used the first and last 
time points as a gradient and did not take into account intermediate data 
points.   This may account for the null result for the rate of change 
analysis for ORF 73 in the CLR model.  The model presented of linear 
regression adjusted using GEE uses the antibody dilution as the outcome 
rather than case-control status.  It allows for the fact that each individual 
has multiple time points and does not make assumptions about patterns 
of antibody change between time points.  It also allows examination of 
trend in titre over time, in addition to allowing investigation of 
differences in the trend between cases and controls.  This model also 
allowed production of a graph, an aid to interpretation. A potential 
disadvantage of this model is that it does not allow for the matching.   
 
The only small difference in results between conditional logistic 
regression model and GEE is that the estimate of change in antibody 
level over time is stronger (smaller p-value) for the GEE.   Possible 
reasons for this are that the GEE takes into account all time points, if 
there is a large intermediate value then this is taken into account in the 
GEE analysis but not in the CLR analysis, or that GEE does not allow for 
the matching.  
  
As an alternative to using linear regression adjusted using GEE a full 
random effects model (random intercept linear regression) was also used 
to estimate KSHV antibody level (results not shown).  The results were 
similar between the two approaches. The full random effects model has 
the advantage when inference about individual variability in a population 
is of major interest whereas the GEE approach models group or 
population differences.  
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7.6.4 Importance of determining risk of Kaposi’s sarcoma in sub-
Saharan Africa 
 
In HIV-infected individuals ART is associated with a reduction in the 
incidence of KS138, and among those who do develop KS the disease is 
less extensive383.  Targeting individuals in need of ART may be 
particularly important in resource-poor settings where drugs to treat HIV 
are in short supply and clinicians may have to prioritize individuals to 
receive treatment.  Furthermore, modalities to treat or palliate more 
bulky symptomatic tumours, including radiotherapy and chemotherapy, 
may not be available.  Currently no ART guidelines for early intervention 
in preventing KS are in general practice; in part this is due to the 
inability to predict those at greatest risk of KS.  This is in contrast to 
other co-infections such as the hepatitis B virus (HBV) and hepatitis C 
virus (HCV).  ART is recommended in HBV infection in HIV co-infected 
individuals, regardless of CD4 cell count as treatment prevents liver 
fibrosis, reduces risk of cirrhosis, end-stage liver disease, and 
hepatocellular carcinoma (HCC)384.  Recent guidelines recommend 
treatment of HIV in HCV-infected patients, regardless of HIV RNA and 
CD4 cell counts as ART slows liver fibrosis progression rates385 and 
development of HCC386.   
 
The use of anti-herpesvirus treatment to prevent or influence the course 
of KSHV infection and KS might also be considered but has been 
disappointing.  Reduction in KSHV replication with Valganciclovir has 
been reported387.  Small reductions in the risk of KS in a UK based HIV-
positive cohort were reported with both foscarnet and ganciclovir; 
acyclovir had no effect388.  But this potential benefit has not been 
replicated389, 390.  The null findings are also supported by in-vitro studies 
that continued to detect KSHV in the PBMCs of patients receiving 
foscarnet and/or ganciclovir391.  New agents that may target specific 
KSHV proteins involved in angiogenesis for prevention of KS are currently 
under development.  
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7.7 Conclusion 
 
HIV-infected individuals in Uganda who develop KS have high antibody 
titres prior to diagnosis compared to those who do not develop KS.  
Antibody titres increase with time towards KS diagnosis in individuals 
that develop KS compared to those who do not.  Prior to HIV 
seroconversion K8.1 antibodies may already be higher in those who go 
on to develop HIV-associated KS compared to those who do not.  
 
7.8 Study comments, strengths, and limitations 
 
This is the largest longitudinal study to date examining patterns of 
antibody titres to both K8.1 and ORF 73 in individuals with HIV-
associated KS, in a KSHV endemic population in sub-Saharan Africa.  
CD4 count was well matched and this was of particular importance since 
the CD4 count is the most important factor associated with the 
development of KS. In a case series, for a new diagnosis of KS while on 
treatment with ART, the rate ratios for developing KS in patients with 
CD4 counts less than 200, and 200-499 cells/mm3 were about 19 and 4, 
compared to those with ≥500 cells/mm3139.  Given that the development 
of KS is closely associated with CD4 count it is not surprising that low 
CD4 count is associated with increased KSHV viral loads and elevated 
KSHV antibody titres113.  A likely consequence of matching CD4 count 
was that cases and controls were similar for HIV viral load and whether 
or not they were on ART.  It is perhaps surprising, given the CD4 counts 
of this cohort, that relatively few had a detectable HIV viral load.  While 
CD4 counts are a more important prognostic indicator in late stage HIV 
disease compared to HIV viral load392, the rate of CD4 cell decline 
correlates with the HIV viral burden393.  
 
The definition of case-control status in this study relied in the majority of 
cases on clinical diagnosis made at the time of clinical check-ups.  While 
large dermal KS lesions are relatively easy to diagnose, lack of 
histological confirmation may have lead to misclassification of cases and 
controls and small dermal lesions may have been missed.  Further, no 
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diagnostic tests were available to ensure controls did not have visceral 
involvement.  Date of KS diagnosis was based on the clinical review date, 
which may have been affected by how regularly the HIV clinic was 
attended.  
 
The measure of exposure within the GEE analysis was antibody titre to 
KSHV antigens K8.1 and ORF 73.  The strengths and weaknesses of the 
serological assay have been discussed in the introductory chapters of this 
thesis.  The result of this study relies on the validity of measured 
antibody titre.   
 
The relatively small numbers of individuals on ART at KS 
(pseudo)diagnosis, in spite of low CD4 counts, most likely reflects local 
practices and limited access to ART in Uganda at the time these cases 
were diagnosed.  Further studies will be needed to explore ART and risk 
reduction of developing KS in resource poor settings.  There is a 
theoretically stronger argument for the potential need for early 
intervention with ART to prevent KS in sub-Saharan Africa, compared to 
other regions, because: (1) KSHV infection is endemic; (2) individuals 
present with low CD4 counts394; (3) access to ART may be limited; and 
(4) interventions to control or palliate KS are largely lacking.  
 
Unfortunately no data on staging KS in terms of the extent of the 
tumour, immune status and systemic illness was available.  Oral lesions 
are the initial site in about 15% of cases in European and North American 
populations395, while the gastrointestinal tract is involved in 
approximately 40% of patients with KS at initial diagnosis and in up to 
80%, at autopsy396.  These types of lesions can cause problems with 
nutrition, which may additionally impact on immune function and hence 
risk of KS and/or antibodies to KSHV.  
 
Information on any potential immune reconstitution inflammatory 
syndrome (IRIS) would also be of interest and was not collected in this 
cohort.  IRIS is used to describe a collection of host responses that can 
occur following the initiation of ART.  In addition to worsening symptoms 
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from preexisting infections, the initiation of ART has been associated with 
progression of KS397.  It may be important to investigate whether clinical 
worsening of KS is accompanied by loss of KSHV viral control, increased 
anti-KSHV antibodies and KSHV viral load.  
 
Other limitations of this study include the fact that some individuals had 
few samples available for testing and the timing of samples was not at 
regular intervals.  Furthermore, HIV seroconversion data was only 
available in a small number of individuals and the number of samples 
available for K8.1 titre was small.  Due to limitations in data collection it 
was not possible to investigate mortality or response of KS to ART or 
other treatments. 
 
7.9 Further directions 
 
Recent advances in biotechnology offer the hope of KS screening and 
prevention, along with improved drug development.  Unfortunately 
neither a biomarker to accurately predict individuals at greatest risk of 
KS, nor a preventative therapy is currently available.  At present, once 
KS is clinically evident the main aims of treatment are symptom 
palliation, prevention of disease progression, and reducing psychological 
stress.  The median survival for advanced KS in first world centers using 
ART in combination with systemic chemotherapy is about one year398, 399.  
Where available, treatment is primarily centered on ART, and systemic 
chemotherapy is normally reserved for individuals with advanced 
disease.  Advanced disease is defined by the AIDS Clinical Trial Group 
and includes presence of gastrointestinal or extensive oral disease, a CD4 
cell count <200/µL and a history of opportunistic infections400.  Liposomal 
anthracycline agents in Western settings have response rates of about 
50% in advanced KS401 and may marginally increase median survival399.  
Biological indicators specific for detecting early risk of developing HIV-
associated KS are a key area for future research and are discussed 
below.    
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Increasing KSHV viral load is associated with risk of KS occurrence.  
Further studies with HIV viral load data would be of interest to clarify its 
role as a predictive marker of the risk of KS in sub-Saharan Africa and to 
clarify the relationship between HIV viral load and antibodies to KSHV in 
a cohort in this setting.  In a study of HIV treatment-naïve adults with 
HIV-associated KS in Zimbabwe, KSHV DNA levels in PBMCs of <660 
copies/ml prior to ART treatment were associated with a greater survival 
and tumour regression402.  Whether KSHV DNA levels could be used as a 
clinical tool to stratify individuals with KSHV-HIV co-infection into KS risk 
groups is currently not known.  Guidelines for treatment to prevent 
pathology caused by other oncogenic infections are well recognized; anti-
viral therapy based on HBV DNA levels is well validated403.  
 
The results from this study and others suggest that antibody titre to 
KSHV proteins may help characterise increased KS risk.  Current 
serological assays have limitations and are only deemed valid for 
epidemiological studies rather than those in clinical settings173.   Testing 
for antibodies to KSHV in addition to K8.1 and ORF 73 may improve 
clinical validity.  The transition from KSHV latency into the lytic cycle is a 
critical step in disease pathogenesis.   The expression of lytic genes has 
been defined for immediate–early (IE) and late genes.  IE genes include 
ORF K8.1 and ORF 50.  The KSHV ORF 50 gene product is known as the 
‘replication and transcriptional activator’ or Rta, and plays a critical role 
in the switch from latency to lytic replication404.  Transcript expression of 
IE genes or their protein products could be prime candidates for markers 
of initial KSHV pathogenesis.  Testing for a panel of multiple KSHV 
antibodies may also improve utility.  Studies are underway by VOS, NCI 
to define a panel of antigenic epitopes that may refine serology into a 
more predictive tool.  Multiplex platforms could be used to detect 
multiple antibodies in a single biological sample.  
 
Whether changes in KSHV viral load and/or antibody titres could be used 
as a risk assessment tool remains unclear.  It seems likely that a 
clinically valid test will require the combination of molecular or 
immunological measures.   Viral parameters may be required in 
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conjunction with host factors.  Important viral measures could be viral 
microRNA profiles151, 152 or viral IL-6 levels405.  Potential host molecular 
markers could include activation events of nuclear factor kappa B (NFκB) 
pathways406.  NFκB, involved in cellular responses to stress and dys-
regulation, has been linked to KS development.  Vascular endothelial 
growth factor (VEGF) is a protein produced by cells that stimulates 
vascular development and angiogenesis.  Expression of VEGF has been 
linked to poor prognosis in a number of cancers.  Early immunological 
changes that may herald KSHV pathogenesis include changes in the 
profile of KSHV-specific T cell responses.  Human cytokine levels are 
measurable in disease; human IL-6 has an important role in 
pathogenesis of MCD407 and the chemokine receptor CCR5 has been 
implicated in HIV-associated cancers408. 
 
In conclusion, clinical tools to screen for risk of KSHV pathogenesis and 
therapies to prevent KS in those at greatest risk are urgently required.  
Given recent advances in technology and our understanding of KSHV 
oncogenesis, much progress is hoped for in the coming decade.  
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Chapter 8.  Conclusion  
 
 
8.1 Introduction 
 
 
Infectious agents are responsible for over 20% of cancer deaths in the 
developing world409.  These cancers are potentially preventable.  The 
scale of the problem is significant.  Nearly 60 000 people in sub-Saharan 
Africa alone died in 2002 from cancers caused by co-infection with KSHV 
and HIV410.  In Uganda, KS is the highest registered cancer and the 
attributed morbidity and mortality are significant32.  With the ultimate 
goal of reducing the burden of KS, there is an opportunity to prevent KS 
at a number of points on the trajectory of KSHV infection from 
transmission to frank malignancy.  This thesis potentially contributes 
knowledge in two key areas of KS prevention: preventing transmission 
and preventing progression to KS.    
 
8.2 Chapter outline 
 
In this final chapter the key results from this thesis are discussed within 
the context of plausibility, potential public health impact and future 
research directions.  The first section relates to KSHV transmission and 
includes the following:  
1. hypotheses for the influence of malaria on KSHV infection; 
2. the potential impact of public health measures to control malaria 
on KSHV transmission;  
3. the interaction between HIV and KSHV and how preventative HIV 
interventions may affect the spread of KSHV; 
4. the co-factors that may be important for KSHV transmission; and 
5. future research directions. 
 
The second part of this chapter deals with KS prevention and has the 
following sections:   
1. the search for risk factors for HIV-associated KS oncogenesis; 
2. speculation on malaria as a co-factor for KS and potential research 
directions; and 
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3. the development of a risk assessment tool for KS. 
 
This, the final chapter of this thesis closes with an overall final 
conclusion. 
 
8.3 Kaposi’s sarcoma associated-herpesvirus transmission 
 
8.3.1 Hypotheses for the influence of malaria on Kaposi’s 
sarcoma associated-herpesvirus infection 
 
One of the novel findings presented is that malaria parasitaemia is 
associated with antibodies to KSHV.  If this result reflects a true 
interaction between malaria and KSHV it may be due to a number of 
mechanisms including the following: (1) polyclonal activation of B-cells 
leading to an increase in antibody titre above the cut-off for defining 
seropositivity; (2) an increase in primary KSHV infection; and (3) lytic 
reactivation of KSHV, with the resulting higher KSHV viral load leading to 
an increase in antibodies.  In contrast to the first scenario, it is plausible 
that scenarios two and three could increase the spread of KSHV (Table 
8.1).  Lytic reactivation of KSHV infection is known to be key to the 
maintenance of lifelong KSHV infection within the host and for 
transmission to new hosts411.  KSHV transmission is likely via saliva 26, 
326.  A potential hypothesis is that malaria could cause reactivation of 
latent KSHV, increased oral shedding of KSHV and thus increase the 
chance that a host will transmit to a new individual (Figure 8.1).  Indeed, 
P. falciparum is known to trigger reactivation of other herpesviruses, 
EBV253 and herpes simplex360.  One could further postulate that malaria 
could increase vulnerability to secondary infection with KSHV, possibly by 
altering the mucosal barrier or immune response.   
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Figure 8.1: Proposed pathway for KSHV infection dynamics and KS pathogenesis and 
points at which malaria may modify the process.  
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8.3.2 The potential impact of public health measures to control 
malaria on Kaposi’s sarcoma associated-herpesvirus transmission  
 
Extensive efforts are underway to control malaria by mosquito 
eradication, prophylactic drugs, vaccination and prevention of mosquito 
bites.  This raises the question if a by-product of these efforts will be to 
reduce KSHV transmission.  Indeed, reduced KSHV seroprevalence 
related to suppression of Anopheles density in Italy has been reported334.  
In this thesis, the use of bed nets and spraying insecticide in the home 
were not associated with reduction in detection of antibodies to KSHV, 
but neither were they associated with reduction in malaria.  This should 
be repeated with home checks for use of nets and sprays.   
 
8.3.3 Interaction and preventative interventions for HIV and 
Kaposi’s sarcoma associated-herpesvirus co-infection  
 
The study of mother-child pairs reported that children infected with HIV 
were at an increased risk of KSHV seropositivity7.  This result was 
supported by the meta-analysis.  Among mothers the evidence for an 
association between HIV and antibodies to KSHV was weaker8.  The 
biological mechanism for this was outside the scope of this thesis.   
However, within the context of the limitations addressed in chapters 5 
and 6, it is interesting to speculate that HIV may be associated with 
vulnerability to KSHV infection.  If this is true, HIV prevention or early 
ART intervention could prevent or delay primary KSHV infection.  In 2012 
MRC Uganda reported that among HIV-infected children in the General 
Population Cohort, mortality was extremely high in the first two years of 
life compared to children not infected with HIV412.  HIV disease 
progression among children tends to be rapid, especially in resource-
limited settings.  With the introduction of paediatric anti-retroviral 
therapy to Uganda, prevention of HIV-associated disease will become 
more important.  While preventing HIV infection would always be the 
public health priority, interventions to prevent primary KSHV infection or 
reactivation may become important as the HIV trajectory shifts to one of 
a chronic illness. 
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8.3.4 Additional co-factors for Kaposi’s sarcoma associated-
herpesvirus transmission  
 
Risk factors for KSHV transmission are likely to be multifactorial and 
differ between geographic areas.  Certainly, the co-spatial distribution of 
KSHV and P. falciparum is not exact, implying that if malaria is a co-
factor for KSHV transmission or KS pathogenesis, it acts in combination 
with other factors.   Background risk factors for KSHV infection, 
reactivation or disease pathogenesis may include age7, 8, 13, 22, 25, 191, 259, 
exposure to KSHV7, 218, 257, residence256 and genetic profile244, 245 (Figure 
8.1).  Other factors that impact the host immune function may also be 
important, including nutritional status, parasites and other infectious 
agents.   
 
To reach the goal of reducing KSHV transmission and prevalence, further 
research is needed to increase current knowledge (Table 8.2).  This 
thesis highlights parasites including malaria in addition to HIV as 
potential co-factors for KSHV transmission but broad searches for other 
co-factors are still required. There is good evidence to support age7, 8, 13, 
22, 25, 191, 259 and KSHV status of close relatives7, 218, 257 as key 
determinants of risk of KSHV seropositivity in sub-Saharan Africa.  Other 
co-factors for KSHV infection are less clearly defined.  This is in part due 
to the fact that KSHV research has sometimes been limited by studies 
not being specifically designed to investigate KSHV and so can lack the 
breadth and power to study risk factors.  There is a particular paucity of 
data collection on co-infections.  This is important as simultaneous 
infection by KSHV and other pathogens may impact the detection of 
KSHV antibodies in a number of ways.  While financially costly, KSHV 
viral load and potentially, information on KSHV-specific T-cell responses 
will be key to determine the biological interaction between KSHV and 
“factor”.    
 
Future studies can be approached a number of ways (Table 8.2) and if 
risk factors are to be clarified diligent collection of data on potential 
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confounders along with biological samples for KSHV assays are required.  
A cross-sectional survey of KSHV prevalence among populations with and 
without malaria control could be relatively easily done and results may 
inform the plausibility of malaria as a co-factor for KSHV.  A case-control 
study of individuals with and without KSHV would allow multiple 
exposures to be studied while keeping cost and time to a minimum.  
Information from a study of this type could then be used to inform a 
cohort study which would allow the study of the natural evolution of 
KSHV infection and allow the complexities of timing and duration of 
exposure to co-factors to be investigated. 
 
KSHV activity (antibody titre, viral load and specific T-cell responses) 
could be measured among individuals before and after treatment for 
certain parasite infections.  It would be of particular interest to determine 
if drugs that clear P.falciparum also reduce markers of KSHV reactivation.  
A birth cohort study would allow the temporal relationship between 
primary infections with KSHV and other infectious agents to be 
investigated.  The age of the host is an important determinant of 
outcome for P.falciparum.  Any potential interaction between malaria and 
KSHV may also be governed by age.  Quantitative laboratory based 
studies will be needed to investigate biological mechanisms of factors on 
KSHV control.  Perturbations in adaptive T-cell function could affect KSHV 
transmission and/or KSHV disease pathogenesis and are a good 
candidate for investigation102.  If malaria is involved, the order, timing 
and frequency of P.falciparum and KSHV is likely be important.  Acute 
and chronic P.falciparum malaria infections may preferentially impact T-
cell immunity and hence KSHV infection253.  Finally, a review of the 
literature will be required to pool results and review potential co-factors 
for KSHV transmission.   
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8.4 Prevention of Kaposi’s sarcoma 
 
8.4.1 The search for risk factors for HIV-associated Kaposi’s 
sarcoma oncogenesis 
 
The results from chapter 7 suggest that high antibody titres to two KSHV 
proteins are associated with risk of developing HIV-associated KS.  Two 
key questions stem from this study: (1) what risk factors determine why 
some individuals get KS; and (2) what sort of test would be ideal for 
predicting risk?  The answers to these may allow for KS preventative 
measures. 
 
This thesis reported that some individuals with HIV-KSHV co-infection are 
more likely to progress to KS than matched individuals (also infected 
with HIV-KSHV).  Current evidence suggests that in HIV-KSHV co-
infected individuals, factors that cause additional immune modulations 
change the risk of KS and the factors include ART124, steroids144, 145 and 
immune reconstitution inflammatory syndrome397.  Additional risk factors 
for HIV-associated KS may be present and these could conceivable 
include parasites and immune modulating genes.    There is a clear need 
to fully define risk factors for KS in addition to HIV infection because if 
identified, these risk factors may have the potential to be avoided or 
modified to reduce the risk of KS oncogenesis.  Furthermore, in the era 
of ART, KS occurring at CD4 counts above 500 and KS not remitting with 
treatment may be rising413, 414, increasing the need for risk factors in to 
be fully understood.  Information on a large number of co-factors could 
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be accrued through a case-control study and followed with a longitudinal 
cohort study (Table 8.3).  Samples collected from such studies could be 
used to determine biological interaction between KSHV and any co-
factor. 
 
8.4.2 Malaria as a co-factor for Kaposi’s sarcoma  
 
The immunomodulatory effects of P.falciparum parasitaemia make it a 
potential co-factor354.  So, in addition to influencing the transmission of 
KSHV, it is intriguing to speculate that malaria could also be implicated in 
the oncogenesis of KS in at least one of two ways: (1) malaria could 
induce the KSHV reactivation required for pathogenesis of KS; and (2) 
malaria could facilitate the dissemination of the virus to sites of disease.  
A point to further speculate is if malaria prophylaxis in HIV-KSHV co-
infected individuals could reduce their risk of progression to KS.  It may 
be possible in some parts of sub-Saharan Africa with establish malaria 
programmes and cancer registration to demonstrate an association 
between malaria transmission rates and KS incidence.       
 
 
 
 
8.4.3 The development of a risk assessment tool for progression 
to Kaposi’s sarcoma 
 
Whether antibody levels could be used to determine clinical risk of KSHV-
related disease remains undetermined.  Following multiple KSHV 
antibodies may increase the clinical validity of serology as a risk 
assessment tool.  It may be that compared to a defined “normal range” 
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both the absolute difference and dynamics of antibody titre may be 
important.  It is likely that the patient clinical profile and/or other 
biomarkers, perhaps in combination with antibodies to KSHV, will be 
required.  Indicators of risk of KS that are valid in a clinical setting are 
urgently needed to screen for and prevent KSHV-related pathology.   At 
the current time, once KS is clinically evident the main aims of treatment 
are symptom palliation, prevention of disease progression, and reducing 
psychological stress.  Targeting individuals in need of ART may be 
particularly important in resource-limited settings where drugs to treat 
HIV are lacking and clinicians may have to prioritize individuals to receive 
treatment.  Furthermore, modalities to treat or palliate more bulky 
symptomatic tumours, including radiotherapy and chemotherapy, may 
not be available.  Currently no ART guidelines for early intervention in 
preventing KS are in routine practice and in part this is due to the 
inability to predict those at greatest risk of KS.    
 
Risk assessment tools that allow the calculation of 5-year absolute risk 
are currently available for cancers such as breast cancer and lung 
cancer415, 416.  A risk assessment tool for KS will likely require a 
combination of information on the background of the patient and 
parameters about the patient’s immune status and KSHV viral protein or 
genetic profile.    Patient information may include age, gender, residence 
and length of time with HIV-KSHV co-infection.  Immune status 
parameters may include, nadir CD4 count, current HIV viral load and 
history of opportunistic infections. The KSHV profile may include KSHV 
antibody titre, and KSHV viral load.  Monitoring of risk and data collection 
will likely need to be dynamic as parameters may alter over time due to 
environmental and treatment related changes.  Future studies may 
identify and allow the inclusion of KSHV viral proteins or genes that are 
oncogenic markers. 
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8.4 Final conclusion 
 
The results from this thesis suggest a potential biological interaction 
between P.falciparum and KSHV.  If this paradigm is true, basic malaria 
control measures could reduce KSHV population prevalence.  As HIV may 
impact vulnerability to KSHV infection, it is an intriguing possibility that 
primary infection with KSHV in certain risk groups may be further 
reduced with HIV prevention or ART.  Transmission of KSHV is likely 
dependant on many factors; research is required to elucidate this further.  
Risk factors for progression to KS among HIV-KSHV co-infected 
individuals include immune modulators.  However, those currently known 
only explain part of the risk and research is needed to inform prevention 
measures.  A valid risk assessment tool to identify those at the highest 
risk of KS oncogenesis is urgently needed and the information that may 
be required for such a tool is proposed.  
 
The impact of oncoviruses on the health of large numbers of people 
across the world remains huge and yet these cancers have the potential 
to be prevented. KSHV transmission and halting pathogenesis are 
attractive targets to prevent KS.  It is hoped that the findings 
documented in this thesis go some small way to achieving that much 
needed goal.   
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Appendices 
 
1. Table of papers rejected from meta-analysis 
 
2. Wakeham K, Webb EL, Sebina I, Muhangi L, Miley W, Johnson WT, 
Ndibazza J, Elliott AM, Whitby D, Newton R. Parasites and 
Kaposi’s’s sarcoma associated herpesvirus (KSHV) in Uganda.  
Infect Agent Cancer. 2011 Sep 30;6(1):15 
 
3. Wakeham K, Webb EL, Sebina I, Muhangi L, Miley W, Johnson WT, 
Ndibazza J, Whitby D, Newton R, Elliott AM.  Transmission of 
Kaposi’s’s sarcoma associated herpesvirus (KSHV) in mother-child 
pairs in Uganda.  J Acquir Immune Defic Syndr. 2013 June 
1;63(2):228 
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